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CHAPTER 1
GENERAL INTRODUCTION
Immunotherapy and the role of the minor histocompatibility antigens
Allogeneic hematopoietic stem cell transplantation (HSCT)
Allogeneic hematopoietic stem cell transplantation (HSCT) has emerged as immunotherapy and is the main 
curative treatment of hematologic malignancies and disorders [1-3]. It is also applied as a rescue procedure 
to replace the damaged hematopoietic stem cells from the patient, after chemotherapy and radiotherapy, and 
generate a new healthy hematopoietic system with the donor stem cells in the patient. The donor T cells, 
transplanted with the stem cells into the patient, mediate immune reactions in the patient and induce graft 
versus leukemia (GVL) [4]. There is evidence that genetic disparity between donor and the patient is required 
for a significant GVL effect [5]. The main complication of this immunotherapy is the induction of graft versus 
host disease (GVHD) [6,7]. It is a major source of morbidity and mortality following HSC administration. 
Reducing its incidence and severity is a major challenge [8]. T cell depleted stem cell transplantation has 
been applied as an option to reduce the severity of GVHD while the incidence of relapse is increased in these 
patients [9,10] and is reviewed in [11]. Therefore, donor lymphocyte infusion (DLI) has been administrated 
several months after HSCT to restore the GVL response. The lymphocytes  are derived from the same do-
nor and infused into the patient who received the T cell depleted stem cell transplantation [12-14]. DLI can 
produce complete remissions in a high number of chronic myeloid leukemia (CML) patients while in other 
cases additional chemotherapy or antibody administration may be required to achieve complete remission 
[5]. Improving the outcome of HSCT remains one of the highest priorities in immunotherapy and this can be 
achieved by finding a strategy to increase the rate of GVL while preventing GVHD [5,11].
Graft versus Leukemia (GVL) and Graft versus host disease(GVHD)
The key to GVL and GVHD in an HLA matched donor/patient pair is minor histocompatibility antigens 
(MiHA). MiHA are polymorphic peptides, derived from endogenously processed cellular polymorphic pro-
teins and presented on the cell surface by human leukocyte antigen (HLA)- class I and class II molecules. 
HLA-class I molecules are expressed on the surface of all eukaryotic cells, presenting peptides for CD8+ T 
cells. After allogeneic HSCT of an HLA matched donor/patient pair the donor T cells recognize MiHA pre-
sented in HLA molecules on the surface of malignant cells of the patient and induce GVL (Figure 1). In 1976 
for the first time the involvement of minor histocompatibility antigens (MiHA) was reported in hematopoi-
etic stem cell transplantation [15]. Since, the recognition of MiHA by T cells has been described by different 
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Comprehensive knowledge of MiHA would greatly improve allogeneic HSCT. In addition, the identification 
of MiHA presented only on hematopoietic cells may allow infusion of T cells recognizing only hematopoi-
etic cells from the patient thereby increasing the likelihood of specific GVL response and decreasing the 
incidence of GVHD. Clearly, antigen processing plays a crucial role in the presentation of MiHA.
HLA molecules and antigen processing 
Human leukocyte antigen (HLA) molecules
HLA molecules are divided in two classes: HLA-class I and HLA-class II. HLA-class I has six different iso-
types, namely HLA-A, HLA-B, HLA-C, HLA-E, HLA-F and HLA-G. HLA-class II molecules are termed 
HLA-DR, HLA-DQ and HLA-DP. The HLA-class I molecule consists of an α chain, comprising domains α 
1, α 2 and α 3, and β2¬-microglobulin. The latter is necessary for the stability of the HLA-class I molecule, 
Figure 1. Schematic overview of graft versus leukemia (GVL) and graft versus host disease (GVHD). The donor T cells 
recognize MiHA on the patient cells. Note; the small difference (usually just one amino acid, indicated in red in some 
of the presented peptides (in green).
groups. The distribution of MiHA determines the effect of this therapy. If the MiHA is presented only 
on the hematopoietic cells, including the malignant cells, the donor T cells recognize the malignant cells 
inducing GVL, while, if the MiHA are also presented on the surface of non-hematopoietic cells of the 
patient the donor T cells attack the healthy cells of the patient , which is called GVHD (Figure 1). GVHD 
is still the major life-threatening complication of this therapy. The cells of liver, skin, gut, and lungs are 
most prone to GVHD [16].                         
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while the α3 domain is membrane-spanning. HLA-A, HLA-B, and HLA-C are highly polymorphic and the 
variability is most pronounced in the α1 and α2 domains, which form the peptide binding groove [17,18]. It 
consists of two α helices forming a wall on each side and eight β-pleated sheets forming a floor (Figure 2A 
and 2B). The most polymorphic residues in the groove interact with amino acids in certain positions within 
the peptide sequence. Most of these peptides that bind a specific isoform of an HLA-class I molecule have 
the same amino acid or chemically similar amino acids at particular positions. These amino acids are called 
anchor residues, and the pattern of these preferred amino acids in the peptides is called the peptide binding 
motif [19,20]. Not all theoretically possible peptide stretches with the correct binding motif will eventually 
bind to HLA molecules, because of the complexity of the intracellular processing. It has been reported that 
only 0.1% of the peptides survive intracellular processing to eventually bind to the available HLA molecules 
and become presented on the cell surface [21].
HLA-class I molecules can now be produced by in vitro folding of recombinant HLA α chain and β2m in 
Figure 2. HLA class I molecule consist of  alpha (α) chains and β2-microgobulin (β2-m). The trans membrane do-
main (α-3domain ) bound non-covalently to the β2-m. (A) is the side view of the HLA- class I molecule and (B) is the 





combination with the peptide of interest [22]. The assembled molecules are called monomers. The monomers 
can be utilized in different applications, for instance production of multimers (tetramers), which serve as a 
platform for peptide specific T cell recognition [23,24] and (Chapter 4). Tetramers are indispensable tools to 
fish out selected peptide-specific T cells from donor blood. Monomers can also be used for absolute quanti-
fication of HLA-presented peptides, and determination of the yield of peptide elution experiments (Chapter 
5), by addition of isotopically labeled peptides during the monomer assembly. 
Antigen processing and presentation
Classically, HLA-class I associated peptides (antigens) are generated inside  the cell by multi step process 
from endogenous proteins, or e.g. of viral proteins. Proteins can be degraded by various enzymes,  the most 
prominent being the proteasome. In addition, nardilysin and/or thimet oligopeptidase (TOP), insulin degrad-
ing enzyme (IDE) can also play roles, in combination with other endo or exoproteases, to produce peptides 
from 4 to 20 amino acids long [21,25]. The peptides are subsequently transported to the ER via an ATP 
dependent transporter for antigen processing, TAP, comprising TAP1 and TAP2 [26,27]. Longer peptides 
will be further trimmed by endoplasmic reticulum aminopeptidase (ERAP) to a size that can fit the bind-
ing groove of HLA-class I molecules [28]. In addition to TAP, other molecules as Tapasin [29], Calreticulin 
(CRT) [30] and ERp57 [31] are involved in the loading of the peptides into HLA-class I molecules [32,33]. 
In the ER, peptides that have survived the intracellular processing and that have the correct binding motif can 
be loaded in HLA-class I molecules (Figure 3). The complex of the HLA-class I molecule and the peptide is 
Figure 3. Schematic overview of antigen processing pathway for HLA-class I molecules from endogenous proteins. 
Endogenous proteins are degraded by the proteasome into smaller units called peptides and transported via ATP 
dependent antigen transporter (TAP) to endoplasmic reticulum (ER). In ER the peptides bind to HLA molecules and 
transported via Golgi apparatus to the cell membrane to be presented to CD8+ T cells. Adopted from [34].
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transported to the cell surface through the secretory pathway via the Golgi apparatus to be presented on the 
cell surface for CD8+ T cells.
T cell recognition of a peptide associated with HLA-class I molecule
The CD8+ T cell receptor (TCR) consists of two different polypeptide chains: α chain and β chain. These 
two chains have a variable region (V region) and a conserved region (C region). The V region is involved 
in antigen recognition of the HLA-class I- peptide complex [35]. All T cells undergo negative and positive 
selection in thymus. T cells with intermediate or low avidity against self-antigens are tolerated.  High avid-
ity T cells against self-antigens will be deleted while the high avidity T cells against non self (foreign) anti-
gens will be tolerated. These selection steps are crucial to avoid autoimmunity and maintain responsiveness 
to infectious diseases, respectively [36-39]. T cells are generally tolerant only to HLA-restricted peptides 
(ligands) presented during T-cell development in the thymus [40]. Presentation of an altered repertoire of 
HLA class I binding peptides will be perceived as foreign and will trigger CD8+ T-cell responses. In this 
respect an interesting disturbance of the immune balance was observed in some patients, carrying HLA-
Figure 4.  Top View of the HLA-B*5701-abacavir (green) and peptide (purple) complex structure. adapted from [42].
B*5701, who displayed hypersensitivity to treatment with the antiviral drug Abacavir. The hypersensitivity 
was found to be related to binding of Abacavir in the binding groove of the HLA-molecule, thereby altering 
the presented peptide repertoire [41-43], see Figure 4.
In summary, CD8+ T cells can recognize previously not presented (new) HLA-presented peptides, such as 
derived from viruses, post translationally modified peptides, endogenous peptides bound to the altered HLA 
binding grooves due to a small reactive molecules from drug metabolites [42] and polymorphic peptides de-
rived from endogenous proteins (MiHA) after allogeneic HSCT [6,43-45].
17
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Peptides associated with HLA- class I molecules
Generally HLA-class I associated peptides have a length of 8-11 amino acids, typically 9 [46]. However, 
longer peptides  have  also  been  reported. Because  of the longitudinal restriction of the binding groove, 
longer  peptides  have  to bulge out of  the  groove, see  e.g. the 13 mer (viral  epitope)  bound to HLA- 
B*3508  molecule, see  Figure 5  [47,48].                      
In addition,  the synthetic elongation of  known T cell epitopes between the P2 and PΩ anchors demonstrated 
binding up to at least 25 mers to some HLA-class I molecules, by so-called superbulging [50]. There is also 
evidence that N-terminally extended peptides can bind to HLA-B*35 [51]. Until now, naturally processed 
and presented peptides up to 14 amino acids have been published to bind HLA-A*0201 molecules [52]. 
From analysis of the eluted peptides we could demonstrate that also longer naturally processed peptides can 
be presented by HLA-A2 molecules (Chapter 7). In addition to peptide length, the binding motif is another 
criterion for binding to HLA-class I molecules. The two most important positions are position 2 (P2) and the 
carboxyl terminal (PΩ) in the peptide sequence. At P2 and PΩ one (or a few) amino acid (anchor residue) 
is dominant per HLA-class I molecule [53-55]. Furthermore, auxiliary anchor residues have been described 
to enhance the binding of the peptides to HLA-class I molecule as P3 and P5 [55,56].  
The peptides (ligands) associated with HLA-class I molecules derived from endogenous proteins originate 
from different compartments in the cell (e.g. nucleus, cytoplasm, plasma membrane, etc.) representing ev-
ery protein [57,58]. The presented peptides can be derived either from mature proteins, degrading due to 
age, due to unfolding, or from defective ribosomal products (DRiPs). The DRiPs/ SLiPs or rapidly degraded 
polypeptides (RDPs) are considered important sources of peptides. DRiPs consist of prematurely termi-
nated polypeptides and misfolded polypeptides produced from translation of mRNAs in the proper reading 
Figure 5. A super-bulged 13mer EBV antigen BZLF1 (52LPEPLPQGQLTAY6) (blue) in the antigen-binding cleft of 
HLA B35 in comparison with the 8 mer HIV1 Nef (75VPLRPMTY82) peptide (green). Adopted from [49].     
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frame [59-61]. The turnover kinetics of the MHC peptides confirm the presence of DRiP and SLiP-derived 
peptides in MHC molecules [62]. Recently, it has been reported that specific groups of proteins, such as ri-
bosomal and T complex protein 1, contributed DRiPs to the HLA ligandome [61].  In addition the alteration 
in cellular metabolism resulted  in changes in peptides presented in HLA-class I molecules [63]. It has been 
reported that the peptides presented in HLA-class I molecules are preferentially derived from transcripts 
bearing miRNA response elements [64]. Furthermore, also post-translationally modified peptides can be 
presented in HLA-class I molecules. These modified peptides can induce T cell responses. The common 
example for modifications of the peptides is phosphorylation [65-69]. Phosphorylated peptides can be as-
sociated with deregulated signalling in cancer cells, and could be used as targets for immunotherapy in the 
Table 1. Summary of the number of HLA-class I ligands identified and published by different groups regardless of the 





HLA-A2 & B7 3000 human cancer cell line 72
HLA-B*2705 1268 human chondrosarcoma cells 73
HLA-B*2705 200
human lymphoid cell line transfected with B27-
C1R
74
HLA-A*6801 816 human lymphoid cell line 75
HLA-A2 3686 32 x GBM (stage VI glioma) tumor cell line 76
HLA-A*0201 1266 B-lymphoblastoid cell line 68
HLA-A & B 2375 B-lymphoblastoid cell line 64
HLA-B44 402 B-lymphoblastoid cell line 77
HLA-class I 12199 B-lymphoblastoid cell line 71
HLA-class I 7137 JY cell line 61
HLA-class I 2359 RPMI8226 61
HLA-class I 1651 U937 61
HLA-A*0201, B*0702, B*4402 & HLA-C 10867 HHC-B-lymphoblastoid cell line Chapter 2
HLA-A*0201, B*0702  & HLA-C 6493 JY-B-lymphoblastoid cell line Chapter 2
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treatment of cancer. In fact, PhosImmune Inc, a spin off company of the University of Virginia, by Hunt 
and co-worker, develops vaccines bases on aberrantly expressed phosphorylated antigens. Their studies are 
currently in clinical phase I. In addition to phosphorylated ligands, cysteinylated HLA-class I ligands are 
often observed, which can be crucial for T cell recognition [44,45,70,71] (Chapter 2).
The number of reports on identified HLA-class I peptides is increasing, as is the number of identified 
ligands. However, due to both biochemical and technical limitations, most publications only identify a 
glimpse of the ligandome. A summary of the identified number of HLA-class I ligands for a number of stud-
ies is listed in Table 1 and the phosphorylated ligands in Table 2.
Polymorphic peptides/MiHA
HLA molecules present, next to monomorphic peptides, also polymorphic peptides on the cell surface to T 
cells. Polymorphic peptide is derived from a protein translated from a gene containing Single Nucleotide 
Polymorphism (SNP). Although at least 90,000 non-synonymous SNPs exist in the human genome, which 
provides for a potentially large number of polymorphic proteins [72], only 10% of the  HLA-class I ligands 
are derived from polymorphic proteins (Chapter 2). Within an individual, polymorphic peptides have un-





HLA-A & B 11 RCC tumor tissue 67
HLA-A & B 71 JY-B-lymphoblastoid cell line 65
HLA-A & B 103 Ruppen 65
HLA-A & B 36 ABB 65
HLA-A & B 9 VBT2 65
HLA-A2 & B7 99 Primary hematological malignant tissue 69
HLA-A*0201 35 JY-B-lymphoblastoid cell line 66
HLA-class I 59 B-lymphoblastoid cell line 71
HLA-A*0201, B*0702, B*4402 & HLA-C 221 B-lymphoblastoid cell line Chapter 2
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dergone the thymic selection process and do not elicit T cell responses. However, polymorphic peptides can 
elicit T cell responses after allogeneic HLA-matched HSCT, and are called minor histocompatibility antigen 
(MiHA) [6,7,72]. The first human MiHA described is HA-1 that arises as a consequence of a SNP in the 
HMHA1 gene (73). MiHA can also arise from homozygous gene deletion of one gene of a polymorphic gene 
family in the donor (UGT2B17). So far, 49 MiHA (from HLA-class I and II)  have been identified from differ-
ent genes [18]. Different biochemical and molecular approaches have been used to identify MiHA, and mass 
spectrometry based approaches have played an important role.
Mass spectrometry based approaches used in identification of MiHA  
To identify novel MiHA for immunotherapy, forward and reverse approaches have been used for a decade. 
Utilization of mass spectrometry in both approaches has resulted in the identification of several MiHA. The 
identification of MiHA was pioneered by Hunt and co-worker [74]. HA-1, HA-2, H-Y minor histocompat-
ibility antigens were identified using mass spectrometry [44,65,75]. Other groups have also used mass spec-
trometry in the identification of HLA ligands [34,67,76]. Nowadays, mass spectrometric sensitivity allows 
detection of low attomole to high zeptomole amounts of peptide depending on the physicochemical properties 
of the peptide [77,78].
The forward approach 
The forward approach to identify MiHA is powerful because of its sensitivity and the availability of relevant 
T-cells, which have been isolated from patients after allogeneic HSCT. In the forward biochemical approach, 
B- cells from the patient are used to generate Epstein Barr virus transformed B lymphoblastoid ( EBV-LCL) 
cell lines, from which the MiHA can be eluted. This is done by isolation of the HLA molecules by immuno-
purification using an anti HLA-antibody, either specific for a certain type of HLA (like BB7.1 (anti HLA-A2), 
BB7.2 (anti HLA-B7)), or a pan HLA-class I antibody, like W6/32. After acid elution and isolation of the pep-
tide pool and fractionation by HPLC [73], the fractions are screened with the T cells isolated from the same 
patient. The fraction containing the MiHA, the active fraction, elicits a T cell response. The active fraction is 
further fractionated using a preferably orthogonal liquid chromatography method and is finally analyzed by 
mass spectrometry. This process, although having been successful regularly, is still challenging because of 
the complexity of the sample in combination with sensitivity needed. An important limitation of the forward 
approach is the need of establishing the T cell response after allogeneic HSCT to start looking for MiHA [34]. 
The reverse approach
The reverse approach classically does not need a T cell as starting point, but starts with the prediction of 
MiHA. Algorithms are used to find potential MiHA in e.g. selected genes present in the target cell. Different 
software packages have been developed to predict the binding affinity and presentation of peptides on the 
21
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cell surface [79-81]. These include SYFPEITHI, which is the first web-based epitope prediction program 
[82], NetMHC [81], BIMAS [83]. The prediction programs use the experimental information from previ-
ous sequencing efforts, Edman sequencing and tandem mass spectrometry [46,84]. In addition, a wealth of 
information is compiled in the immunoepitope database (IEDB) [85,86].The main limitation of reverse ap-
proaches is that most potential ligands do not reach the  HLA-groove.  Less than 0.1% of the specific peptides 
survive the intracellular processing [21]. In addition, post translation modified peptides, peptides derived 
from alternative open reading frames, splice variants, gene insertion/deletions cannot be predicted by the 
available algorithms. Alternative reverse approaches are cDNA libraries screening  [87,88], whole genome 
association scanning [52,89], and synthetic peptide library based approach [90-93].
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AIM OF THIS THESIS
MiHA play an essential role in immunotherapy for the treatment of hematological malignancies. Due to the 
high frequencies of polymorphisms of the population, a large panel of possible target MiHA is essential to 
develop new immunotherapeutic to cure the majority of patients. Therefore, the aim of this thesis was the 
large-scale identification of relevant MiHA to improve the chances of success in therapy of hematological 
malignancies by a peptidomics approach. In chapter 2, therefore, we attempted to develop an approach to 
identify as many HLA ligands, and thus MiHA, as possible. To improve the identification of MiHA from 
the raw data, i.e. the huge number of tandem MS spectra of a majority of monomorphic and a minority of 
polymorphic HLA-ligands eluted from the cells, we developed a specific database described in chapter 3 
which is called the human short peptide variation (HSPV) database. In chapter 4 we applied in our group 
developed database and algorithm to the data obtained from the peptidomics approach described in chapter 
2 to identify novel MiHA. Obviously, the abundance of the presented peptides plays an important role in T 
cell recognition. Therefore, in chapter 5 we developed an SRM/PRM-based method to accurately quantitate 
the ligand copy number. Remarkably, in chapter 2 several MiHA were identified together with their allelic 
counterparts. Generally, however, the T cell response appears to be unidirectional. In chapter 6, we deter-
mine the relative copy number of some MiHA and their AC on the surface of heterozygous cell lines, using 
the hpMHC-method developed in chapter 5 . The large number of ligands identified in chapter 2 allowed an 
in-depth view of many aspects of the HLA-ligandome, amongst others the peptide length distribution. The 
ligandome appeared to contain a substantial number of relatively long (non-canonical) peptides. In chapter 
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ABSTRACT
Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface play a crucial role in 
adaptive immunology, mediating the communication between T cells and antigen presenting cells. Knowledge 
of these peptides is of pivotal importance in fundamental studies on T cell action, and in cellular immunotherapy 
and transplantation. In this study we present the in-depth identification and relative quantification of 14,500 
peptide ligands constituting the HLA-ligandome of B-cells. This large number of identified ligands provides 
a general insight in the presented peptide repertoire and antigen presentation. Our uniquely large set of HLA-
ligands allowed us to characterize in detail the peptides constituting the ligandome in terms of relative 
abundance, peptide length distribution, physicochemical properties, binding affinity to the HLA molecule and 
presence of post-translational modifications. The presented B-lymphocyte ligandome is shown to be a rich 
source of information by the presence of minor histocompatibility antigens, virus-derived epitopes and post-
translationally modified HLA ligands and can be a good starting point to solve a wealth of specific immunological 
questions. These HLA ligands can form the basis for reversed immunology approaches to identify T cell 




Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface play a crucial role in 
immunology, and mediate the communication between T cells and antigen presenting cells. Knowledge of 
these peptides is of pivotal importance in fundamental studies on T cell action and in design of T cell-mediated 
therapy, like tumor immunotherapy [1], and treatment of hematological malignancies by a combination of 
hematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusion (DLI) [2]. In addition, T cells 
can play an important role in organ rejection following transplantation. 
The presented HLA class I ligands are the products of the intracellular processing machinery with its continuous 
cycle of protein synthesis and degradation [3]. Much is known about the proteins involved in antigen processing, 
but high fidelity ligand/epitope predictions are at present not possible. The complexity of antigen processing 
has been shown to be even more complex by the discovery of new enzymes involved in antigen processing [3, 
4] and the exciting discovery of peptide splicing [5]. Moreover, gene expression studies have shown many 
non-standard, unexpected protein products, including the production of antigens derived from aberrant protein 
fragments as a result of expression in alternative reading frames [6]. Several studies report on the identification 
of HLA ligands [7-10]. Many results have been collected and discussed in a recent review on large-scale 
analysis of HLA class I ligands [11]. Collectively, these reports illustrate the need for in-depth elucidation of 
the HLA-ligandome.
Elucidation of T cell epitopes has traditionally been achieved by a forward immunological approach, as 
pioneered by Hunt and coworkers [12, 13]. In this approach, the cognate peptide of T cells with the appropriate 
activity profile is elucidated by repeated rounds of chromatographic separation in combination with T cell 
recognition assays. Since T cells are not always available from the start, reverse immunological approaches 
[14-17] have been developed to predict T cell epitopes by a combination of bioinformatics and e.g. in vitro 
proteasome digests. Predicted epitopes are synthesized and tested for their capability to activate T cells. The 
main disadvantage of this approach is that less than 0.1% of the peptides that survive intracellular processing, 
are presented on HLA- class I molecules [3].
Therefore, we developed a large scale peptidomics approach, which is a reverse immunology approach, not 
based on algorithms, but based on the bona fide eluted ligandome, which means that the identified peptides are 
known to have survived processing and are bona fide HLA-ligands. Following the identification of the 
ligandome as comprehensively as possible, T cells can subsequently be selected on the basis of the 
immunological question at hand, as will be illustrated in a separate paper. The development of MHC exchange 
tetramers for finding relevant T cell epitopes is instrumental to this approach [18, 19]. 
To improve ligandome coverage we applied and compared three off-line first dimension separation techniques, 
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followed by on-line nanoHPLC-tandem MS. 
The tandem mass spectra were interrogated by matching against the IPIhuman database [20]. In a second step 
post translation modifications (phosphorylation, cysteinylation) were allowed in the database search. In a third 
step the tandem mass spectra were matched against a newly in-house developed database for optimal finding 
of polymorphic ligands, for finding potential minor histocompatibility antigens [21]. This led to the identification 
of approximately 14,000 HLA class I ligands, the majority of which was also relatively quantitated. Next, we 
analyzed the peptides constituting our ligandome as detailed as possible to confirm the correct identification 
of the vast majority of the ligands. We achieved this by a combination of several physicochemical and biological 
checks and comparison with existing ligand and epitope databases. 
Finally, as an additional quality check, we illustrate the functional relevance of the ligandome by the 
identification of previously known and new minor histocompatibility antigens, virus-derived epitopes and 
post-translationally modified HLA ligands (phosphorylated ligands, and cysteinylated ligands) [22-24]. Since 
this is the largest ligandome reported to date, it allows a general insight in the presented peptide repertoire. 
This study supports the building of the ‘immunopeptidome’ as has recently been suggested [25]. A proteomics 
approach as a starting point to contribute to immunology by providing a peptidome landscape can be used in 
many immunological studies, both fundamental and applied. 
EXPERIMENTAL PROCEDURES
Sample preparation
The Epstein-Barr virus (EBV) transformed B lymphoblastic cell lines B-LCL-HHC (typing: HLA-A*0201, 
B*0702, B*4402, Cw*0501 & Cw*0702) and B-LCL-JY pp65 (typing: HLA-A*0201, B*0702 & Cw*0702) 
were used as source of HLA-class I molecules. The CMV-derived pp65 transduced cell line was used to 
introduce an internal control for the ligandome since the CMVpp65-derived T cell epitopes are known [26]. 
Cells were expanded in roller bottles using IMDM supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), penicillin/streptomycin and  L-glutamine, were collected, washed with ice cold PBS, and stored 
at -80oC until use. 
The hybridoma cell line was expanded in roller bottles to obtain W6/32 (anti HLA-Class I) antibody using 
protein free hybridoma medium supplemented with penicillin/streptomycin, and L-glutamine. Antibodies 
produced by the hybridoma cell lines were purified from the supernatant using Prot-A sepharose beads, and 
eluted from the Prot-A beads with Glycine pH 2.5. The eluted antibodies were used to produce immunoaffinity 
column (W6/32- Prot-A sepharose 2.5 mg/ml). The W6/32 antibodies were covalently bound to Prot-A 
sepharose beads using dimethylpimelimidate (DMP). The columns were stored in PBS pH 8.0 and 0.02% 




Isolation of HLA class I-presented peptides
Extraction of peptides associated with HLA-class I molecules was performed as described previously [13, 27]. 
Briefly, pellets from 60 x109 B-LCL-JYpp65 cells  and 40 x109 B-LCL-HHC cells were lysed in 50 mM Tris-
HCl, 150 mM NaCl, 5 mM EDTA, and 0.5% Nonidet-P40, (pH 8.0) and supplemented with Complete® 
protease inhibitor (Sigma Aldrich). The total concentration of the cells in the lysis buffer was 0.1x 109 cells/
ml.
After 2 hours incubation with tumbling of the cells in the lysis buffer at 4 oC, the preparation was centrifuged 
for 10 minutes at 2,500 rpm and 4 oC. The supernatant was transferred to a new tube and centrifuged for 35 
minutes at 11,000 rpm and 4oC. The supernatant was pre-cleared with CL4B beads and subjected to the 
immunoaffinity column with a flow rate of 2.5 ml/min. After washing, bound HLA-class I/peptide complexes 
were eluted from the column, and dissociated with 10% acetic acid. Peptides were separated from the HLA-
class I molecules by passage through a 10 kDa membrane (Pall macrosep centrifuge devices). The filtrate was 
freeze dried. If an oily sample remained after freeze drying, the sample was  dissolved and the peptides were 
further purified by solid phase extraction (C18 Oasis, 100 µl bed volume, Waters). The peptides were eluted 
from the C18 Oasis column with 500 µl 50/50/0.1 water/ACN/FA, v/v/v. The eluted peptides from B-LCL-
HHC cell lines were divided into two equal portions, freeze dried and  dissolved in 95/3/0.1 water/ACN/FA, 
v/v/v. The eluted peptides from B-LCL-JYpp65 cell lines were divided into three equal portions, freeze dried, 
and  dissolved in 95/3/0.1 water/ACN/FA, v/v/v. 
Peptide separation
For peptide IEF separations, the OFFGEL Agilent 3100 fractionator (Agilent Technologies, Waldbronn, 
Germany) was used. A modified method was applied by addition of 1 M urea to the buffer sample and 
rehydration buffer, instead of 5% glycerol only. The commercially available 13 cm IPG dry strips with a linear 
pH gradient ranging from 3-10 (GE-Health care) were used. The strips were rehydrated with 40 µL/well 
rehydration solution in the assembled device for 30 min. 150 µL of the prepared samples were loaded on each 
well, the cover fluid (mineral oil, Agilent technologies) was added onto both ends of the gel strip. The focusing 
methods, OG12PE01, as supplied by the manufacturer was applied for 12 well fractionations. The performance 
of the 3100 OFFGEL fractionator was checked under similar conditions in a separate run by determination of 
the pH using a pH indicator pH 3-10 (Fluka Analytical, Germany). Fractions were recovered and desalted by 
solid phase extraction, to desalt the fractions and to avoid the presence of oil and gel pieces in the samples, 
using C18 Oasis columns. The column was prewetted with 10/90 water/ACN v/v and equilibrated with 95/3/0.1 
water/ACN/FA v/v/v. The samples were eluted with 50/50/0.1 water/ACN/FA v/v/v, freeze dried and  dissolved 
in 100 µL 95/3/0.1 water/ACN/FA v/v/v. The twelve fractions generated from IEF were analyzed in triplicate 
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and duplicate for B-LCL-HHC and B-LCL-JYpp65 cell lines, respectively, with nanoLC-MS/MS.
Next to the peptide IEF separation, two chromatographic separation techniques were applied, strong cation 
chromatography (SCX) and RP-C18 chromatography. For SCX separations, one portion of the eluted peptides 
from the W6/32 column was fractionated with a home-made SCX column (320 µm ID, 15 cm, polysulfoethyl 
A 3 um, Poly LC), run at 4 ul/min. Gradients were run for 10 min at 100% solvent A (100% water/0.1% TFA), 
after which a linear gradient started to reach 100% solvent B (250 mM KCl, 35% ACN/0.1% TFA) in 15 min, 
followed by 100 % solvent C (500 mM KCl, 35% ACN/0.1% TFA) in the next 15 min and remained at 100 % 
solvent C for 5 min, then switched again to 100 % solvent A. Twenty 4 ul-fractions were collected in vials 
prefilled with 100 µl 95/3/0.1 water/ACN/FA v/v/v. 
One portion of the eluted peptides from B-LCL-JY pp65 cell lines was fractionated on a home-made RP 
Reprosil-Pur C18-AQ column (200 µm ID, 3 µm x 15 cm) (Dr. Maisch, GmbH, Ammerbuch, Germany). The 
sample was loaded in solvent A (10/90/0.1 water/ACN/FA v/v/v), and the gradient was run from 0-50% B 
(10/90/0.1 water/ACN/FA v/v/v) in 30 min at a flow rate of 3 ul/min. The samples were taken up in a make-up 
flow of 50/50/0.1 water/ACN/FA at 100 ul/min supplied via a T-piece through the annular space between the 
separation capillary and an auxillary capillary. In this way 45 half a minute wide fractions were collected, 
subsequently freeze dried, and  dissolved in solvent A for analysis by nanoLC-MS/MS.
LC-MS/MS analysis
The  dissolved fractions were analyzed by on-line nano-HPLC mass spectrometry with a system, consisting of 
a conventional Agilent 1100 gradient HPLC system (Agilent, Waldbronn, Germany), described by Meiring et 
al [28], and a LTQ-FT Ultra mass spectrometer (Thermo, Bremen, Germany). Fractions were injected onto a 
home-made pre-column (100 um×15 mm; Reprosil-Pur C18-AQ 3 µm, Dr. Maisch, Ammerbuch, Germany) 
and eluted via in home-made analytical nano-HPLC column (15 cm×50 µm; Reprosil-Pur C18-AQ 3 um). The 
gradient was run from 0% to 50% solvent B (10/90/0.1 water/ACN/FA v/v/v) in 90 min. The nano-HPLC 
column was drawn to a tip of approximately 5 µm and acted as the electrospray needle of the MS source. The 
mass spectrometer was operated in data dependent mode, automatically switching between MS and MS/MS 
acquisition. Full scan mass spectra were acquired in the FT-ICR with a resolution of 25,000 at a target value 
of 5,000,000. The two most intense ions were then isolated for accurate mass measurements by a selected ion 
monitoring scan in FT-ICR with a resolution of 50,000 at a target accumulation value of 50,000. The selected 
ions were then fragmented in the linear ion trap using collision-induced dissociation at a target value of 




    Data analysis
The tandem mass spectra were matched against the International Protein Index (IPI) human database version 
3.87, using the mascot search engine version 2.2.04 (Matrix Science, London, UK)), with a precursor mass 
tolerance of 2 ppm, with methionine oxidation as a variable modification, and a product ion tolerance of 0.5 
Da. For finding post-translationally modified HLA-ligands phosphorylation on serine, threonine and tyrosine 
were allowed, and cysteinylation of cysteine in separate searches. Scaffold software version 3 (www.
proteomesoftware.com) was subsequently used to process the mascot output files and generate spectrum 
reports. Duplicates were removed, and peptides with a best mascot ion score >35 and 8-11 amino acids long, 
were selected for the production of supplemental Table 1. For the immunological examples a best mascot 
score of >20 was selected, and the length was restricted to 8-18 amino acids. Next to the above mentioned 
procedure, Proteome Discoverer 1.3 (Thermo, Bremen, Germany) was used to extract all identified peptides 
from the input *.RAW-files, using the mascot server mentioned above, and calculate their intensity, as reported 
in supplemental Table 1. False discovery rates were as determined by Proteome Discoverer, for the Homo 
Sapiens-extracted Uniprot/SWISSProt database [29] (release 2010_11) (www.ebi.ac.uk) containing 20,259 
protein sequences, and the IPIhuman 3.87 database (www.ebi.ac.uk/IPI/IPIhuman.html) see also supplemental 
Table 2. Icelogo version 1.2 was used to generate the binding motifs as presented in Figure 5 and supplemental 
Figure 1 [30]. The GRAVY index was calculated using http://www.bioinformatics.org/sms2/ protein_gravy.
html. The pIs of the identified peptides were calculated using http://www.expasy.org/tools/pi_tool.html. 
NetMHC 3.2 (http://www.cbs.dtu.dk/services/NetMHC) was used to predict the binding affinity (nM) of the 
identified peptides to HLA-A*0201, HLA-B*0702 and HLA-B*4402. NetMHCpan 2.4 (http://www.cbs.dtu.
dk/services/NetMHCpan) was used to predict the binding affinity of the identified peptides to HLA-C*0501 
and HLA-C*0702. Overall protein turnover values were taken from Cambridge et al. [31]. Phosphosite.org 
[32] (www.phosphosite.org) and Phospho.ELM 8.3 [33] (http://phospho.elm.eu.org) were used to find known 
phosphosites in the identified peptides. NetPhos 2.0 [34] (http://www.cbs.dtu.dk/services/NetPhos) was used 
to predict phosphosites in identified phosphorylated ligands. For the identification of polymorphic peptides, 
the tandem mass spectra were matched against the HSPVdb, a database optimized for finding polymorphic 
peptides [21]. For searching CMV pp65-derived ligands/epitopes in B-LCL-JYpp65, a separate database was 
constructed only containing the DNA sequence of the pp65 protein (NCBI; pp65_AD169_seq with intron 
Human herpesvirus 5, complete genome). For searching EBV-derived epitopes, a separate database was 
constructed containing the DNA sequence of EBV selected from RefSeq database [35] 
(>gi|82503188|ref|NC_007605.1| Human herpesvirus 4 type 1, complete genome). 
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Peptide synthesis
Peptides were synthesized according to standard fluorenylmethoxycarbonyl (F-moc) chemistry using a SyroII 
peptide synthesizer (MultiSynTech, Witten, Germany). The integrity of the peptides was checked using RP-
HPLC and MS. Phospho peptides were synthesized using the building blocks Fmoc-Ser(PO(OBzl)OH)-OH 
or Fmoc-Thr(PO(OBzl)OH)-OH. Couplings of these building blocks were performed identical to normal 
couplings with one exception. A 3-fold excess of N-methylmorpholine was used instead of the routinely 
applied 2-fold excess. 
RESULTS
The peptides constituting the HLA-ligandome
The pool of HLA-peptides eluted from two Epstein-Barr virus-transformed B lymphoblastoid cell lines 
(EBV-B-LCL), either B-LCL-JYpp65 or B-LCL-HHC, is quite complex. From previous experiments a simple 
count of the total number of peaks in the MS1 spectra in all fractions following a first dimension C18-
separation resulted in a number of approximately 30,000. Because of this complexity, multidimensional 
separations were performed to reduce the complexity before mass spectrometric analysis. Three first dimension 
separations were chosen, reverse phase C18 (RP-C18) chromatography, strong cation exchange (SCX) 
chromatography, and peptide isoelectric focusing (IEF), since these are based on a different separation 
mechanism, and most commonly used. The second dimension separation was RP-C18 chromatography 
coupled on-line to the mass spectrometer in all cases. Below the results of the three first dimension separations 
in combination with the second dimension on-line HPLC-MS are compared and discussed.
Peptide isoelectric focusing as the 1st dimension
Before starting our IEF-experiments with HLA-eluted peptides, the separation performance of the OFFGEL 
3100 system was tested using a trypsin-digested cell lysate, using 13 cm IPG strips, pH range of 3-10 (GE-
Healthcare). Separation efficiency was studied as a function of loading. The results were as reported in [36], 
with approximately 83% of peptides present in a unique fraction and 96% present in one or two unique 
fractions , with peptide amounts up to100  ug, confirming the high separation efficiency of the IEF process. 
Peptide loading below 10 μg results in considerable sample losses, which precludes use of IEF for HLA-
ligandome studies of smaller cell amounts. Application of a pH indicator (pH 3 - pH 10) after IEF fractionation 
showed that the low pH side of the strip was not pH 3, but was actually close to pH 4. 
The 12 fractions obtained from the IEF fractionation were analyzed by on-line nanoHPLC tandem mass 
spectrometry, and the tandem mass spectra were matched against the IPI human protein database. The results 
for both B-LCLs are summarized as Venn diagrams in Figure. 1(A & B). As can be seen, analysis of the 
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B-LCL-HHC ligandome yielded 6878 unique 8-11 mer peptides with BMI>35, and the B-LCL-JYpp65 
ligandome yielded 3531 unique peptides. The large difference in the number of peptides found for B-LCL-
JYpp65 and B-LCL-HHC can be largely explained by the additional HLA-molecules expressed on B-LCL-
HHC compared to B-LCL-JY cells. B-LCL-JY is homozygous for the B-allele (HLA-B7*0702) and C allele 
(HLA-Cw*0702), while B-LCL-HHC is heterozygous for the B-allele (HLA-B*0702 and HLA-B*4402) and 
C-allele (HLA-Cw*0501 and HLA-Cw*0702). The additional HLA-molecules can present two additional sets 
of peptides. 
Strong cation exchange (SCX) chromatography as the 1st dimension
Twenty fractions were collected after separation on the SCX-column. These fractions were analyzed, like the 
IEF-fractions, by on-line nanoHPLC tandem mass spectrometry and they were matched against the IPI human 
protein database. The results for both B-LCLs are summarized as Venn diagrams in Figure. 1 (C& D) . Analysis 
of the B-LCL-HHC ligandome yielded 7766 unique peptides (BMI>35) and the B-LCL-JYpp65 ligandome 
yielded 3410 unique peptides (BMI>35). 
Reverse Phase-C18 Chromatography as the 1st dimension
Forty five fractions were collected after separation on the RP-C18-column. These fractions were analyzed, like 
the IEF- and SCX-fractions, by on-line nanoHPLC tandem mass spectrometry and the tandem mass spectra 
were again matched against the IPI human protein database. Analysis of the B-LCL-JYpp65 ligandome yielded 
2725 unique peptides (BMI>35). The results for B-LCL-JY are summarized as Venn diagrams in Figure. 1 (E). 
The B-LCL-HHC ligandome was not measured with the combination of RP-C18 and on-line nanoHPLC.
Combination of the results of IEF, SCX and RP-C18
To get an overview, a non-redundant list of all peptides obtained via the above-mentioned first dimension 
separation techniques was produced. The results are shown as Venn diagrams in Figure. 2. The analysis of the 
B-LCL-HHC ligandome yielded 10,867, Figure. 2 (A) unique peptides (BMI>35) and the B-LCL-JYpp65 
ligandome yielded 6,493, Figure. 2 (B) unique peptides (BMI>35). Combination of the two B-LCL-derived 
peptide lists yields a non-redundant peptide list containing 14,065 members, Figure. 2 (C), of which 11,511 
could be relatively quantified. This is by far the most comprehensive list of HLA-ligands reported to date. A 
complete listing of the HLA-presented peptides, sorted by intensity, is given in supplemental Table S1, 
including the protein name and IPI accession number they are derived from and their intensity in B-LCL-JY 
and/or B-LCL-HHC, the best mascot ion score, the predicted binding affinity by NetMHC, the GRAVY 
hydrophobicity value, the protein half-life, the copy number per cell calculated from the intensity and work-up 
yield, the peptide length and if peptides are present in the IEDB [37] and/or SYFPEITHI database [38], and 
the calculated FDR using the Uniprot/SWISSProt database and IPIhuman database. In addition, we compared 
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our data with those reported by [7-10].
The NetMHC algorithm was used to predict the HLA-binding affinity of the ligands. It is clear from the results 
that the majority of peptides is a binder in its particular HLA-molecule, see supplemental Table S1. In the table 
a NetMHC cut-off score of 1000 was used.
The number of peptides found in every experiment, independent of the work up procedure, is 835 of which 
770 could be quantified, Figure. 2 (B). Because of the shotgun nature of the experimental approach these 835 
peptides are expected to be the most abundant on average, the peptides detected in either overlap of 2 
experiments to be less abundant, and the peptides detected only in a single first dimension experiment to be 
the lowest. This was checked for the peptides presented on B-LCL-JY and the result displayed in Figure. 3. 
Peptide length distribution
Our large set of peptides allows a closer look at the length distribution of peptides constituting the HLA-
ligandome, as presented in Figure. 4. As can be seen, most ligands have a length of 9 amino acids, while a 
substantial part is either 10 or 11 amino acids long. The 8-mers, and 12-14 mers are all below 5%. However, 
still 708 long (>11 amino acids) peptides (amounting to 5% of the ligandome) are present, having the correct 
anchors for binding to the HLA-A and B alleles. Figure. 5 shows the HLA-A2 binding motif for the 9, 12 and 
14-mers. All different peptide lengths display the same binding motif, and a binding motif can still be discerned 
for 15-mers. 
The dynamic range of the HLA-ligandome
To get an impression of the dynamic range of the presented peptide repertoire, the intensities of the presented 
peptides in the ligandome were determined. To this end, the *.RAW-files were processed in Proteome 
Discoverer.
A complete listing of all peptides, including their intensity, presentation on the particular B-LCL, and its best 
mascot ion score is given in supplemental Table S1. Intensity extremes, expressed as peak area values in PD, 
range from 4E9 to 1E5, but the majority ranges from 1E9 to 1E6, a range of a factor of 1000. So the dynamic 
range of the peptide repertoire is quite high.
The summed intensity (integration value) of all peptides eluted from 2E10 B-LCL-JY or B-LCL-HHC cells is 
approximately 3E11, as reported by Proteome Discoverer (PD), see supplemental Table S1. To determine to 
what amount of peptide this number corresponds, we followed the same analytical procedure with a known 
amount of a mix of 20 synthetic peptides. An integration value of 1E8 as reported by PD corresponds to 1 
pmol. From this we determine the total eluted peptide amount to be 3 nmol (3E11/1E8). 
The composition of the ligandome can also be represented in terms of relative intensity of the peptides, as 
shown in Figure. 6 (A). The intensities have been translated to copy number in Figure. 6 (B).
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The 14065 HLA-ligands are derived from 7059 different proteins, a graphical representation is shown Figure. 
7 (A). In Figure. 7 (B) the average protein length is plotted against the number of peptides/protein. The higher 
the protein mass, the higher the number of derived HLA-ligands. 61 proteins are even represented by 10 
peptides or more on the cell surface, with the exceptional case of 29 and 41 peptides/protein. The intensity of 
the peptides derived from the same protein varies greatly, as presented in Table 2.
Physicochemical properties of the peptides comprising the HLA-ligandome
To check if peptide detection depended on the peptide physicochemical properties, with either one of the 
employed first dimension separation techniques, we studied the influence of isoelectric point and hydrophobicity. 
To study the influence of the isoelectric point of the peptide we calculated the theoretical pIs of all identified 
ligands. The calculated pIs ranged from 3.2 to 10.4. When the peptides were assigned to pI-bins as shown in 
Figure. 8 (A), it was immediately clear that ligands with pI extremes migrate out of the pI-strip (since these 
were not detected with IEF as the 1st dimension separation technique, but in contrast were detected using SCX 
and C18 as the 1st dimension separation technique) and are, therefore, lost for detection using IEF. In addition, 
the actual pH at the low pH side of the strip is not 3, but almost 4, which accounts for extra losses experienced 
by application of IEF. Since peptides binding to HLA-B44 are on average more acidic, they are more prone to 
be lost in IEF. Next, we studied the influence of peptide hydrophobicity on the peptide’s chance to be detected. 
To this end we calculated the gravy index of all identified peptides and plotted them in hydrophobicity bins as 
shown in Figure. 8 (B). As can be seen, the distribution of the peptides is evenly spread independent of the 1st 
dimension separation technique employed. The more hydrophilic peptides are slightly disfavored by RP-C18 
as the first dimension separation technique. In summary, peptides with pI extremes might be lost during IEF, 
but, generally the majority of peptides was detected independent of the 1st dimension separation technique 
used. 
The overall quality of the presented HLA-ligandome data
To illustrate that the majority of the peptides reported here was indeed derived from the expected HLA-
molecules, we showed above that these peptides carry the correct anchor residues required for binding. Another 
way to verify the overall quality of the ligandome reported, is to check the predicted binding affinity for the 
HLA-molecule. In addition, the overall physicochemical characteristics of the peptides bound depend on the 
particular HLA-molecule. 
The HLA-binding affinity can be approximated theoretically by the NetMHC algorithm. In Figure. 9, the 
hydrophobicity distribution for HLA-A2, HLA-B7 and HLA-B44 predicted peptides is plotted. The HLA-A2 
presented peptides are centered around a GRAVY value of +1, those from HLA-B7 around 0 and those from 
HLA-B44 around -1. 
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In addition to the overall quality check as described above, we compared our data on the individual peptide 
level with the two main public sources of HLA-ligands, which are the SYFPEITHI-database and the Immune 
Epitope Database (IEDB). These databases are collections of ligands and/or epitopes that result from different 
immunological experiments on a variety of cell types, and generally not fed by proteomics-type of experiments 
but by individual immunological reports. To compare our peptide lists with the SYFPEITHI-database we 
selected the reported HLA-A2, HLA-B7 and HLA-B44 ligands and compared it to our eluted peptide sequences. 
In addition, we compared our results with the peptides presented in the papers by K.E. Scull et al. on B-cells 
[7], N. Hillen et al. on HLA-B44 supertypes on B-cells [8], D. Granados et al. on B-cells [9] and C. Bade-
Doeding et al. on B-cells [10] The results of this comparison are shown in supplemental Table S1. 
We found 253 of the 784 ligands described in the SYFPEITHI database, and 72 out of 263 ligands described 
in the IEDB. Out of cumulative 1179 (8-11 mer) selected HLA-A2 ligands recently published by Scull et al. 
889 were found in our dataset [7]. 
Immunological and biological values
Below a number of immunologically relevant ligands are described. These include minor histocompatibility 
antigens and virus-derived epitopes.
MiHA
Minor histocompatibility antigens (MiHA) are peptides derived from polymorphic proteins and are relevant 
in allogeneic hematopoietic stem cell transplantation (HSCT) as targets for immunotherapy for the treatment 
of hematological malignancies [2, 13, 39-42]. 
To find and identify polymorphic peptides in the eluted peptides from B-LCL-HHC and B-LCL-JYpp65 cell 
lines the tandem mass spectra were matched with a dedicated database, HSPVdb [21]. We found 1439 
polymorphic peptides of 8-11 mer length and mascot ion score >35, accounting for 10% of the number of 
peptides in the ligandome. 6 out of 16 MiHA and 4 allelic counterparts of known minor antigens, which could 
potentially be present on our cells, considering the SNP-typing of the B-LCL were found in our eluted dataset 
which was confirmed by matching the MS/MS spectra of the synthetic peptides with the eluted peptides. These 
peptides are listed in Table 1. It should be noted that 3 out 10 of the peptides listed have a BMI<35, but were 
correctly identified. 
Virus-derived peptides
Since EBV-transformed cell lines were used in this study, our tandem mass spectra were matched with a 
specific database containing the genomic EBV information. Four EBV peptides were found in our data, see 
supplemental Table S3. The binding affinity of the newly identified peptides was predicted using NetMHC. 
Two peptides displayed high binding affinity for HLA-A2 and the other two showed a high binding affinity for 
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HLA-B7. The correct identification of these four peptides was confirmed by matching the tandem mass spectra 
of the eluted peptides with their synthetic counterparts. These four EBV-derived peptides have not been 
reported before. 
The B-LCL-JY cell line used in this study was transduced with the CMVpp65 protein, which gave us the 
opportunity to study the presentation of CMVpp65-derived ligands. To identify pp65-derived ligands, we 
matched the tandem mass spectra with a specific database containing the pp65 sequence. We could find two 
known pp65-derived epitopes, see supplemental Table S3. One epitope is presented in HLA-A2, the other 
Figure 1. Venn diagrams of identified HLA-ligands per separation. The number of identified unique 
peptides per mass spectrometric replicate for IEF (A), SCX (C) and RP-C18 (E) for cell line B-LCL 
JYpp65. IEF (B) and SCX (D) for cell line B-LCL HHC. The area of the circles corresponds with the 
number of peptides. Total, fractional and overlapping numbers of unique peptides are indicated.
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epitope is presented in HLA-B7 [26]. Again the identification of these two epitopes, with BMIs of 28 and 12, 
was confirmed by matching the tandem mass spectra of the eluted peptides with their synthetic counterparts. 
In summary, we identified four new EBV-derived ligands peptides and two known epitopes derived from the 
transduced CMVpp65 protein. The EBV peptides might be candidates for new EBV epitopes. It is important 
to note that low scoring peptides should not be discarded lightly in this field of application, without checking 
their functional relevance.
Independent immunological testing in combination with the synthesis of good candidates provides a good 
strategy to exclude false positive identifications without losing the immunologically relevant false negative 
identifications.
Together, the above clearly illustrates that our list of ligands harbours immunologically relevant peptides, 
suggesting that many more relevant peptides are in this list.
Post-translationally modified HLA ligands
The presentation of post-translationally modified peptides has been reported before [22, 24, 43], although not 
in large numbers. Therefore, we investigated our tandem mass spectra for the presence of phosphorylation of 
serine, threonine and tyrosine, or cysteinylation of cysteine residues, since both modifications have been 
Figure 2. Venn diagrams of cumulative number of identified HLA-ligands. Cumulative number of 
identified unique peptides per cell line for B-LCL HHC (A) and cell line B-LCL JYpp65 (B). Cumulative 
number of identified unique peptides for B-LCLs JYpp65 and HHC (C). The area of the circles 




reported to influence T cell recognition [23, 43].
Aberrant phosphorylation has been implied in cancer. Inclusion of phosphorylation in our database matching 
process yielded 451 phosphopeptide hits of lengths 8 to 11 amino acids with a BMI>35 (phosphorylation on 
anchor positions was not allowed), of which 221 were estimated to be correctly identified, see supplemental 
Table S4 and discussion. Similarly, a cysteinylated cysteine as PTM was set as a modification in the database 
matching, which resulted in 1221 identified peptides with a cysteinylated cysteine (cysteinylation on anchor 
positions was not allowed). The peptides are listed in supplemental Table S5. 
Phosphorylated HLA ligands
Inclusion of phosphorylation in the database matching process yielded 451 phosphopeptide hits of length 8 
to 11 amino acids with a best mascot score of greater or equal to 35, as listed in supplemental Table S4. The 
distribution was as expected: 267 on serine, 154 on threonine and 30 on tyrosine. Most peptides were singly 
phosphorylated, 13 peptides were doubly phosphorylated. 
To evaluate if these phosphopeptides were properly assigned we compared our results with previously 
reported phosphopeptides at Phosphosite.org (http://www.phosphosite.org). This yielded 72 hits. Phospho.ELM 
8.3 (http://phospho.elm.eu.org) yielded 38 hits, all of which were also present in phosphosite.org. Next we used 
Figure 3. Shotgun nature of the experiment. The weighted intensity distribution of the peptides found 
in the various regions in the Venn diagrams of Fig. 2B. Three regions were defined (X-axis): (1) 
peptides found in only a unique first dimension separation technique (i.e. the ‘outer’ regions), (2) 
peptides found in either of two overlapping regions, and (3) peptides always found irrespective of the 
first dimension separation technique. Average peptide intensity increases from region 1 to 3, as 
expected in a shotgun-type of proteomics experiment. The median peptide intensity is indicated.
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NetPhos 2.0 to predict phosphosites in the peptides, which resulted in 83 phosphosites, of which 28 overlapped 
with the 72 phosphosites detected with the two other sites mentioned above. In total 127 out of 451 
phosphopeptides with either a known or predicted phosphosite were found. 
As shown in Figure. 7 proteins can be represented by several peptides in the HLA-ligandome. Here three 
proteins were chosen that are represented by 7, 5 and 5 peptides in HLA in B-LCL HHC. As can be seen these 
peptides can be presented by different alleles, have greatly differing hydrophobicity. Importantly, peptides 
derived from that same protein have greatly differing abundance. So, the abundance of a HLA-ligand derived 
from a certain protein does not simply correlate with its protein intensity.
To confirm the identification of the phosphorylated peptides in our dataset we chose to synthesize a selection 
of peptides and compare the synthetic phosphopeptides with their eluted counterparts. 26 peptides were 
selected, of which 9 peptides with a known phosphosite or predicted phosphosite and 17 peptides without a 
known or predicted phosphosite with varying phosphorylation position in the peptide sequence and different 
mascot ion scores. These were synthesized and the MS/MS spectra of these peptides were matched with their 
eluted counterparts. The 9 peptides with a known or predicted phosphosite appeared to be correctly identified. 
Figure 4. Peptide length distribution of the HLA-ligandome. Of note are the longer peptides and 
the relative high number of HLA-B7 binding peptides of 8-mer length, and the relatively wide 
spreading of HLA-B44 binding peptides over 9-11 amino acids length. Number of 13-mers 
approximately 80 per allele and 14-mers approximately 20 per allele.
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Of the other 17 peptides without known of predicted phosphosite, 29 % (5 out of 17) were found to be correctly 
identified. 
First the 127 hits found in our study and which were also either known from previously identified proteomics 
studies or predicted, were extrapolated to be correctly identified, leaving (451-127)= 324 hits. Of these 324 
hits 29% (=94 hits) was extrapolated to be correct. Therefore, we estimate that 221 out of 451 (49%) have been 
correctly identified.
Cysteinylation of HLA ligands
To find peptides with a cysteinylated cysteine as PTM in our eluted dataset we searched the dataset obtained 
from B-LCL-HHC and B-LCL-JYpp65 cell lines with variable modification on cysteinylation (+119 Da). We 
found 1221 identified peptides with cysteinylation, see supplemental Table S5. Since the binding affinity of 
the peptides probably does not change due to cysteinylation we used NetMHC server to check the binding 
affinity of these peptides. The vast majority was predicted to bind to either HLA-A2 (594), HLA-B7 (143) or 
HLA-B44 (294).
Figure 5. Binding motif of various HLA-A2 
length variants. Icelogo plots of HLA-A2 
binding peptides of 9-mer (N=3302), 12-
mer (N=137), and 14-mer (N=17) length. 
Peptides of different length clearly display 
a similar binding motif.
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DISCUSSION
The quality of the data
The quality of the elucidated ligandome was checked on three independent levels. First, by application of false 
discovery rates. Second, by consideration of chromatographic criteria in combination with the correct 
distribution over physical parameters. Third by the predicted binding strength. Additionally, the presence of 
biologically relevant peptides illustrates the good quality of our dataset, but these peptides will be discussed 
separately. 
Mass spectrometry in HLA-ligandomics and choice of false discovery rates
HLA-presented peptides arise from the complex antigen processing process, involving many enzyme 
specificities. Therefore, enzyme restriction during the database matching process is not possible, leading to a 
large increase in database search space. The best way to reduce the number of falsely identified peptides is to 
apply a strict precursor mass tolerance of 2 ppm, which was achieved by including a SIM scan in the FTMS-
measurements. Strict application of a tight FDR of 1%, or even 5%, as in trypsin-based proteomics experiments, 
leads to loss of a wealth of valuable peptides (false negatives) as we will illustrate below. To our opinion this 
is unacceptable in immunological workflows. We have chosen for a BMI>35, which we know from experience 
Figure 6. Occupation of the ligandome. The 
intensity distribution of peptides constituting 
the ligandome is shown for B-LCL JYpp65. 
(A) The outer rim of the pie chart displays the 
percentage occupation of the HLA-ligandome 
and the number within each pie segment is 
the number of unique peptides in that 
segment  Of the total number of 6,500 
identified peptides, the top 5 abundant 
proteins occupy 6% of all HLA molecules. 
The top 50 abundant peptides occupy 27% of 
all HLA-molecules, etc. Note that the lowest 
abundant 5,500 peptides occupy only 17% of 
all HLA-molecules. (B) The numbers in (A) 
have been converted to copy number, i.e. the 
number of ligands per cell. The outer rim of 
the pie chart displays the number of unique 
peptides and the number within each pie 
segment is the average copy number for the 
peptides in that segment The top 5 abundant 
peptides are on average present with 16500 
copies on the cell surface. Peptides 5-50 are 
on average present with 5700 copies, etc. 
The average copy number of the lower 
abundant peptides is 43, the very lower 
abundant peptides are present at copy 
numbers close to 1 or even less.
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is a decent starting cut-off. Many known immunologically relevant peptide ligands are still found far below 
this limit. In supplemental Table S1, we listed peptides with a BMI>35, but also indicated below what FDR 
percentage the peptides are, after searching either the smaller SWISSProt (homo sapiens) or the larger 
IPIhuman database. We included 1%, 5% and 10% FDR. The results of these searches and the effect of the 
different search conditions is summarized in supplemental Table S2. A 10% FDR has e.g. been applied by 
Dudek et al. in a HLA class I-peptidomics-based study [44]. An FDR of even 37% has been used in a HLA-
class II-based peptidomics study by Chornoguz et al. [45]. Importantly, in targeted immunological approaches, 
i.e. searching for ligands/epitopes or post-translationally modified epitopes derived from a specific antigen, we 
advise not to use a strict statistical cut-off score, be it a BMI or a false discovery rate during the first discovery 
phase. In the next step first round ‘hits’ should be tested independently, be it by MS/MS analysis of the 
synthetic candidate epitope or by a biological assay, e.g. a T cell activity assay. As illustrated by the BMI 
scores < 35 for 3 out of 10 validated MiHA (and 6 out of 10 with BMI<39), and both CMV peptides, with one 
CMV peptide having a BMI of 12 (!), low scoring peptides should be prevented from being assigned as false 
negatives. It is important to note that initially wrongly assigned peptides will immediately be filtered out by 
immunological follow-up experiments. Next to the MS-methodology available, additional non-MS checkpoints 
were applied to estimate the value of a peptide, see below.
Figure 7. Representation of proteins in the HLA-ligandome. (A)This figure depicts the number of 
proteins as a function of the number of peptides identified per protein. HLA-ligands derived from 7059 
unique proteins are in our dataset. In our dataset about 50% of the proteins is represented by 1 
peptide, 20% is represented by 2 peptides, 10% is represented by 3 peptides, and so on. As can be 
seen there is a gradual decrease in the number of peptides by which a protein is represented. Up to 
41 peptides/protein are present in our dataset. (B) The protein length is depicted as a function of the 
number of peptides by which the protein is represented in HLA. The number of peptides in HLA of a 
protein correlates well with its protein mass.
A B
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Chromatography and physicochemical properties
Sample (pre)treatment might inadvertently favor peptides with certain physicochemical properties. Therefore, 
we checked the distribution of our peptides over the hydrophobicity scale (GRAVY index), see Figure. 8 (B) 
and pI scale, see Figure. 8 (A). The peptides were evenly distributed, so sample pretreatment has not favored 
peptides on the basis of their physicochemical properties. However, peptides at the pH extremes of the IEF 
strips were lost. It appeared that the real pH range of the strips is not 3-10, but instead are closer to pH 4-9, 
which explains their loss. The  hydrophobicity distribution of the peptides is shown in Figure. 9 for peptides 
eluted from each of the three alleles used in this study. The centre of the hydrophobicity distribution is clearly 
shifted to the hydrophobic side for HLA-A2, and shifted to the hydrophilic side for HLA-B44. The HLA-B7 
peptides are at intermediate hydrophobicity. This is in perfect agreement with the general notion that HLA-A2 
presented peptides are more hydrophobic [46], while HLA-B44 derived peptides are hydrophilic and HLA-B7 
peptides have intermediate hydrophobicity [47-50]. The relative position of the hydrophobicity distributions 
supports the correct overall assignment of the ligandome.
In addition to the identification of the peptides we determined their relative intensity. From the shotgun nature 
of the experiments, peptides found in three experiments (the 835 peptides found Figure. 2 (B) are expected to 
have a higher intensity than those peptides present in only one experiment. The results as shown in Figure. 3 
clearly illustrate that this is the case in our experiments. 
A B
Figure 8. HLA-ligandome physicochemical properties. (A) Distribution of HLA-peptides over the pI range as a 
function of the first dimension separation technique used. As can be seen IEF, SCX en RP-C18 do not discriminate 
for peptides based on their theoretical pI. The only exception is that peptides with low pI are clearly underrepresented 
in the IEF process. This is caused by the actual pI in the pI 3-10 strips, which in fact appear to be pI 4-10, as also 
independently checked with a pH-indicator after isoelectric focusing. (B) Distribution of HLA-peptides over the 
hydrophobicity range depending on the first dimension separation technique used. As can be seen IEF, SCX en 
RP-C18 do not discriminate for peptides based on their hydrophobicity. The above plots illustrate our HLA-ligandome 




Because of the large number of peptides found, peptide identities cannot be verified by MS/MS of their 
synthetic counterpart. Alternatively, the NetMHC algorithm was used to predict binding affinity. As can be 
seen in supplemental Table S1 the large majority of our reported peptides has a low NetMHC score, i.e. is 
predicted to be a (strong) binder. Although at the NetMHC-website a score <50 is considered a strong binder 
and between 50 and 500 a weak binder, from our experience with known epitopes, we know this value is too 
strict. 
From the mass spectral quality, the distribution of physicochemical parameters, the expected shotgun 
distribution, in which the overlapping regions in the Venn diagram represent the most abundant peaks and the 
excellent binding affinity we are convinced that the sample pretreatment and mass spectrometric analysis have 
not resulted in skewing of the identified ligandome as a whole. The fact that many known biologically relevant 
peptides are found is another strong indication of the high quality of our ligandome. 
Ligandome characteristics
Our large dataset opens up opportunities to discuss a number of properties of the HLA-ligandome. It is 
important to realize that the peptides we report here are the survivors of the intracellular processing. Therefore, 
this listing is valuable for studies on antigen processing, to all in silico studies on ligand/epitope definition and 
the definition of antigen processing rules. In addition, it can be used to look up if peptides from specific protein 
antigens can survive the intracellular processing and are presented on the cell surface. Thus, it provides an 
indirect view of cellular processes. Many more peptides are probably presented in HLA-molecules, but may 
escape detection because of low abundance and/or a relatively low sensitivity in the electrospray ionization 
process.
The Venn diagrams of Figure. 2 still display relatively large regions unique to either 1st dimension separation 
technique, which shows that many peptides are just detected, or may still escape detection. Although the 
Figure 9. Allele-specific distribution of HLA-
peptides over the hydrophobicity range. These 
plots show a clear average hydrophobicity shift 
going from HLA-B44 (most hydrophilic, median 
gravy-index of -0.84) via HLA-B7 (median gravy 
index of -0.08) to HLA-A2 (median gravy index of 
0.64). The positions of the three distributions are 
as expected and illustrate the overall quality of our 
dataset.
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ligandome presented here is the most comprehensive report to date, we interpret the occurrence of many 
unique peptides in a single type of ‘precursor dimension’ as a strong indication that the HLA-ligandome must 
contain many more peptides than we report. This notion is supported by our experience with 3- and 4-dimensional 
separations before MS-analysis in the classical forward approach to find T cell epitopes. Every additional 
chromatographic dimension yields peptides, not detected in ‘precursor’-dimensions, indicating that a significant 
part of the presented HLA-ligandome still goes undetected. Based on the current listing of 14,000 peptides, 
the many false negatives, i.e. correct peptides with a BMI<35 and the peptides going undetected, we estimate 
the HLA-ligandome to comprise at least 3 times more peptides, i.e. at least 50,000 members.
Binding motif and peptide length
The ligandome contains a sizeable fraction of unusually long peptides for HLA class I binding. We found 5% 
of the peptides to be longer than 11 amino acids. This is in line with the results of Scull et al. on a smaller set 
of HLA-A2 peptides [7]. 
 In supplemental Figure 1 the Icelogo graphs show the HLA groove can accommodate at least up to 
14-mers. Peptides need to bulge out of the groove considerably to accommodate the extra amino acids between 
the fixed anchors at position 2 and the C-terminus, as beautifully shown by crystallographic data [51]. Our 
Table 1. MiHA. Listing of known MiHA and allelic counterparts of known MiHA identified in our data set 
by searching the HSPV database (16), illustrating that immunological relevance of our dataset. In 
addition several potential MiHA are present in our dataset, which form the basis for finding new clinically 
relevant MiHA.
Gene name HLA type Peptide sequence Eluted cell line BMI
HA-2V A*02:01 YIGEVLVSV B-LCL-JY, B-LCL-HHC 50
HA-8R A*02:01 RTLDKVLEV B-LCL-JY 34
LB-SSR1-1S A*02:01 VLFRGGPRGSLAVA B-LCL-HHC 29
SSR1-1L* A*02:01 VLFRGGPRGLLAVA B-LCL-JY 37
LB-ERAP1-1R B*07:02 HPRQEQIAL B-LCL-JY, B-LCL-HHC 36
LB-GEMIN4-1V B*07:02 FPALRFVEV B-LCL-JY 43
SMCY-B7 B*07:02 SPSVDKARAEL B-LCL-JY 58
EBI3-1V* B*07:02 RPRARYYVQV B-LCL-JY, B-LCL-HHC 26
PDCD11-1L * B*07:02 GPDSSKTLLCL B-LCL-JY 39
ACC-2G * B*44 KEFEDGIINW B-LCL-HHC 81
* allelic counterpart of known MiHA
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data on the peptide length distribution, Figure. 4, underline the need to take into account longer peptides in the 
search for epitopes, both in practical MS-based strategies and in silico prediction approaches. 
Intensity, dynamic range and number of peptides of the ligandome
The total peptide intensity (sum of all identified peptide intensities) of both cell lines was similar, and amounts 
to 3 nmol of total eluted peptide), which corresponds to approximately 3 ug of peptides. Our experience from 
previous elutions is that the amount of isolated HLA after immunoaffinity precipitation (IP) is 150-200 ng 
HLA/1E6 B-LCL-JY cells, which is in line with the independently reported amount of 150 ng/1E6 cells [52]. 
Therefore, assuming 150 ng/1E6 cells, a yield of 3 mg HLA/2E10 cells, corresponding to 60 ug of peptides 
was expected. Therefore, the overall work-up efficiency is about 5%. From the above the copy number (ligands 
per cell) can easily be calculated. These numbers are shown in supplemental Table 1. Intensity extremes, 
expressed as peak area values in PD, range from 4E9 to 1E5, so the dynamic range of the peptide repertoire is 
quite high. Considering that the lowest intensity ligands are most prone to go undetected, the actual dynamic 
range is probably even higher. This translates to a range from 24,000 copies/cell to (<)1 copy/cell. Clearly the 
chance of a protein being represented by a peptide in the ligandome varies enormously. 
 Of cells available in limited amount, e.g. DCs, the ligandomes have been studied of only (!) a few tens 
of millions of cells [53, 54].The number of identified ligands, however, is low (a few hundreds). Considering 
the large dynamic range as discussed above, it is intrinsically impossible to find the relatively low intensity 
ligands using small cell populations for full ligandomics experiments. An inventory of the possible ligandome 
on a large scale followed by MRM [55] on the selected small population might be a fruitful approach. However, 
‘more is better’ definitely seems to apply to HLA-ligandomics.
The composition of the ligandome in terms of relative intensity of the peptides is shown in Figure. 6. 
Interestingly, it appears that in B-LCL JYpp65 the 5 most abundant peptides already ‘fill’ 6% of the HLA 
molecules. The top 50 abundant peptides ‘fill’ 27%, the top 300 ‘fill’ 59% and the top 1000 ‘fill’ 83%. 
Importantly, this leads to the observation that all other ligands, i.e. approximately 5,500 peptides, fill the final 
17%, as shown in Figure. 6 (A). The intensities have been translated to copy number in Figure. 6 (B).
The 14,065 HLA-ligands are derived from 7,059 different proteins, a graphical representation is shown in 
Figure. 7 (A). Half the proteins is represented by 1 peptide while the other proteins are represented by more 
peptides. A gradual decline in peptide number/protein is seen. In Figure. 7 (B) the average protein length is 
plotted against the number of peptides/protein. 61 proteins are even represented by 10 peptides or more on the 
cell surface, with the exceptional case of 29 and 41 peptides/protein. The longer the protein, the more ligands 
are derived from it. It also appeared that the position of the ligands in their ‘precursor’ proteins is evenly 
distributed (data not shown). In addition, the intensities of the ligands derived from the same protein can differ 
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greatly, see Table 2 for a few examples, which makes it impossible to predict ligand copy number from overall 
protein copy number. This is in line with previous work on correlation between mRNA/protein expression and 
ligand density on the cell surface [56]. Furthermore, no correlation could be found between peptide intensity 
and binding strength to HLA. The former observations may seem logical, but these imply that there is no clear 
selection on the basis of protein properties during antigen processing. In fact, every part of the proteome seems 
equally suitable for sampling by the HLA-molecules. Selection of particular ligands takes place at another 
level, namely the binding affinity to the available HLA-molecules
From our peptide listing it is tantalizing to speculate on the origin of HLA-presented ligands and the cellular 
processing machinery and distill a glimpse of the cellular protein processing landscape. A courageous effort 
based on a rather limited data set has been made to describe the presence of peptides in relation to their 
corresponding protein turnover in terms of protein stability, DRiPs and SLIPs [57]. Studies on the scale as 
presented here might be required to provide a better view at the origin of HLA-presented peptides. 
Protein turnover times, as in supplemental Table S1 cannot be correlated with HLA-ligand intensity. This lack 
of correlation might be seen as reinforcement of the DRiPs hypothesis [58]. Pulse chase experiments have 
shown that some HLA-presented peptides make it to the cell surface within 30 minutes of the pulse [57]. A 
general predictive description of the route from protein to its presented peptides in the HLA-ligandome is 
disturbed by the many underlying processes leading to antigen presentation, (transient) protein abundance, 
HLA-peptide complex stability and re-internalization of HLA-peptide complexes. Compartmentalization and 
multiple sources of peptides, and a subset of rapidly degraded polypeptides (RDPs) have been suggested to be 
needed to get a grip on the intricate antigen processing pathways [58]. However, the final result of the complex 
cellular protein machinery is the representation of virtually all proteins on the cell membrane. In this way all 
cellular proteins are under the scrutiny of T cell surveillance.
The biological value
Our reversed immunology approach based on the bona fide eluted ligandome was started to explore its 
possibilities for finding T cell epitopes. The above were global observations and considerations concerning the 
ligandome. Below the focus is on the immunological value of the data contained in our data set. 
Comparison with sources of known epitopes
First we looked for known epitopes contained in the International Immuno Epitope Database, and the 
SYFPEITHI database for HLA-A2, HLA-B7 and HLA-B44. Comparison showed that 50% and 29% listed in 
the IEDB and SYFPEITHI database, respectively, were found in our ligandome, as indicated in supplemental 
Table S1. Considering that both the IEDB and the SYFPEITHI databases are a collection of ligands from 
many studies on a variety of cells, the biological value of our data set is clearly demonstrated. In addition, 
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there are probably many more epitopes in our list, which are to be explored in the field of immunology. 
MiHA
The first category of biologically important T cell epitopes are the minor histocompatibility antigens, important 
in the treatment of hematological malignancies. Analysis of the data set, using our in house developed human 
short peptide variation database (HSPVdb) [21], led to the identification of approximately 1,400 polymorphic 
ligands. Among these were known MiHA, underlining the possibilities of our proteomics approach to find 
MiHA. From the set of 1400 polymorphic peptides 80 were selected for further study to investigate their 
potential for medical application. The details of the selection method and the immunological follow up will be 
described in detail elsewhere. The total length of all proteins in Refseq release 46, expressed in base pairs (bp), 
is 56,113,216 bp. The total number of non-synonymous SNPs and in/del within a coding sequence (CDS) is 
296,901. Thus the chance that a nucleotide is polymorphous is 0.5%. Therefore, for a 10-mer peptide (30 
nucleotides), the chance of not containing a SNP is (0.995)30 is 0.86. Therefore, the chance of a 10-mer peptide 
containing at least one polymorphic amino acid is 14%. The number we experimentally found is 10%, so of 
the same order as the theoretical number. From our data there is no reason to suspect that polymorphic peptides 
represent a ‘special case’. The same conclusion was drawn in the recent paper by D. Granados et al. on B-cells 
[9].
Virus-derived peptides
The antigen presenting cells in this study were EBV-transformed, and B-LCL-JY was also CMVpp65 
transduced. Therefore, the presence of EBV- and CMVpp65-derived peptides was checked in our ligandome, 
and the results listed in supplemental Table S3. Four EBV-derived ligands and 2 CMVpp65 derived epitopes 
were found. All identifications were checked by comparison of the tandem mass spectra to those of their 
synthetic counterparts. All four EBV-derived ligands were newly found. 
We expected that most of the previously reported EBV epitopes would not be detected, since HLA-A2 and 
HLA-B7 restricted T cell clones isolated from EBV seropositive individuals and specific for the different EBV 
proteins BZLF-1, BRLF-1, and EBNA-3A are not reactive or low reactive against HLA-A2 and HLA-B7 
positive EBV-LCLs, whereas the T cell clones are reactive when the genes encoding these proteins are 
additionally introduced into EBV-LCLs. These results indicate that the published EBV epitopes are not or 
hardly presented by EBV transformed B cells, and therefore it is very well possible that these peptides were 
not detected in our elutions from HLA of the EBV-LCLs. The reason why these epitopes are not efficiently 
processed and presented is most likely due to the fact that only a minority of the cells in the EBV transformed 
cell lines is in a lytic cell cycle state.  The four epitopes described in the manuscript are derived from other 
EBV proteins: BGLF4, RPMS1 (derived from an alternative reading frame) and EBNA3B/C and HS4ENVGP 
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(the latter two both derived from the UTR), and are indicated in supplemental Table S3. CMVpp65 specific 
HLA-A2 restricted T cells (peptide NLVPMVATV (found)) and CMV-pp65 specific HLA-B7 restricted T cells 
(peptides RPHERNGFTV (found) and TRPVTGGGAM (not found)) efficiently recognize pp65 transduced 
EBV-LCLs, indicating that the three pp65 peptides are processed and presented in HLA-A2 and HLA-B7. 
Two out of the three peptides were detected in our study, whereas one peptide was not. The exact reason why 
we did not detect this particular peptide is unknown, but this peptide may have a low expression or may have 
been missed due to the shotgun nature of the experiment. 
Together, the presence of the IEDB matching peptides, the MiHA, and the virus-derived peptides in our list 
proves the relevance of our peptide listing for immunological research. The fact that not all previously reported 
epitopes were found in our analysis illustrates that still a considerable fraction of the ligandome goes undetected.
Post-translationally modified ligands
Inclusion of phosphorylation and cysteinylation as a PTM in the database matching process yielded 
approximately 221 phosphorylated ligands and 1221 cysteinylated ligands. Previously 36 and 18 HLA-A2 and 
8 HLA-B7 phosphorylated peptides were reported by Zarling et al. [22, 43] and Meyer et al., [24] respectively. 
15 peptides of these overlap with our dataset. In summary, 2 out of 150 ligands in our study are phosphorylated. 
Many cysteinylated ligands were identified. The total number of cysteine-containing (modified and unmodified) 
peptides is 1386, which represents 9% of all peptides (15286). The frequency of cysteine in the Swissprot 
human database is 2%. Therefore, we calculate the chance of a peptide ligand containing a cysteine residue to 
be 15% and 13% for a 10-mer (1-(0.98)8=0.15) or 9-mer (1-(0.98)7=0.13) ligand respectively (we excluded the 
two anchor positions for this calculation because cysteine is not favorable at anchor positions). 9% of our 
peptides contain a cysteine residue. Scull et al. find a cysteine residue in 4% (50 out of 1179 unique 8-11 mer 
peptides) of their identified peptides [7]. The numbers indicate that we are close to the theoretically expected 
number of cysteine-containing HLA-ligands. Whether the cysteinylation has occurred in vivo or in vitro, the 
identified cysteine-containing peptides are true identifications. Since there is no suitable criterion for (de)
selecting biological relevance of these cysteinylated peptides we do not wish to discard these true identifications. 
Both phosphorylation and cysteinylation have been shown to play a role in T cell recognition [23, 24, 43]. The 
number of phosphorylated HLA-ligands described here is by far the largest reported to date. Considering we 
did not apply a specific phosphopeptide-directed work up procedure, such as described in [59], we expect a 
considerably larger number of phosphorylated ligands to be presented. Other PTM, not included in this study, 
will certainly raise the number of post-translationally modified ligands. 
In summary, our in-depth HLA-ligandome study enabled a detailed look at antigen processing and provided 
relevant ligands. From the presented data we estimate the ligandome to comprise at least 50,000 ligands. 
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Considering the above number and the average number of peptides per protein being between 2 to 3, the 
intracellular peptide pool generated by protein breakdown, represents most, if not all, proteins, which seems 
the perfect way to present the cellular state on the outside of the cell for immune surveillance. Overall, every 
part of the proteome seems equally suited for sampling by the HLA-molecules, although even the abundance 
of peptides from the same protein varies greatly. The final composition of the ligandome is determined by the 
enzymes involved, the transporter associated with antigen presentation (TAP), the location of a particular 
protein, and the relative contribution of DriPs for a given protein. The available HLA-molecules select “what 
fits them best”. Overall this process leads to ‘delegates’ from many proteins (5,000 found for B-LCL-HHC) in 
our set. 
A rich and diverse repertoire of ligands is presented to the immune system, including a considerable number 
of post-translationally modified ligands, an additional 10% is derived from polymorphic peptides and 5% is 
>11 amino acids.
We have shown that the ligandome presented here can be a good starting point to solve a wealth of specific 
immunological questions. Our large list of peptides presented here fits in the efforts towards a human 
immunopeptidome project [25]. 
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Table 2. Peptide intensities derived from the same protein. Intensity of different HLA-presented 
peptides from some selected proteins. 







Isoform 1 of Clathrin 
heavy chain 1
NENSLFKSL 7.6E+7 B44 59 359 -0.622
NPASKVIAL 2.6E+7 B7 51 13 0.7
AEELFARKF 2.3E+7 B44 39 351 -0.267
EEAFAIFRKF 6.4E+6 B44 47 17 0.11
AETGQVQKI 5.3E+6 B44 41 671 -0.556
FVHDLVLYL 3.3E+6 A2 41 13 1.622
LLMVLSPRL 1.1E+6 A2 43 16 1.6
Mediator of RNA 
polymerase II 
transcription subunit 24
SLVEQLTMV 2.0E+7 A2 70 12 1.044
SPTDRSMSSSL 1.9E+7 B7 56 10 -0.782
KERWSDYQW 6.4E+6 B44 36 123 -2.533
AEQMHKTGF 3.6E+6 B44 53 594 -0.967
SLMDPPGTAL 1.3E+6 A2 35 31 0.27
Isoform 1 of Dedicator 
of cytokinesis protein 2
KMWEEAISL 3.4E+8 A2 58 9 -0.067
SPRLSQTFLQL 5.3E+7 B7 52 21 -0.109
IPGMVGPIL 5.2E+7 B7 36 89 1.656
LEAYIQQHF 4.3E+6 B44 39 145 -0.233
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Source Gene name Peptide sequence BMI Allele
EBV EBNA3B/C (UTR) ITAPLLPAV 54 HLA-A2
EBV BGLF4 GLKDAVYFL 46 HLA-A2
EBV HS4ENVGP (UTR) SPLSPmARL 40 HLA-B7
EBV RPMS1 (ARF) APGGGERAL 45 HLA-B7
CMV PP65 NLVPMVATV 28 HLA-A2
CMV PP65 RPHERNGFTV 12 HLA-B7









mascot ion score ≥35 14065
Supplemental Table 1: Summary of the number of identified unique 8-11 mer peptides after searching 
the indicated database with the indicated FDR and/or best mascot ion score >35, and the number of 
overlapping peptides with the listing based on the use of a best mascot ion score of >35. 
Supplemental Table 2: Virus-derived peptides identified, and confirmed by MS/MS of their synthetic 
counterpart, in our dataset. UTR=untranslated region. ARF=alternative reading frame.
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T cell epitopes derived from polymorphic proteins or from proteins encoded by alternative reading frames 
(ARFs)  play  an  important  role  in  (tumor) immunology. Identification of these peptides is successfully 
performed with mass spectrometry. In a mass spectrometry-based approach, the recorded tandem mass spectra 
are matched against hypothetical spectra generated from known protein sequence databases. Commonly 
used protein databases contain a minimal level of redundancy, and thus, are not suitable data sources for 
searching polymorphic T cell epitopes, either in normal or ARFs. At the same time, however, these databases 
contain much non-polymorphic sequence information, thereby complicating the matching of recorded and 
theoretical spectra, and increasing the potential for finding false positives. Therefore, we created a database 
with peptides from ARFs and peptide variation arising from single nucleotide polymorphisms (SNPs). It is 
based on the human mRNA sequences from the well-annotated reference sequence (RefSeq) database and 
associated variation information derived from the Single Nucleotide Polymorphism Database (dbSNP). In this 
process, we removed all non-polymorphic information. Investigation of the frequency of SNPs in the dbSNP 
revealed that many SNPs are non-polymorphic “SNPs”. Therefore, we removed those from our dedicated 
database, and this resulted in a comprehensive high quality database, which we coined the Human Short 
Peptide Variation Database (HSPVdb). The value of our HSPVdb is shown by identification of the majority 
of published polymorphic SNP and/or ARF-derived epitopes from a mass spectrometry-based proteomics 
workflow, and by a large variety of polymorphic peptides identified as potential T cell epitopes in the HLA- 




T cell-mediated immunotherapy is an attractive treatment of cancer as it exploits the potential of cytolytic 
T cells to specifically recognize antigens that are selectively expressed on tumor cells [1-6]. The enormous 
specificity of T cells involved in killing tumor cells  makes  this  kind  of  treatment  very  attractive. An excellent 
example is the powerful graft-versus-leukemia (GVL) effect witnessed after allogeneic hematopoietic stem 
cell transplantation. GVL is characterized by remission of a hematological malignancy coinciding with the 
in vivo expansion of tumor-specific T cells. These T cells react to a patient-specific epitope presented in 
human leukocyte antigen (HLA) molecules on tumor cells [7, 8]. T cell epitopes are peptides with a length 
of generally 8–11 amino acids. T cells are capable of distinguishing epitopes differing by only one amino 
acid, caused by a single nucleotide difference  between  patient  and  donor [9]. T cell epitopes, identified 
to play a role in (tumor) immunology, may arise from regular reading frames, but can also be encoded 
by alternative reading frames (ARFs) [10]. Given the need for therapeutically useful T cell epitopes, the 
identification of new epitopes is of unceasing importance. The identification of T cell epitopes has been 
achieved with an array of methods, among which mass  spectrometry  is  one  of  the  most  prominent 
techniques [11-13]. Peptide identification by tandem mass spectrometry is most successfully applied in an 
ever increasing number of proteomics studies. In a typical high throughput proteomics/ligandomics setting 
[14], the experimentally determined tandem mass spectra are  matched against  a  database  of  hypothetical 
spectra generated from known peptide sequences using search engines like Mascot [15] and Sequest [16].
For mass spectrometry-based identification of epitopes from polymorphic proteins, like minor 
histocompatibility antigens (MiHA) and peptides arising from ARFs, the commonly  used  protein databases 
like UniProt [17], IPI [18] and RefSeq [19] are unsuitable data sources, since these display very incomplete 
information  about  polymorphisms. Most  of the published polymorphic MiHA are, therefore, not present 
in the standard protein databases, used in mass spectrometry-based workflows. Several strategies have been 
employed to address this problem (MSIPI [20], PepHum [21]), each with its own merits and  limitations, 
trying to  find  the  right  balance between database size and completeness. In addition, there is a wealth of 
ligand and/or epitope information databases [22], but these are not applicable in mass spectrometry (MS)-
based workflows. Knowing that customized  search  databases  that  provide  detailed  control over the search 
space can vastly outperform standard strategies [23], we designed a database dedicated to MiHA, thereby 
improving the chance of their identification in a proteomics type of experimental set up.
Our approach is based on the coding potential of the human genome, including its documented variations, 
as described in the RefSeq database. We chose RefSeq because it contains minimal redundancy, while still 
retaining  splice  variants,  incorporates single  nucleotide polymorphism (SNP) data from Single Nucleotide 
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Polymorphism Database (dbSNP) [24], which are richly annotated. We have created a database that contains 
all possible short peptides in  different reading frames from a non-redundant mRNA set, combined with 
the known and annotated variations/SNPs. In this process, we removed all non-polymorphic information. 
Investigation of the frequency of SNPs in the dbSNP revealed that many of these SNPs are non-polymorphic 
“SNPs”. Therefore, we removed those from our dedicated database as well, and this resulted in a high quality 
comprehensive polymorphic peptide database. Centered on the amino acid polymorphisms of non-synonymous 
SNPs, our dedicated Human Short Peptide Variation Database (HSPVdb) outperforms existing databases in 
MS/MS-based T cell epitope identification.
The value of our HSPV database is shown by identification of the majority of published polymorphic SNP and/ 
or ARF-derived epitopes from a mass spectrometry-based proteomics workflow, as well as by a large variety 
of polymorphic peptides identified as potential T cell epitopes in the HLA-ligandome presented by EBV cells.
MATERIALS AND METHODS
Database preparation
The HSPVdb consists of peptides derived from genomic sequence variations. The database only contains 
peptides of seven amino acids or longer. The RefSeq database release 32 was downloaded from the NCBI 
FTP site and indexed using our local SRS installation [25], (http:// srs.bioinformatics.nl). The human mRNA 
subsection of RefSeq was extracted by selecting records with molecule type “mRNA” and organism source 
“Homo sapiens”. The resulting list of RefSeq records was subsequently processed using a series of Perl scripts.
To create the peptides derived from genomic sequence variations, we made use of the variation annotations 
that were  added  to  RefSeq  by  the  dbSNP  staff.  Variations found in the 5′ and 3′ UTRs were purposely 
included to allow detection of T cell epitopes derived from ARFs. For  each annotated variation, the  nucleotide 
sequences corresponding to the different alleles were generated. Instead  of  duplicating  the  complete  mRNA 
sequence for each allele, we took a fragment starting from 30 nucleotides upstream and ending 32 nucleotides 
down- stream of the variation. The three forward reading frames of each allele were translated to amino 
acid sequences. This typically results in three peptide sequences of 20 amino acids. Translation ignored the 
presence or absence of start codons. Codons that could not be translated to a single  amino acid  due  to 
ambiguous nucleotides were translated to a stop codon. The amino acid translation was split on stop codons to 
get peptides derived from a continuous reading frame. Only the peptides,  including the variation were kept in 
the database. To minimize redundancy, a translation for an allele was only included when the variation gives 
rise to a change in amino acid sequence (non-synonymous SNPs). This part of the database  is  optimized  for 
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finding  peptides  in  the  size range between 8 and 11 amino acids, but databases containing  other  peptide 
lengths  can  be  produced  at will. The database presented here consists of 20-mer peptides.
Each peptide sequence that was created, was stored as a separate database record and annotated with the 
ID of the originating mRNA sequence and the location of its encoding reading frame. If the RefSeq entry 
contains a coding sequence (CDS), the protein identifier and the position of that CDS on the mRNA with 
corresponding protein identifier, were added as annotation to the database record. For variations, we included 
the corresponding dbSNP identifiers, the positions of the variations, the nature of the amino acid changes 
and the percentage heterozygosity. If a variation causes an amino acid substitution, a SAP (single amino 
acid polymorphism), the possible amino acids were listed. Insertions or deletions were annotated as “in/del”. 
The resulting database was stored as a flat file in FASTA format for mass spectrometry-based proteomics 
purposes. This HSPVdb  is  fully dedicated  to  finding  polymorphic epitopes. To reduce the size of this 
database, all duplicate amino acid sequences were deleted. These peptides contain  both  polymorphisms for 
each  position, thereby describing all possible SNP information.
Subsets of the HSPV database were created based on reported heterozygosity. Three heterozygosity categories 
were defined: 0/1, unknown, all others. Additionally, for all categories ARFs were either included or left out.
Peptides for which the encoding DNA sequence is not part of the RefSeq-annotated open reading frame are 
labeled  as  alternative  reading  frame  or  ARF  peptides. These include CDS that are in a different reading 
frame and sequences that are located up- or downstream of the annotated open reading frame.
SNP genotyping assays
Genomic DNA was isolated from 192 HLA A*0201- positive patient and donor samples (peripheral blood 
mononuclear or bone marrow cells) by the Gentra Systems PUREGENE genomic isolation kit (Biocompare, 
San Francisco,  CA).  SNPs  rs4848158,  rs61378134,  rs3602 31 50,   rs1 1 540 52 6,   rs1 1 5 5 4 279 ,   rs 
359 58 18 9, rs56013141, rs11541290, rs34422048, rs11541416, rs28 6599 89,   rs2 0701 59,   rs4 2610 
80,   rs11 5 571 42, rs11555631, rs11479605, rs11541519, rs5030742, rs11548263 were analyzed using a 
KASPar assay with allele-specific primers labeled with VIC and FAM dyes, (KBioScience, Hoddesdon, 
UK). Genotyping was per- formed according to manufacturer’s instructions. 
Ilumina custom array was used for genotyping rs10960, rs1143 138 ,   r s1 298 600 2,   rs346 691 46, 
rs10 478 44, rs11266765, rs11539866, rs11541416, rs11541519, rs11542419, rs11542836, rs11544489, 
rs11545551, rs11548082, rs11553285, rs11553982, rs11554156, rs11554279, rs11555631, rs11557142, 
rs11558570, rs13202878, rs17848351, rs17851857, rs17853301, rs17853718,   rs1803 181,   rs2070159, 
rs2261324, rs2 893 488 7,  r s289 351 71,  rs28 940 302 ,  rs3 180 96 1, rs3 413 69 99 ,   r s34 4 1 8 7 12,   rs39 
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62 697 ,   r s4 848 15 8, rs5030742, rs6112008, rs6686209, rs6794514. Genotyping was performed according 
to manufacturer’s instructions.
Sample preparation for test set
Peptide synthesis
Peptides were synthesized by standard Fmoc chemistry on a Syro II peptide synthesizer as described previously 
[26]. The integrity of the peptides was checked by reversed-phase high-performance liquid chromatography 
(HPLC) and mass spectrometry. Liquid chromatography–mass spectrometry
The  peptides  studied  are  listed  in  Table  1.  These  are minor histocompatibility antigens as identified 
by different research groups around the world. A more complete listing of MiHA can be found at http://
www.lumc.nl/dbminor. To perfectly mimic the conditions used in a normal mass spectrometry-based HLA-
ligand identification process, all peptides included in Table 1 were measured by on-line chromatography/mass 
spectrometry (see below), and tandem mass spectra were recorded of their singly, doubly, and triply charged 
form. Subsequently, a selection of relevant charge states was made for each peptide, and charge states with 
a substantial contribution to the overall intensity only were used to construct a Mascot generic file (MGF) 
containing 31 tandem mass spectra, see Table 2.
Sample preparation for determination of the EBV-LCL ligandome
Cell collection, preparation, and HLA elutions
Peripheral blood samples were obtained from healthy donors after approval by the Leiden University 
Medical Center Institutional Review Board and informed consent according to the Declaration of Helsinki. 
Mononuclear cells (MNC) were  isolated by  Ficoll-Isopaque  separation and cryopreserved. Stable Epstein–
Barr virus (EBV)-transformed B  cell  lines  (EBV-LCL)  were  generated  using  standard procedures. EBV-
LCL and HeLa cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM, BioWhittaker, Verviers, 
Belgium) supplemented with 10% bovine fetal serum (FBS, BioWhittaker).
Peptide isolation
Peptide isolation was performed with protein A beads (GE healthcare) covalently linked to the major 
histocompatibility complex (MHC) class I mAb W6/32 (3 mg W6/32 on 1 ml of ProtA sepharose) using dimethyl 
pimelimidate according to the standard protocol [27].The complex MHC-peptide pool was prefractionated on 
a C18 RP-HPLC system (2 mm × 15 cm; Reprosil-C18-AQ 3 um; Dr. Maisch GmbH, Ammerbuch, Germany), 




Peptide fractions were reduced to near dryness and resuspended in 95/3/0.1 v/v/v water/acetonitrile/formic 
acid. These resuspended fractions were analyzed by on-line nano-HPLC  mass spectrometry with a  system 
described by  Meiring et  al [28].  Fractions were injected onto a precolumn (100 um × 15 mm; Reprosil-
Pur C18-AQ  3  um,  5  um,  Phenomenex) and  eluted  via  an analytical nano-HPLC column (15 cm × 50 
um; Reprosil- Pur C18-AQ 3 um). The gradient was run from 0% to 50% Solvent B (10/90/0.1 v/v/v water/
acetonitrile/formic  acid) in 90 min. The nano-HPLC column was drawn to a tip of approximately 5 um and 
Table 1  Overview of known MiHA used as a test set in this study. It displays the epitope name and 
the HLA-molecule it is presented in. In addition, its immunogenicity is indicated together with the gene 
name and  the polymorphisms are indicated. *Names  according to  http://www.lumc.nl/dbminor
Epitope name*/ 
HLA
Sequence Charge remarks Gene polymorphic AA
dnSNP 
entry
HA1 / A2 VLHDDLLEA 1, 2 immunogenic HMHA1 VL[R/H]DDLLEA rs1801284
HA2 / A2 YIGEVLVSV 1 immunogenic MYO1G YIGEVLVS[V/M] rs61739531
HA3 / A1 VTEPGTAQY 1, 2 immunogenic AKAP13 V[M/T]EPGTAQY rs2061821
HA8 / A2 RTLDKVLEV 1, 2, 3 immunogenic KIAA0020 [R/P]TLDKVLE[V/I]
rs2173904;
rs2270891
HA1 / B60 KECVLHDDL 1, 2 immunogenic HMHA1 KECVL[R/H]DDL rs1801284
LB-ADIR-1F / A2 SVAPALALFPA 1, 2
immunogenic;  
ARF in 5’UTR
TOR3A (ADIR) SVAPALAL[F/S]PA rs2296377
LB-ADIR-1S / A2 SVAPALALSPA 1, 2 allelic counterpart
CTSHr / A31 ATLPLLCAR 1, 2 immunogenic CTSH ATLPLLCA[G/R] rs2289702
CTSHr / A33 WATLPLLCAR 2 immunogenic CTSH WATLPLLCA[G/R] rs2289702
ACC1y / A24 DYLQYVLQI 1, 2 immunogenic BCL2A1 DYLQ[C/Y]VLQI rs1138357
ACC1c / A24 DYLQCVLQI 1, 2 immunogenic
ACC1c +cystinylated DYLQCVLQI 1, 2 immunogenic
HB1h / B44 EEKRGSLHVW 2, 3 immunogenic HMHB1 EEKRGSL[H/Y]VW rs161557
ACC2d / B44 KEFEDDIINW 1, 2 immunogenic BCL2A1 KEFED[G/D]IINW rs3826007
ACC2g / B44  KEFEDGIINW 1, 2 allelic counterpart





Table  2. Summary of the searches with the test set of known MiHA against the IPI, MSIPI, PepHum, and HSPV 
database. The peptide names and sequences are given  together with the charge of the precursor, submitted 
to  tandem  mass  spectrometry. For  each  database,  three columns are displayed: (1) whether the peptide 
is present in the database (Pr?), followed by (2) the mascot ion score assigned to the tandem mass spectrum 
(black filling if the mascot ion score is above the threshold of the search), and (3) the evaluation, i.e., was the 
tandem mass spectrum matched to the correct peptide (black filling and (Y)  if  correct, and above the mascot 
threshold (cut-off score),  gray filling if correct and below (ye) the mascot  threshold.  In short, the blacker the 
better. Wr wrong interpretation of MS2 spectrum;  np no matching/no proposal from mascot search. The HSPVdb 
scores very well, due to its reduced format in  combination with a high density of relevant SNP  information. 4+ 
was the most abundant in the charge distribution of  peptide LB- ECGF-1H, but its MS2 spectrum was of such 
poor quality that it was not included for database  searching. LB-ADIR peptides are from an ARF.  ACC1+  Cys 
represents a  special case  in which the cysteine residue in the epitope can be modified by formation of an S–S 
bridge with free cysteines. This is relevant for both  in  vivo recognition and mass spectrometric interpretation.
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acted as the electrospray needle of the MS source.
The mass spectrometer was an LTQ-FT Ultra (Thermo, Bremen, Germany) and was operated in data- 
dependent  mode,  automatically  switching  between  MS and MS/MS acquisition. Full scan mass spectra 
were acquired in the FT-ICR with a resolution of 25,000 at a target  value  of  5,000,000.  The  two  most 
intense  ions were then isolated for accurate mass measurements by a selected ion monitoring scan in FT-
ICR with a resolution of 50,000 at a target accumulation value of 50,000. The selected ions were then 
fragmented in the linear ion trap using collision-induced dissociation at a target value of 10,000. In a post 
analysis process, raw data were converted to peak lists using Bioworks Browser software, Version 3.1. For 
peptide identification, MS/MS data were submitted  to  the  human  IPI  database  using  Mascot Version 
2.2.04 (Matrix Science) with the following settings: 2 ppm and 0.8-Da deviation for precursor and fragment 
masses, respectively; no enzyme was specified. The Mascot output files were loaded into Scaffold (http:// 
www.proteomesoftware.com) and exported to Excel as peptide reports and duplicates were removed.
RESULTS
To investigate the value of our database, we studied two sets of samples. First, a test set comprising 
approximately 30% of all MiHA known today, as listed in Table 1, and second, a set of peptides eluted from 
HLA from an EBV- cell line.
Validation of HSPVdb with a test set of known MiHA
Our test set of known  polymorphic peptides and  allelic counterparts were synthesized and measured in 
standard on-line nanoHPLC/MS experiments, as in our normal proteomics  workflow  on  HLA-ligands  [29]. 
Of all significantly occurring charge states, tandem spectra were recorded. Tandem  mass spectra of  varying 
quality are present in this data set, reflecting a “real-world” situation, where the spectral quality depends 
on intrinsic peptide properties. A combined peak list was constructed from these spectra for searching the 
databases used in this work.  This led to a set of 31 experimental tandem MS derived from 15 peptides (Table 
2).
For validation of our HSPVdb, we compared it to the MSIPI and PepHum databases that were specifically 
constructed to address the lack of peptide variation in common databases like IPI. A summary of the databases 
used in this study is shown in Table 3. 
The HSPVdb is similar to the size of the IPI and MSIPI databases, but it includes all SNP information in all 
forward and  ARFs  (MSIPI:  170.242  SNPs;  HSPVdb:  380.182
SNPs).  When  leaving  out  the  alternative reading  frame information (i.e., HSPVdb subset 1, see Table 
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3), the size of our HSPVdb is reduced to only 25% of the size of IPI and MSIPI, which is of great importance 
when searching databases.
The test set containing the tandem mass spectra of known MiHA was searched against the IPI, MSIPI, PepHum, 
and our HSPVdb. Searches were performed using the Mascot search engine (Matrix science), with various 
settings  for  mass  accuracy  (1,  2,  5,  10,  and  50  ppm) representing the mass accuracy of various MS 
and/or experimental setups. The enzyme setting was “none”. It is important to note that in the elucidation of 
HLA-ligands, the  peptide termini are unknown in contrast to the vast majority of cases in standard proteomics 
experiments, in which peptide matching against databases can be done with an additional and very stringent 
condition, namely an enzyme cleavage site (in most cases, trypsin). In the standard proteomics approach, the 
enzyme restriction has an enormous positive impact on specificity and search time. For the sequencing of T 
cell epitopes, enzyme restriction is not applicable. However, for binding to the presenting HLA molecule, 
HLA-ligands have to satisfy certain conditions imposed  by the HLA molecule, the binding motif. This binding 
motif can be used as additional help to some extent to assess the value of the matched sequence by the search 
engine. In addition, netMHC, http://www.cbs.dtu.dk/ services/NetMHC/, could be applied to some extent, but 
neither of the two can be directly applied in the database search as a fixed condition. The best proof of a correct 
peptide assignment, in spite of improvements in peptide matching algorithms, is still the comparison of the 
tandem spectrum of the proposed eluted epitope with its synthetic counterpart.
All output of the Mascot search engine was assessed manually, and a summary of the results for a 1-ppm mass 
accuracy  is  shown in  Table  2,  and  a  full report of  the searches is given in Supplemental Table 1.
Table 2 shows a selection of the searches in the four databases with a 1-ppm mass measurement accuracy. For 
every  individual tandem mass spectrum, the Mascot ion score is reported. The results from the database search 
were classified by  the  following criteria: (1) was the  tandem  mass spectrum correctly identified by 
the search engine 30 (indicated by black and gray filling in the first column) for each database? and (2) was 
the identification score above (indicated by black filling in the second column for each database) or below the 
Mascot significance threshold (cut-off score)? Therefore, “the blacker the better”. The presence (“Pr”) of each 
peptide in the particular database is indicated by “Y” in the appropriate column. Supplemental Table 1 shows 
the results of all searches performed with the test set of 31 tandem mass spectra to the IPI 3.69, MSIPI 3.67, 
PepHum, and HSPVdb. 
From  Table  2,  it  is  immediately  clear  that  the  IPI database is not  useful for finding MiHA, since it lacks 
essential variation information. The  PepHum database, based on  expressed sequence tags  (ESTs)  information, 
including  ARFs,  is  relatively large,  by  which  relevant  information  for  finding  our polymorphic  epitopes 
is  “diluted”,  and  consequently,  a serious  amount  of  “noise”  is  generated,  increasing  the chance of 
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finding false positives. The consequence of this is reflected  in  the  outcome  of  the  database  search  for 
PepHum. The number of significantly scoring peptides is only 5 as compared to the 19 peptides identified by 
our HSPVdb, see also Figure 1a. This low score is only partially rescued by the number of correctly assigned 
peptides with a score below the Mascot significance threshold. In addition, ESTs  may  be  more  prone  to 
experimental  sequencing errors, leading to occurrence of false SNPs.
The elegantly produced MSIPI does quite well, but also here,  most  correct peptide hits  are  below  the 
statistical significance threshold score, which makes it hard to decide if a hit is true or a false positive in a 
“non-test set” setting. In addition, the MSIPI does not contain information from ARFs and UTRs.
For the HSPVdb, out of 31 MS/MS spectra, 19 are identified correctly above the Mascot significance threshold, 
while another 7 are also correctly identified, but below the significance threshold. Only three tandem mass 
spectra were wrongly assigned (false positives).
These wrong assignments are caused by the poor quality of the tandem mass spectra of these peptides, due to 
intrinsic peptide properties. To two tandem mass spectra, no match was assigned. These tandem mass spectra 
represent two peptides, “YIGEVLVSV”, which yields a bad mass spectrum and “RPHAIRRPLAL”, which 
is not present in the HSPVdb subset, because it is derived from a SNP not found in the dbSNP database. The 
HSPVdb, designed to reduce non-informative sequence information, outperforms the other databases.
Next to the size of the database, relieving the accuracy condition from 1 to 50 ppm (Figure 1b) has a detrimental 
effect on both the number of correctly assigned peptides above  and below  the Mascot significance threshold. 
This effect can even lead to a false-positive score, as illustrated by a high and significant Mascot score of 63 
(!) for MS/MS/query #6 (in HSPVdb, 50 ppm), see supplemental Table 1a. This result emphasizes the value 
of high mass accuracy.
So far, the good performance in the MS/MS-based identification of T cell epitopes of HSPVdb can be attributed 
to the compact nature and the special focus on polymorphic peptides. A reduced database size directly translates 
to a lower noise level in the database search, which  is  especially important  in  high-throughput T cell epitope 
elucidation, where search space limiting constraints like an enzyme cleavage site cannot be used. Another 
parameter affecting search quality is mass accuracy, which is also proven to be a prominent factor in avoiding 
false positives.
To further improve the quality of our HSPVdb, we focused on the quality of the SNPs in dbSNP, since we 
noted that the reported frequency of a substantial number of SNPs in dbSNP is “0” or “1” or “unknown”. This 
made us decide to study a random set of 52 SNPs with no frequency reported in dbSNP. We developed a SNP 
assay to screen a random HLA-A*02-positive Dutch donor population using the KASPar assay (92 DNA 
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samples) and a SNP array (192 DNA samples). In our test population, 46 out of the 52 SNPs (90%) were not 
polymorphic, having an allele frequency of 1 or 0 in the SNP assays. Two SNPs (4%) were very rare (allele 
frequencies of 0.97, and 0.99), and 4 SNPs (8%) had a reasonable distribution in our population (0.77; 0.70; 
0.20; 0.13).
A large number of reported “SNPs” in dbSNP is apparently not polymorphic, thereby contaminating our 
proteomics  approach  and  the  chance of finding suitable patient/donor MiHA pairs. Therefore, since 
reduction of the search space greatly enhances the chance of finding true positives in database searches, 
we decided to test our HSPVdb after removal of either “unknowns” or “0” and “1”,  or  both.  The  results 
are  shown  in  supplemental Table 1b. Subset 3, the leanest form of HSPVdb with both “0” and “1” and 
“unknown frequency” SNPs removed and without ARFs, is reduced to only one fourth of its original size. 
Therefore, the significance threshold is clearly lowered (from 28 to 22 for 1-ppm mass accuracy), increasing 
the chance of finding true positives. In particular, those derived from tandom mass spectra of relatively 
poor quality with accompanying intrinsic low Mascot scores. Only one true positive is lost, because its 
frequency is not reported in the dbSNP. Similarly, the other subsets (subsets 1–8) of HSPVdb  have  reduced 
significance thresholds (data  not shown). The application of these various forms of the database can be 
adapted to the needs of the user.
So far, we have shown that the selective reduction of the database size by removal of both the non-polymorphic 
peptide stretches and the SNPs of limited value, leads to a comprehensive high quality database file dedicated 
to improving the elucidation of MiHA.
Database quality and inconsistencies
During  this  work,  we  discovered inconsistencies  in  the number of SNPs included in several RefSeq and 
MSIPI versions, see Figure 2a and b. The number of reported human SNPs dropped by 50% going from 
RefSeq release 28 to release 30, and by more than 50% in MSIPI going from version 37 to version 38. We 
reported this in October 2008 to the respective database producers who acknowledged there were problems 
and improved their efforts. Recently, we encountered a problem with  the  SNPs reported by 1000 genomes.
org in  dbSNP which is being solved. Therefore, we continued using version 3.32 (on our website the HSPVdb 
version based on either Refseq release 32 or release 40 can be chosen). We would like to warn users for the 
status of the RefSeq with respect to this. MSIPI, also being a secondary database, suffered from the same 
errors during several versions, but this has been repaired, starting from version 49, although a strong decrease 
can be seen in version 3.67 (Figure 2b). In general, as a user of these databases, it is very hard to judge the 




































































Application of HSPVdb to finding potential MiHA presented in HLA on EBV-cells
To investigate the effects of application of our database to a representative HLA-ligand elution experiment, 
we eluted peptides from an EBV-LCL cell line (EBV-JY). After lysis, affinity purification was performed with 
BB7.2 antibody for HLA-A2, followed by separation of HLA and peptides. Subsequently, the complex 
peptide pool was analyzed by on-line nanoHPLC-tandem MS. The tandem mass spectra were matched 
against several databases for comparison, in particular, MSIPI and various subsets of our HSPV database.
Here, MSIPI is compared to the smallest subset of our HSPV database without ARFs (subset 3) and with 
ARFs included (subset 7), the advantages of which have been illustrated for the test set described above. 
These trimmed subsets do not include SNPs of which the frequencies in dbSNP are reported to be 0/1 or 
unknown. By searching against the smaller compact database containing all relevant SNPs, intermediate 
scoring peptides appear in the database search that would otherwise fall below the significance threshold 
when matching tandem mass spectra against larger databases.
This  is  illustrated  by  the  number  of  intermediate scoring  peptides, i.e.,  those  peptides that  score 
below the Mascot significance threshold when matching against  MSIPI,  and  are,  therefore, peptides  not 
found otherwise. An  additional 130  peptides  were  found  for subset 3 and an additional 400 for subset 7. 
Figure 1. (A) Summary of the 
searches with 1-ppm accuracy 
against the IPI, MSIPI, PepHum, and 
HSPV databases. The color coding 
is as follows: black correct hit and 
above the MASCOT significance 
threshold; gray correct hit, but 
below the significance threshold. 
(B) Summary of the searches 
against HSPVdb with various mass 
measurement accuracies. The color 





These extra peptides need to be checked for false positives (peptides with  tandem mass spectra that match 
better with non- SNP  containing  peptides),  and  for  the  presence  of  a SNP. The extra peptides found 
can, e.g., be evaluated by application  of  netMHC.  This  approach,  starting  from our small experimental 
elution experiment, yielded eight peptides from subset 7 (including ARFs), and five peptides from  subset 
3 with a netMHC score below 50 (i.e., a stringent condition for strong binding). These peptides, shown in 
Table 4,  are  currently evaluated as  potential MiHA.
All peptides found only by searching against the dedicated HSPV database increase the chance of finding 
relevant MiHA. The excellent annotation of the SNPs reported in our HSPV database enables the user to 
directly jump to the relevant information about the polymorphism, a feature that was largely lacking so far.
The HSPV database described here is an integral part of a complete peptidomics pipeline for finding 
therapeutically  useful MiHA, a  strategy that  is  currently under development.
Availability and web interface
A flat file with the content of the HSPV database can be requested by sending an e-mail to hspv@
bioinformatics.nl. A simple interactive query interface is available at: http:// srs.bioinformatics.nl/hspv/.
This  web  interface allows  the  biologist to  query  the database for peptide sequences. It returns a list of 
RefSeq mRNA entries that contain a continuous reading frame encoding  the  query  peptide,  the  start 
position  of  that reading  frame,  the  position  of  the  encoding  nucleotide Sequence with respect to any 
Table  3. Overview of the databases used in this study,  listing the number of entries and the number 
of amino  acid residues present in each database. In addition, the  presence of ARFs and the (type 
of) SNP information in the various databases is indicated. The number of residues of each database 
relative to the IPI database and the relative size of the HSPV subsets is given. The number of SNPs in 
MSIPI 3.67 is 170.242; the number of SNPs  in  HSPVdb (subsets 1 and 5) is 380.182
Database
Nr. of 
sequences Nr. of residues
Size relative to IPI 
3.69 ARFs? 0/1? Unk?
IPI (HUMAN v3.69) 87130 35200044 1
MSIPI (HUMAN v3.67) 87040 42553286 1.209 √ √
PepSeq 75237 176019757 5.001 √ √ √
HSPV20 1575171 45422884 1.290 √ √ √
Rel. to set 5
HSPV subset 1 423015 8344552 0.184 √ √
HSPV subset 2 377269 7440614 0.164 √
HSPV subset 3 106379 2108989 0.046
HSPV subset 4 152125 3012927 0.066 √
HSPV subset 5 2634086 45422884 1 √ √ √
HSPV subset 6 2378073 41106669 0.905 √ √
HSPV subset 7 729721 12444311 0.274 √
HSPV subset 8 985734 16760526 0.369 √ √
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annotated CDS, and a description of the variations if the peptide contains any, see Figure 3a. This is a great 
feature for the initial assessment of the quality and potential usefulness of the output of our database searches.
The  richness  of  SNP  information of  our  database is shown in Figure 3b, for the peptide “TLSELHCD” 
displaying SAPs at every position in the peptide.
Improvements in the quality and quantity of dbSNP entries, among others by the 1000 genomes project 
(http:// www.1000genomes.org), if well controlled, will greatly enhance the use of our database by reporting 
useful frequencies  and  removal  of  spurious  frequencies in  the current dbSNP releases.
The  website  (http://srs.bioinformatics.nl/hspv/) provides easy access to relevant information about SNPs by 



























Figure 2. Number of incorporated 
SNPs per release of RefSeq (A) 






We have shown that selective reduction of the database size by removal of both the non-polymorphic peptide 
stretches and the non-polymorphic “SNPs” leads to a comprehensive high quality database file dedicated to 
improving the elucidation of MiHA.
Figure 3. Screen shots show the output of a query for the peptides (A) SVAPALALFPA and (B) 
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Peptide mRNA Gene Protein    rel2cds
   in 
frame   dbSNP        SNP    Het   NetMHC
FLIPKTLVGV NM_017700 FLJ20184 NP_060170.1 down stream y rs2121558 FLIPKTLVG[E/V] 0,47 9
SLSDLIYAL NM_001080837 SEBOX NP_001074306.2
inside
y rs9910163 SLSDLIYA[L/S] 0,13 7
GLWEQENHL NM_024713 C15orf29 NP_078989.1 inside y rs34998154 GLW[E/K]QENHL 0,05 41
FIVTVIHTI NM_024607 PPP1R3B NP_078883.2
down stream
n rs330915 FIVTVIHT[I/F] 0,49 30
FLSEHPNVTL NM_145298 APOBEC3F NP_660341.2 inside y rs17000697 FL[A/S]EHPNVTL 0,28 19
FLNQRSIML NM_030956 TLR10 NP_112218.2 up stream n rs9998678 FLNQ[R/W]SIML 0,05 29
LLQSLVSI NM_198889 ANKRD17 NP_942592.1 inside n rs6855349 LLQS[S/L]VSI 0,46 46
TLLDPNEKYLL NM_016243 CYB5R1 NP_057327.2 inside y rs2232842 TLLDP[N/S]EKYLL 0,31 31
Table 4. Exclusive peptides with selected info from the HSPVdb. Peptides are either in frame (y) or in an ARF 
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T-cell recognition of minor histocompatibility antigens (MiHA) plays an important role in the beneficial 
graft-versus-leukemia (GVL) effect of allogeneic stem cell transplantation (allo-SCT) but also mediates 
serious graft versus host disease (GVHD) complications associated with allo-SCT. Using a reverse immu-
nology approach we aim to develop a method enabling the identification of T-cell responses directed against 
predefined antigens, with the goal to select those MiHAs that can be used clinically in combination with 
allo-SCT. In this study, we used a recently developed MiHA selection algorithm to select candidate MiHAs 
within the HLA-presented ligandome of transformed B-cells. From the HLA-presented ligandome,that pre-
dominantly consisted of monomorphic peptides, 25 polymorphic peptides with a clinically relevant allele 
frequency were selected. By high-throughput screening the availability of high-avidity T-cells specific for 
these MiHA-candidates in different healthy donors was analyzed. With the use of MHC-multimer enrich-
ment, analyses of expanded T-cells by combinatorial coding MHC-multimer flow cytometry, and subsequent 
single cell cloning, T-cell clones directed to 2 new MiHA: LB-CLYBL-1Y and LB-TEP1-1S could be dem-
onstrated, indicating the immunogenicity of these 2 MiHAs. The biological relevance of MiHA LB-CLYBL-
1Y was demonstrated by the detection of LB-CLYBL-1Y specific T cells in a patient suffering from acute 




Allogeneic HLA-matched hematopoietic stem cell transplantation (allo-SCT) and subsequent donor lym-
phocyte infusion (DLI) to eradicate persistent or relapsed malignant cells are considered an effective cu-
rative treatment for patients with high-risk hematological malignancies or patients who fail to respond to 
chemotherapy [1]. The curative potential of this therapy has been attributed to the recognition of malignant 
cells by donor T-cells. Detailed analyses of T-cell immune responses in patients responding to DLI have 
demonstrated that the donor T-cells recognize minor histocompatibility antigens (MiHA) presented in the 
context of HLA-molecules on malignant cells. MiHA are peptides derived from polymorphic proteins that 
differ between donor and recipient due to single nucleotide polymorphisms (SNP) [2-5]. Previously it has 
been demonstrated that T-cells directed against MiHA that are ubiquitously expressed can mediate life-
threatening graft-versus-host-disease (GVHD) [6], whereas T-cells directed against MiHA with hematopoi-
etic restriction may mediate graft-versus-leukemia (GVL) response in absence of GVHD [7].
Although the introduction of various molecular and genomic technologies resulted in an increased number 
of HLA-class I restricted MiHA identified by forward immunological approaches, the number of MiHA with 
therapeutic relevance is still limited [8,9].  A major limitation for clinical implementation of MiHA is the 
small number of identified MiHA derived from genes that are exclusively expressed in hematopoietic cells. 
To allow the selective analysis of hematopoietic restricted MiHA, we and others have used reverse immuno-
logical approaches in which predicted polymorphic peptides are the starting point and peptide candidates are 
subsequently screened for their capacity to induce a specific T-cell response. This approach has the potential 
to specifically screen for T-cells recognizing MiHA that are exclusively expressed by hematopoietic cells. 
However, it has been reported that when such peptide predictions are solely based on computer algorithms 
that predict peptide-HLA binding affinity and proteolytic cleavage, the detected T-cell responses are often 
directed against epitopes that are not naturally processed and presented and therefore fail to lyse malignant 
target cells [10-12]. To circumvent this peptide selection problem we and others previously introduced mass 
spectrometry (MS) based HLA-ligandomes as a reliable source for naturally processed and presented pep-
tides and developed an algorithm that can be exploited to identify T-cells specific for potential clinically 
relevant MiHA[13,14]. 
The emerging availability of high quality SNP data in combination with the implementation of HLA-ligan-
domes provides a large supply of MiHA-candidates with guaranteed processing and HLA-restricted presen-
tation at the cell surface [15]. We used our recently established algorithm [13] to select the top 25 MiHA 
candidates from our newly established large set of B-lymphocyte derived HLA-class I eluted peptides [16]. 
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To validate these MiHA candidates is essential to demonstrate their immunogenic potential by isolation of 
high avidity specific T-cells. We therefore screened the TCR repertoire of 16 unrelated donors for the presence 
of T-cells specific for these MiHA-candidates. MHC-multimer positive T-cells lines were generated from pe-
ripheral blood mononuclear cells (PBMC) by magnetic activated cell sorting (MACS). Flow cytometric analy-
sis of antigen-specific T-cells, followed by functional testing of MHC-multimer sorted and expanded T-cell 
clones using both IFN-γ and GM-CSF as readout demonstrated the immunogenic potential of LB-CLYBL-
1Y, LB-TEP1-1S and two previously described MiHA. For one of the newly defined MiHA we were able to 
confirm the biological relevance by demonstrating MHC-multimer positive T-cells in a patient suffering from 
AML after treatment with allo-SCT and subsequent DLI. Our data illustrate that with this reverse immunology 
approach biologically relevant MiHA can be identified as well as MiHA that are not frequently induced in vivo 
but can potentially be used for immunotherapeutic strategies.
EXPERIMENTAL PROCEDURE
Cell collection and culture conditions
Peripheral blood was obtained from different individuals after informed consent (Sanquin Reagents, Amster-
dam and Leiden University Medical Center, Leiden, The Netherlands). All experiments were approved by the 
local medical ethics committees. Blood samples were HLA-typed by high-resolution genomic DNA-typing. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient separation and cryopreserved 
for further use. T-cells were cultured in T-cell medium consisting of Iscove’s Modified Dulbecco’s Media 
(IMDM: Lonza) supplemented with 5% human serum (HS), 5% fetal bovine serum (FBS), 100 IU/ml IL-2 
(Proleukin), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). Epstein-Barr 
virus-transformed lymphoblastoid B-cell lines (EBV-LCL) and phytohaemagglutinin (PHA; Murex Diagnos-
tics) blasts were generated using standard procedures. The T2 cell line was cultured in IMDM with penicillin/
streptomycin and 5% FCS.
Peptide library of HLA-class I eluted peptides
The peptides used for this study are derived from a newly established large peptide library that has been re-
cently described by Hassan et al [16]. In short: Peptide elution, reverse phase high-performance liquid chro-
matography (RP-HPLC), and tandem mass spectrometry (MS/MS) were carried out as previously described 
[17,18]. Briefly, 60 x 109 HLA-A*0201 and HLA-B*0702 positive EBV-LCL were washed with ice cold PBS 
and pellets were stored at -80°C until use. Peptide-HLA-class I complexes were purified from cell lysate by 
affinity chromatography. Subsequently, peptides were eluted from HLA-molecules, and separated from the 
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HLA heavy chain fragments and β2-microglobulin by size filtration. The peptide mixture was separated by 
various first dimension separation techniques, after which the peptides were measured by on-line nanoHPLC-
MS/MS.
Selection of MiHA-candidates from a set of eluted peptides
MiHA-candidates were selected based on our recently developed MiHA selection algorithm from the recently 
established peptide elution library [13]. Briefly, the tandem mass spectra of eluted peptides were submitted 
to the HSPVdb [19], a database optimized for finding polymorphic peptides. To select for MiHA-candidates 
within this set we evaluated the polymorphic peptides using strict threshold scores for mass spectrometry 
defined sequence reliability (BMI≥30, ppm≤2.0), peptide length [8-11 amino acids), predicted peptide-HLA 
affinity (<500 nM), allele frequencies of the SNP encoding polymorphism (0.05-0.7%) and specific gene ex-
clusion criteria (no extreme polymorphic genes). After confirming their integrity by comparing the tandem 
mass spectra of the synthetic peptides with that of the eluted counterparts the top 25 MiHA-candidates, with 
the highest threshold scores, were selected for further analysis.
Generation of peptide-MHC complexes
All peptides were synthesized in-house using standard Fmoc chemistry. Recombinant HLA-A*0201 and 
HLA-B*0702 heavy chain and β2m were in-house produced in Escherichia coli. MHC-class I refolding was 
performed as previously described with minor modifications [20]. MHC-class I complexes were purified by 
gel-filtration HPLC in PBS and stored at 4 ºC. The peptide HLA-A*0201 or HLA-B*0702 binding affinity 
was assessed by subjecting prefolded UV-sensitive peptide-MHC complexes (100 μg/ml) to 366 nm UV light 
(Camag) for 1 hr. in presence of the peptide of interest (200 μM) [21]. As controls the CMV PP65 NLVPM-
VATV, CMV PP65 TPRVTGGAM, modified MART1 ELAGIGILTV and wild-type MART1 AAGIGILTV 
peptide were used. After exchange, samples were spun at 16,000g for 5 min and supernatants were used to 
assess HLA-monomer rescue using a bead assay as previously described [22].
Isolation of MHC-multimer positive T-cells by MHC-multimer pull down
Prior to isolation PBMC samples were stained with PE-coupled MHC-multimers for 1 hour at 4 ºC. Subse-
quently, cells were washed and incubated with anti-PE beads (MiltenyiBiotec, BergischGladbach, Germany). 
PE-positive T-cells were isolated by magnetic activated cell sorting (MACS), according to the manufacturer’s 
protocol. Positive fraction was cultured with irradiated autologous feeder cells in T-cell medium supplemented 
with 5 ng/ml IL-15 (Biosource) and anti-CD3/CD28 Dynabeads (Invitrogen). After 2 weeks, T-cell cultures 
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were analyzed by MHC-multimer combinatorial coding flow cytometry. Data acquisition was performed on 
an LSR-II flow cytometer (BD Biosciences, San Diego, USA) and MHC-multimer positive T-cell populations 
were single cell sorted on a FACSAria (BD) into 96-round bottomed well plates containing 100 μl T-cell me-
dium supplemented with 800 ng/ml PHA and 1*105 irradiated feeder cells. T-cell receptor-β variable chain 
(TCR-Vβ) usage was investigated by flow cytometry using specific monoclonal antibodies as included in the 
TCR-Vβ repertoire kit (Beckman Coulter).
Cytokine secretion assay
For analysis of IFN-γ and GM-CSF production, 5000 T-cells were stimulated with 20,000 EBV-LCL or 10,000 
fibroblasts loaded with different concentrations of peptides in 96-round bottomed well plates. Before stimula-
tion, fibroblasts were either pre-treated with IFN-γ (100 IU/ml) or not for 5 days. For recognition of primary 
malignant cells, 1000 T-cells were stimulated with 5,000 malignant cells in a 384-well plate. After 18 hours, 
supernatants were harvested, and the concentration of IFN-γ and GM-CSF were measured by an enzyme-
linked immunosorbent assay (ELISA; Sanquin Reagents). An arbitrary detection limit was set to 100 pg/ml 
for both cytokines.
SNP genotyping and microarray gene expression analysis 
A panel of 100 HLA-typed EBV-LCL was selected for SNP screening as previously described [9]. Briefly, 
genomic DNA was isolated of 5×106 EBV-LCL cells using GentraPuregene Cell Kit (Qiagen) and PCR-
free whole genome amplification (WGA) was performed. The DNA samples were hybridized to Illumina 
Human1M-duo arrays. For gene expression analysis, total RNA was isolated using small and micro scale 
RNAqueous isolation kits (Ambion), and amplified using the TotalPrep RNA amplification kit (Ambion). 
After preparation using the whole-genome gene expression direct hybridization assay (Illumina), cRNA sam-
ples were dispensed onto Human HT-12 v3 Expression BeadChips (Illumina) according to the manufacturer’s 
protocol. Sample collection was performed as previously described [23-25]. Microarray gene expression data 




Selection of high affinity HLA-A*0201 and B*0702 binding MiHA-candidates from a set of HLA-class 
I eluted peptides
We have recently reported a MiHA selection algorithm to be able to select MiHA candidates from a library of 
HLA-class I eluted peptides [13]. This MiHA selection algorithm comprises several evaluation steps that are 
summarized in the material and methods section. This algorithm was used to screen our newly established li-
brary of eluted HLA-class I peptides derived from multiple HLA-A*0201 and B*0702 positive EBV-LCLs, to 
select for potential MiHA candidates [16].To validate this newly established library of approximately 16.000 
eluted HLA class I peptides comprising of mainly monomorphic peptides, we first screened for the presence of 
known MiHA. Peptide sequences or their relevant length variants were identified for 10 out of 13 MiHA that 
Figure 1. Detection of MiHA-specific T-cells after MHC-multimer enrichment and expansion. FACS analyses were per-
formed to detect MiHA-specific T-cells through combinatorial coding MHC-multimer screening after second pull down 
and in vitro expansion. Each peptide-MHC complex was encoded by a unique combination of fluorochromes. Two 
HLA-restricted sets of MHC-multimers were used to screen for detection of all MiHA-candidates specific T-cells. (A)
Representative analysis of the two times enriched T-cell line derived from donor OMH with the HLA-B*0702 restricted 
MHC-multimer set. Total CD8+ T-cells are shown and MHC-multimer negative cells or cells staining with more than 2 
fluorochromes are indicated in black. All dot plots are shown with bi-exponential axes and display fluorescence intensity 
for the fluorochromes indicated on each axis. Frequencies indicate MHC-multimer positive T-cells of total CD8+ cells. (B) 
Total MHC-multimer positive T-cell populations detected in 16 tested PBMC donors after second pull down by combi-
natorial coding MHC-multimer screen. Bars indicate the number of donors homozygous negative for the indicated SNP 
encoding MiHA and applicable for MHC-multimer pull down. The number of MHC-multimer positive T-cell populations 
detected per MiHA candidate is indicated in black. No homozygous negative donors were found for SCRIB-1L, and 





were expressed by the EBV-LCLs as revealed by SNP genotyping (Supplemental Table 1) [3,8,9], illustrating 
the high quality of this peptide elution library.




P1 GLLGQEGLVEI PARP10 rs11136343 L/P 0.66%
P2 ALAPAPAEV NISCHβ rs887515 A/V 0.17%
P3 AMLERQFTV FAM119A rs2551949 T/I 0.19%
P4 FLSSANEHL GLRX3 rs2274217 S/P 0.25%
P5 MMYKDILLL HNF4G rs1805098 M/I 0.40%
P6 SLAAYIPRL CLYBL rs17577293 Y/D 0.05%
P7 SLQEKVAKA HMMR rs299295 V/A 0.20%
P8 VLQNVAFSV BCL2A1 rs1138358 N/K 0.69%
B*07:02
P9 APNTGRANQQM BFAR rs11546303 M/R 0.57%
P10 LPMEVEKNSTL HDGF rs4399146 L/P 0.40%
P11 RPRAPTEELAL C14orf169 rs3813563 A/V 0.40%
P12 APDGAKVASL TEP1 rs1760904 S/P 0.49%
P13 APAGVREVM AKAP13 rs7162168 M/T 0.37%
P14 KPQQKGLRL APOBEC3H rs139298 K/E 0.52%
P15 LPQKKSNAL POP1 rs17184326 N/K 0.10%
P16 LPQQPPLSL SCRIB rs6558394 L/P 0.64%
P17 NPATPASKL C18orf21 rs2276314 A/T 0.21%
P18 SPASSRTDL MTRR rs1532268 S/L 0.68%
P19 SPSLRILAI LLGL2 rs1671036 R/H 0.50%
P20 HPRQEQIAL ERAP1β rs34753 R/P 0.31%
P21 FPALRFVEV GEMIN4β rs1045481 V/E 0.20%
In the next step we selected a set of 25 MiHA-candidates using the MiHA selection algorithm, including 22 
novel MiHA-candidates as well as the previously reported LB-NISCH-1A, LB-ERAP1-1R and LB-GEMIN4-
1V MiHA (Supplemental Table 2). We first analyzed the capacity of the 25 MiHA-candidates to stabilize a 
peptide-HLA complex in a HLA-binding assay that is based on UV-induced conditional ligand cleavage as 
described previously [10,22,26]. After UV-exchange, the HLA-binding affinity of the tested peptides was 
normalized to the high-affinity control peptides CMV-PP65-NLV and CMV-PP65-TPR for HLA-A*0201 and 
B*0702, respectively (Supplemental Figure 1). MiHA-candidates were selected when their HLA-binding af-
finity exceeded that of the MART1-WT-AAG peptide, which binds with low affinity to HLA-A*0201. HLA-
Table I. Validated MiHA candidates
α SNP underlined
β Published MiHA epitope or length variant
Non– and Immunogenic Allele indicated by amino acid code, allele frequencies are calculated by quantification in a 
panel of 100 Dutch individuals using SNP genotyping array.
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binding affinity as measured with HLA-rescue scores exceeded that of the MART1-WT-AAG control for 8 
HLA-A*0201 and 13 B*0702 binding MiHA-candidates. Peptide sequences and allele frequencies of the 
MiHA are shown in Table 1.
Isolation of peripheral blood derived MHC-multimerpositive T-cells by MHC-multimer pull down
To validate the 21 peptides as MiHA with immunogenic potential,we generated MHC-multimers and analyzed 
the T-cell repertoire of 16 healthy HLA-A*0201 and B*0702 positive donors for MHC-multimer reactive T-
cells. MiHA-specific T-cell lines were generated by incubating 100*106 peripheral blood mononuclear cells 
(PBMC) with a specific set of MHC-multimers, followed by enrichment of MHC-multimer positive cells on 
a magnetic column. To allow the isolation of high avidity T-cell populations, the set of MHC-multimers was 
specifically adjusted for each PBMC sample to cover only those MiHA for which the encoding SNP was 
A
B
Figure 2. Isolated T-cell clones 
vary in production of IFN-γ and 
GM-CSF upon αCD3/28 stimula-
tion (A) Distribution of the intrinsic 
IFN-γ secretion capacity of 806 
MiHA-specific MHC-multimer pos-
itive T-cell clones stimulated with 
αCD3/28 beads. (B) Production of 
GM-CSF for 150 selected T-cell 
clones with variable IFN-γ secre-
tion capacity. MiHA specific MHC-
multimer positive T-cell clones 
were stimulated for 18 hours in 
presence of αCD3/28 beads and 
GM-CSF and IFN-γ secretion was 





screened homozygous negative in the respective donor, since in this individual’s T-cell repertoire high avid-
ity MiHA specific T-cells will not have been deleted due to negative selection. The set of PBMC donors was 
specifically adjusted to cover as many applicable donors per MiHA candidate. Unfortunately, no homozygous 
negative donors were found for the SCRIB-1L MiHA candidate. The MHC-multimer enriched T-cells were 
expanded for 14 days in presence of αCD3/28 beads, IL-2 and IL-15. To increase the frequency of MHC-mul-
timer positive T-cells, a second pull down was performed at day 14 using the identical initial set of MiHA can-
didate specific MHC-multimers. After both rounds of MHC-multimer enrichment we analyzed the expanding 
T-cell lines for the presence of MHC-multimer positive T-cells by FACS. A representative FACS analysis after 
two rounds of MHC-multimer enrichment is demonstrated in Figure 1A in which 4 MHC-multimer positive 
T-cell populations specific for HLA-B*0702 binding MiHA-candidates are detected in donor OMH. After the 
first MHC-multimer pull down, MHC-multimer positive T-cell populations were detected specific for 11 of the 
20 tested MiHA-candidates in one or more T-cell cultures. MHC-multimer positive T-cell frequencies varied 
between 0.01% and 5.0% of total CD8+ T-cells (Supplemental Table 3). These low frequencies are most likely 
due to the very low frequency of MHC-multimer positive T-cells in the naïve repertoire. After the second 
MHC-multimer pull down, MHC-multimer positive T-cell populations were detected specific for an increased 
number of 16 of the 20 tested MiHA-candidates with frequencies up to 85% of total CD8+ T-cells (Supple-
mental Table 3). As demonstrated in Figure 1B, T-cells reactive with the CLYBL-1Y and LB-GEMIN4-1V 
MHC-multimer were frequently detected in 8 of the 16 and 6 of the 9 enriched T-cell lines, respectively. In 
contrast, T-cells specific for the other MiHA appeared more restricted to a few donors.
Detection of high avidity T-cell clones by screening for MiHA-specific IFN-γ and GM-CSF production
Next, a total number of 806 MHC-multimer positive T-cell clones representing all detected T-cell populations 
was generated by FACS sorting. To demonstrate recognition of potential MiHA-candidates, all 806 T-cell 
clones were stimulated with specific antigen and cytokine production was determined as a measure for anti-
Figure 3. MHC-multimer positive T-cell clones demonstrate MiHA specific reactivity. Isolated MHC-multimer positive 
T-cell clones were stimulated with HLA-A*0201 and B*0702 positive T2 cells loaded with titrated concentrations of 
peptides for 18 hours [E:T] 5,000:25,000. For each donor the MiHA specific T-cell clone that demonstrated the highest 
peptide avidity is shown for the respective cytokine. MiHA specific IFN-γ production was observed for T-cell clones 
specific for (A) CLYBL-1Y, (B) ERAP1-1R, (C) GEMIN4-1V (D) NISCH-1A, HMMR-1V, C18orf21-1A, APOBEC3H-
1K,and (E) TEP1-1S MiHA-candidates. For the TEP1-1S specific T-cell clone K091 derived from donor EPP both the 
peptide induced IFN-γ and GM-CSF secretion are shown. (F,G,H,I,J) To measure the reactivity of the MiHA specific T-
cell clones against endogenously processed and presented antigens, all MiHA specific T-cell clones that demonstrated 
IFN-γ or GM-CSF production in response to specific peptide were stimulated with a panel of 10 HLA-A*0201 and 
B*0702 positive EBV-LCL target cells positive (+) or negative (-) for the indicated MiHA for 18 hours. Cytokine secretion 
was measured by standard ELISA.
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gen specific reactivity. Because the T-cell clones were most likely derived from the naive T-cell repertoire and 
have presumably not all acquired the capacity to produce IFN-γ upon antigen encounter, we first screened all 
T-cell clones for their potential to secrete IFN-γ after αCD3/28 stimulation. As demonstrated in Figure 2A, the 
generated T-cell clones demonstrated a broad range of IFN-γ secretion. To investigate whether GM-CSF was 
of additional value to improve the screening efficiency, the GM-CSF production of part of the T-cell clones 
with variable IFN-γ secretion potential was measured after αCD3/28 stimulation. The results demonstrate that 
a substantial number of T-cell clones with poor intrinsic IFN-γ production was able to produce pronounced 
GM-CSF levels (Figure 2B). Therefore by using both IFN-γ and GM-CSF as a readout we could increase the 
number of MHC-multimer positive T-cell clones that could be screened. By setting an arbitrary detection limit 
to 100 pg/ml for both cytokines, 98% of generated T-cell clones could subsequently be screened for MiHA 
specific reactivity.
To demonstrate the capacity of the isolated MHC-multimer positive T-cell clones to recognize specific MiHA 
Figure 4. MHC-multimer positive T-cell populations detected in patients after allo-SCT. (A) Number of MHC-multimer 
positive T-cell populations detected by combinatorial coding MHC-multimer analysis in peripheral blood samples of 
16 patients with various hematologic malignancies that received an allo-SCT and demonstrated a clinical response 
to DLI. Patients were only screened when they were positive for the SNP encoding MiHA and received a DLI from a 
donor that was homozygous negative for the SNP encoding MiHA. Bars indicate the number of patients applicable for 
MiHA-specific MHC-multimer screening. The number of MHC-multimer positive T-cell populations detected per MiHA 
candidate is indicated in black. (B) Representative FACS analysis of MHC-multimer positive T-cell populations detected 
in the indicated patients. All dot plots display fluorescence intensity for CD8 and specific MHC-multimer staining. Total 
lymphocytes are shown. Frequencies indicate MiHA specific T-cells of total CD8+ T-cells.
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peptides we stimulated all T-cell clones with HLA-A*0201 and B*0702 positive T2 target cells loaded with 
titrated concentrations of specific peptide. MiHA specific T-cell reactivity was observed for 8 out of 16 tested 
MiHA-candidates and either IFN-γ or GM-CSF was detected after stimulation with CLYBL-1Y, ERAP1-
1R, GEMIN4-1V, NISCH-1A, HMMR-1V, C18orf21-1A, APOBEC3H-1K and TEP1-1S MiHA peptides. For 
each donor the MiHA specific T-cell clone that demonstrated the highest peptide avidity is shown (Figure 3A, 
B, C, D and E). MiHA specific T-cell clones demonstrated variable peptide avidity and half maximum cyto-
kine production (IC50) varied between an IC50 of ±100 pM for the high avidity T-cell clone K156 specific for 
GEMIN4 (Figure 3C) and an IC50 of ±62.5 nM for the low avidity T-cell clone K337 specific for C18orf21 
(Figure 3E). For the CLYBL-1Y MiHA candidate, MHC-multimer positive T-cell clones were successfully 
isolated from 4 different donors. High avidity CLYBL-1Y specific T-cell clones were isolated from donor 
ABM, whereas only low avidity or non-reactive T-cells were isolated from donor UDN, EPP and FHT respec-
tively (Figure 3A). For the previously described MiHA ERAP1-1R, both high and low avidity T-cell clones 
were isolated from the 2 donors that demonstrated MHC-multimer positive T-cell populations after pull down. 
Figure 5. Functional avidity of patient and donor derived CLYBL-1Y specific T-cell clones. (A) FACS analysis of MHC-
multimer positive CLYBL-1Y specific T-cell clones. To prevent doublet formation, CLYBL-1Y specific T-cell clones were 
mixed with CD4 + T-cell blasts. Dot plots display fluorescence intensity for MHC-multimer staining. Total lymphocytes 
are shown. (B) CLYBL-1Y specific T-cell clones derived from donor ABM (K264; white) or from patient MBF (K2-339; 
black) were stimulated with HLA-A*0201 positive T2 target cells loaded with titrated concentrations of CLYBL-1Y pep-




For the previously described MiHA GEMIN4-1V, high avidity T-cell clones were only isolated from 4 out of 
6 donors that demonstrated MHC-multimer positive T-cell populations after pull down (Figure 3B,C; low-
avidity T-cell clones not shown). The NISCH-1A, HMMR-1V, C18orf21-1A and APOBEC3H-1K specific 
T-cell clones were each successfully isolated from one donor and exhibited high (HMMR-1V) to low peptide 
avidity (NISCH-1A, C18orf21-1A and APOBEC3H-1K) (Figure 3D). For the TEP1-1S MiHA candidate high 
avidity T-cell clones were isolated from donor EPP. T-cell clone K091 demonstrated high peptide specific GM-
CSF production and low IFN-γ production (Figure 3E). No peptide specific T-cell clones specific for the other 
MiHA-candidates were observed.
All T-cell clones that demonstrated peptide specific cytokine production were stimulated with a panel of 10 
SNP genotyped HLA-A*0201 and B*0702 positive EBV-LCL target cells to screen for reactivity against 
Figure 6. MiHA specific T-cell reactivity towards hematopoietic malignancies and fibroblasts. Isolated MHC-multimer 
positive T-cell clones were screened for recognition of various primary hematopoietic malignancies and non-hemato-
poietic fibroblasts isolated from different individuals. As a control for T-cell recognition, all T-cell clones were also stim-
ulated with EBV-LCL generated from the same individuals. (A) CLYBL-1Y clone K264 and (C) TEP1-1S clone K091 
were stimulated with HLA-A*0201 or B*0702 positive primary AML, CML and ALL cells either positive (black bars) or 
negative (gray bars) for the specific MiHA, directly after isolation of malignant cells for 18 hours [E:T] 1,000:5,000. To 
measure the recognition of non-hematopoietic cells, (B) CLYBL-1Y clone K264 and (D) TEP1-1S clone K091 were 
stimulated with fibroblasts either pre-treated with IFN-γ (100 IU/ml) or not. MiHA specific recognition of target cells was 






endogenously processed and presented peptide. As demonstrated in Figure 3F, G, H and J all high avidity T-
cell clones specific for CLYBL-1Y, TEP1-1S, ERAP1-1R and GEMIN4-1V demonstrated recognition of all 
target cells that endogenously process and present their respective MiHA, whereas targets that were negative 
for the MiHA were not recognized. Surprisingly, the high avidity T-cell clone K508 specific for HMMR-1V 
did not show a recognition pattern that correlated with MiHA expression. This may be caused by the absence 
of endogenously presented MiHA peptide by some of the SNP positive EBV-LCL or by the recognition of 
allo-HLA molecules expressed by EBV-LCL. No or only marginal target cell recognition was observed for the 
NISCH-1A, C18orf21-1A and APOBEC3H-1K specific T-cell clones (Figure 3I). These results indicate that 
the MiHA CLYBL-1Y and TEP1-1S represent potentially immunological relevant MiHA-candidates.
Detection of MiHA specific T-cell responses in patients after allo-SCT
To validate the biological relevance of the MiHA-candidates we analyzed the peripheral blood of patients 
suffering from various hematopoietic malignancies that received an allo-SCT and DLI and demonstrated a 
clinical response revealed by declining patient chimerism, for the detection of MiHA specific T-cells. Patients 
were only screened with MiHA-specific MHC-multimers when they were positive for the MiHA and received 
a DLI from a donor who was homozygous negative for the SNP encoding MiHA (Supplemental Table 4). 
Tested patient samples were obtained during or after the peak response, 5 to 8 weeks after treatment with 
DLI .For the newly identified CLYBL-1Y MiHA, MHC-multimer positive T-cells were detected in 1 of the 
3 screened patients (Figure 4A) with a frequency of 0.34% of total CD8+ T-cells at day 41 after DLI (AML 
patient MBF, Figure 4B). For the previously described ERAP1-1R and GEMIN4-1V MiHA, MHC-multimer 
positive T-cells were detected in 1 of the 2 and 1 of the 4 screened patients (both multiple myeloma (MM) 
patient CUB at day 86), respectively (Figure 4A,B). Detected frequencies of circulating MHC-multimer posi-
tive T-cells ranged between 0.04% and 0.34% of total CD8+ T-cells. For the other 17 MiHA-candidates with 
validated HLA-binding affinity and SNP occurrence, including the newly identified MiHA  TEP1-1S, no 
MHC-multimer positive T-cells were detected in the peripheral blood of 1 to 5 screened patients (Figure 4 
A,B, Supplemental Table 4).
To investigate whether the MHC-multimer enriched T-cell clones exerted comparable peptide specific avidity 
as the in vivo generated patient derived MiHA specific T-cells, we generated CLYBL-1Y specific T-cell clones 
by single cell sorting of CLYBL-1Y MHC-multimer positive T-cells from patient MBF. After expansion the 
T-cell clones were stained with the MHC-multimer and TCR-Vβ mAbs. The T-cell clone K264, which was 
generated by MHC-multimer enrichment from donor ABM, demonstrated similar MHC-multimer staining 
intensity as the patient derived K2-339 clone (Figure 5A), but a difference in TCR Vβ usage; clones derived 
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from donor ABM expressed TCR Vβ22 and patient MBF derived clones were TCR-Vβ1 positive. Clone K264 
and K2-339 were stimulated with T2 cells loaded with titrated concentrations of either the specific or the al-
lelic variant peptide and IFN-γ production was measured (Figure 5B). Both T-cell clones demonstrated high 
CLYBL-1Y specific peptide reactivity, with IC50 varying between 1-4 pM, whereas the allelic CLYBL-1D 
variant was not or hardly recognized by both T-cell clones, demonstrating that T-cell clones derived from an 
unprimed setting can be equally potent as T-cells derived from an in vivo primed setting.
CLYBL-1Y and TEP1-1S specific T-cell recognition of hematopoietic malignant cells
To investigate the expression pattern of the CLYBL and TEP1 genes we performed a microarray gene expres-
sion array using a panel of primary and cultured malignant (and non-malignant) hematopoietic and non-he-
matopoietic cells (Supplemental Figure 2). The data showed that the CLYBL gene is broadly expressed in he-
matopoietic and non-hematopoietic cells. Expression of the TEP1 gene was not significantly measured in the 
majority of the samples. To investigate whether the CLYBL-1Y and TEP1-1S specific T-cell clones were able 
to recognize hematopoietic malignant cells they were stimulated with primary CML, AML and ALL cells de-
rived from different MiHA positive and negative patients that were positive for the restricting HLA-molecule. 
As a control, T-cell clones were also tested for recognition of EBV-LCL generated from the same individuals. 
Both the high avidity T-cell clones CLYBLK264 and TEP1K091 demonstrated MiHA specific recognition of 
primary hematopoietic malignant cells (Figure 6 A&C). No reactivity was observed against MiHA negative 
target cells. These data indicate that the tested MiHA can be presented in the context of HLA at the surface of 
leukemic cells and may therefore serve as direct targets of CD8+ T-cells involved in a GVL response. In addi-
tion, the potential of the MiHA to serve as target in GVHD was estimated and the MiHA specific T-cell clones 
were tested for recognition of non-hematopoietic fibroblasts. To mimic the pro-inflammatory cytokine milieu, 
early after transplant or during potent GVHD responses, fibroblasts were pretreated with IFN-γ. Although both 
the CLYBLK264 and TEP1K091 T-cell clone poorly recognized non treated fibroblasts they clearly recog-
nized those that were IFN-γ pretreated (Figure 6 B&D). These data indicate that both CLYBL-1Y and TEP1-
1S may be considered as MiHA with potential therapeutic value under non-inflammatory conditions, but they 




In this study we demonstrate the identification of two biologically relevant MiHA by a reverse immunology 
approach. We started our approach by selecting MiHA-candidates from our recently generated B-lymphocyte 
derived HLA-class I eluted peptide library [13,16]. By MiHA candidate specific MHC-multimer enrichments 
and subsequent single cell sorting of MHC-multimer positive T-cells, high avidity MiHA specific T-cell clones 
directed against the MiHA TEP1-1S and CLYBL-1Y could be identified that recognize primary hematological 
malignancies expressing the respective MiHA, indicating the immunogenicity of the two MiHA. In addition, 
we were able to demonstrate an in vivo induced immune response against the new CLYBL-1Y MiHA in a 
patient suffering from AML that experienced an anti-leukemic response after allo-SCT and subsequent DLI 
treatment, demonstrating that by using this reversed immunology approach, biologically relevant MiHA can 
be identified. 
For the CLYBL-1Y MiHA, MHC-multimer analysis revealed the presence of T-cells specific for this MiHA in 
one of the 3 patients screened. These in vivo primed T-cells demonstrated to be high avidity T-cells specific for 
the CLYBL-1Y allelic MiHA variant. For the TEP1-1S MiHA only two patients could be screened for the pres-
ence of TEP1-1S specific MHC-multimer positive cells. Therefore, the absence of an in vivo induced immune 
response against TEP1-1S could either be due to the low number of patients that could be screened or due 
to subdominant of TEP1-1S in the immune response. Our reverse immunology approach has the advantage 
to allow identification of subdominant MiHA as the T-cell repertoire of patients that are screened in forward 
immunology approaches is skewed towards highly immunodominant MiHA specific responses. Subdominant 
MiHA, however, may be of therapeutic interest as they can be exploited in potential peptide vaccination or 
adoptive T-cell therapies when they demonstrate promising gene expression patterns. 
A major limitation for the identification of large numbers of MiHA using a reverse immunology approach may 
be the low frequency of high avidity MiHA specific T-cells within an individual’s T-cell repertoire. By per-
forming two rounds of MHC-multimer enrichments each followed by a 10 days expansion step we increased 
the number of MHC-multimer positive T-cells that was isolated, since we observed that after the second en-
richment round previously undetected MHC-multimer positive T-cell populations were found. In addition, by 
measuring GM-CSF in addition to IFN-γ as readout for T-cell reactivity, we were able to increase the number 
of MHC-multimer positive T-cell clones that could be screened for functional activity. However, the failure 
to isolate high-avidity T-cells for the previously identified LB-NISCH-1A MiHA indicates that isolation of 
high avidity T-cells may still be a matter of chance [13]. Alternatively, T-cells may be tolerant for some MiHA 
due to molecular mimicry with non-polymorphic epitopes or due to their failure to discriminate between both 
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allelic variants of a SNP encoding MiHA [27], explaining why not all MiHA-candidates will be of clinical 
relevance.
For 8 of the 20 MiHA-candidates MHC-multimer positive T-cell clones were isolated that demonstrated 
MiHA specific peptide reactivity. The different MHC-multimer positive T-cell clones however demonstrated 
functional heterogeneity. We have recently demonstrated that CMV-specific MHC-multimer positive T-cells 
isolated from CMV negative individuals by MHC-multimer enrichments also demonstrated a large variation 
in functional avidity [28]. This heterogeneity in functional activity of the MHC-multimer positive T-cell popu-
lations may be specific for T-cells isolated from the naïve repertoire as memory T-cells are skewed toward a 
high-avidity range as a result of antigen encounter in vivo. Non-responsiveness of MHC-multimer positive T-
cell clones has also been reported by others for T-cells derived from the naive repertoire [29,30].The discrep-
ancy between MHC-multimer reactivity and T-cell functionality can most likely be explained by the staining 
with multimerized MHC-peptide complexes. Multimerization of MHC-peptide complexes alters the TCR-
MHC-peptide dissociation on- and off-rate kinetics and will result in increased binding avidity of the mul-
timerized MHC-peptide complex to surface TCR. By measuring the strength of TCR binding to monomeric 
peptide-MHC complexes using the StreptamerKoff rate assay, we recently demonstrated that the dissociation 
kinetics correlated with the observed functional avidity of different MHC-multimer positive T-cell clones, and 
that T-cells demonstrating lower dissociation rates confer significantly better antigen specific reactivity than 
those with fast dissociation rates [28,31].
For the high throughput isolation of antigen specific T-cells using recombinant MHC-peptide complexes the 
use of MHC-multimer complexes is necessary,since MHC-monomers do not stably bind to TCRs. However, 
multimerization of MHC-peptide complexes may false positively increase the binding avidity of the multimer-
ized MHC-peptide complex to T-cells. The analysis of conventional MHC-multimer based TCR dissociation 
kinetics is complicated by multivalent binding and dissociation rates, even when competitor reagents or cold 
MHC-multimer staining are used [32].The controlled disassembly of MHC-multimers to monomers directly 
after MHC-multimer based T-cell isolation and subsequent FACS sorting of T-cells expressing a TCR with 
a low MHC-peptide dissociation rate may further increase the efficiency of future reverse immunology ap-
proaches [33].
In conclusion, with this reverse immunology approach we have demonstrated the immunogenic potential of 
two newly identified MiHA; LB-CLYBL-1Y and LB-TEP1-1S. The biologically relevance of LB-CLYBL-1Y 
was demonstrated by the detection of MHC-multimer positive T-cells with equally high peptide avidity in a 
patient suffering from AML who experienced an anti-leukemic response after treatment with allo-SCT and 
subsequent DLI. The identification of LB-TEP1-1S demonstrated the feasibility of our reverse immunology 
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approach to identify MiHA that are not frequently induced in vivo but can potentially be used for immuno-
therapeutic strategies. In addition, these results demonstrate that this approach will enable the identification 





1. Appelbaum, F. R. 2001. Haematopoietic cell transplantation as immunotherapy. Nature 411:385-389. Falken-
burg, J. H., van de Corp, E. W. Marijt, and R. Willemze. 2003. Minor histocompatibility antigens in human 
stem cell transplantation. Exp. Hematol. 31: 743-751.
2. Feng, X., K. M. Hui, H. M. Younes, and A. G. Brickner. 2008. Targeting minor histocompatibility antigens in 
graft versus tumor or graft versus leukemia responses. Trends Immunol. 29: 624-632.
3. Goulmy, E. 1997. Human minor histocompatibility antigens: new concepts for marrow transplantation and 
adoptive immunotherapy. Immunol Rev 157: 125-140.
4. Mullally, A., and J. Ritz. 2007. Beyond HLA: the significance of genomic variation for allogeneic hematopoi-
etic stem cell transplantation. Blood 109: 1355-1362.
5. Ferrara, J. L., J. E. Levine, P. Reddy, and E. Holler. 2009. Graft-versus-host disease. Lancet 373:  1550-1561.
6. Warren, E. H., P. D. Greenberg, and S. R. Riddell. 1998. Cytotoxic T-lymphocyte-defined human minor histo-
compatibility antigens with a restricted tissue distribution. Blood 91: 2197-2207
7. Bleakley, M., and S. R. Riddell. 2011. Exploiting T cells specific for human minor histocompatibility antigens 
for therapy of leukemia. Immunol. Cell Biol. 89: 396-407.
8. van Bergen, C. A., C. E. Rutten, E. D. van der Meijden, S. A. van Luxemburg-Heijs, E. G. Lurvink, J. J. 
Houwing-Duistermaat, M. G. Kester, A. Mulder, R. Willemze, J. H. Falkenburg, and M. Griffioen. 2010. High-
throughput characterization of 10 new minor histocompatibility antigens by whole genome association scan-
ning. Cancer Res. 70: 9073-9083.
9. Hombrink, P., S. R. Hadrup, A. Bakker, M. G. Kester, J. H. Falkenburg, P. A. von dem Borne, T. N. Schumach-
er, and M. H. Heemskerk. 2011. High-throughput identification of potential minor histocompatibility antigens 
by MHC tetramer-based screening: feasibility and limitations. PLoS. One. 6: e22523.
10. Ofran, Y., H. T. Kim, V. Brusic, L. Blake, M. Mandrell, C. J. Wu, S. Sarantopoulos, R. Bellucci, D. B. Keskin, 
R. J. Soiffer, J. H. Antin, and J. Ritz. 2010. Diverse patterns of T-cell response against multiple newly identified 
human Y chromosome-encoded minor histocompatibility epitopes. Clin. Cancer Res. 16: 1642-1651.
11. Popovic, J., L. P. Li, P. M. Kloetzel, M. Leisegang, W. Uckert, and T. Blankenstein. 2011. The only proposed T-
cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 118: 946-954.
12. Hombrink, P., C. Hassan, M. G. Kester, A. H. de Ru, C. A. Van Bergen, H. Nijveen, J. W. Drijfhout, J. H. 
Falkenburg, M. H. Heemskerk, and P. A. van Veelen. 2013. Discovery of T cell epitopes implementing HLA-
peptidomics into a reverse immunology approach. J Immunol 190: 3869-3877.
13. Gilchuk, P., C. T. Spencer, S. B. Conant, T. Hill, J. J. Gray, X. Niu, M. Zheng, J. J. Erickson, K. L. Boyd, K. J. 
McAfee, C. Oseroff, S. R. Hadrup, J. R. Bennink, W. Hildebrand, K. M. Edwards, J. E. Crowe, Jr., J. V. Wil-
liams, S. Buus, A. Sette, T. N. Schumacher, A. J. Link, and S. Joyce. 2013. Discovering naturally processed 
antigenic determinants that confer protective T cell immunity. J Clin. Invest 123: 1976-1987.
14. The 1000 Genomes Project Consortium. 2010. A map of human genome variation from population scale se-
quencing. Nature 467: 1061-1073.
15. Hassan, C., M. G. Kester, A. H. de Ru, P. Hombrink, J. W. Drijfhout, H. Nijveen, J. A. Leunissen, M. H. Heem-
skerk, J. H. Falkenburg, and P. A. van Veelen. 2013. The human leukocyte antigen-presented ligandome of B 
lymphocytes. Mol. Cell Proteomics. 12: 1829-1843.
16. den Haan, J. M., N. E. Sherman, E. Blokland, E. Huczko, F. Koning, J. W. Drijfhout, J. Skipper, J. Shabanowitz, 
D. F. Hunt, V. H. Engelhard, and . 1995. Identification of a graft versus host disease-associated human minor 
histocompatibility antigen. Science 268: 1476-1480.
17. van Bergen, C. A., M. G. Kester, I. Jedema, M. H. Heemskerk, S. A. van Luxemburg-Heijs, F. M. Kloosterboer, 
W. A. Marijt, A. H. de Ru, M. R. Schaafsma, R. Willemze, P. A. van Veelen, and  J. H. Falkenburg. 2007. Mul-
tiple myeloma-reactive T cells recognize an activation-induced minor  histocompatibility antigen encoded 
by the ATP-dependent interferon-responsive (ADIR) gene. Blood 109: 4089-4096.
18. Nijveen, H., M. G. Kester, C. Hassan, A. Viars, A. H. de Ru, J. M. de, J. H. Falkenburg, J. A. Leunissen, and P. 
A. van Veelen. 2011. HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-
based detection of polymorphic HLA-ligands.Immunogenetics 63: 143-153.
19. Burrows, S. R., N. Kienzle, A. Winterhalter, M. Bharadwaj, J. D. Altman, and A. Brooks. 2000. Peptide-MHC 
Class I Tetrameric Complexes Display Exquisite Ligand Specificity. J Immunol 165: 6229-6234.
20. Rodenko, B., M. Toebes, S. R. Hadrup, W. J. van Esch, A. M. Molenaar, T. N. Schumacher, and H. Ovaa. 2006. 




21. Eijsink, C., M. G. Kester, M. E. Franke, K. L. Franken, M. H. Heemskerk, F. H. Claas, and A.Mulder. 2006. 
Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibod-
ies. J Immunol Methods 315: 153-161.
22. Nauta, A. J., H. S. de, B. Bottazzi, A. Mantovani, M. C. Borrias, J. Aten, M. P. Rastaldi, M. R. Daha, K. C. van, 
and A. Roos. 2005. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 67: 543-553.
23. Griffioen, M., M. W. Honders, E. D. van der Meijden, S. A. van Luxemburg-Heijs, E. G. Lurvink, M. G. Kes-
ter, C. A. van Bergen, and J. H. Falkenburg. 2012. Identification of 4 novel HLA-B*40:01 restricted minor 
histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Haematologica 
97: 1196-1204.
24. Kremer, A. N., E. D. Van Der Meijden, M. W. Honders, J. J. Goeman, E. J. Wiertz, J. H. Falkenburg, and M. 
Griffioen. 2012. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior to-
ward HLA-DM and its natural inhibitor HLA-DO. Blood 120:3246-3255.
25. Toebes, M., M. Coccoris, A. Bins, B. Rodenko, R. Gomez, N. J. Nieuwkoop, W. van de Kasteele, G. F. Rim-
melzwaan, J. B. Haanen, H. Ovaa, and T. N. Schumacher. 2006. Design and use of conditional MHC class I 
ligands. Nat. Med. 12: 246-251.
26. Macdonald, W. A., Z. Chen, S. Gras, J. K. Archbold, F. E. Tynan, C. S. Clements, M. Bharadwaj, L. Kjer-
Nielsen, P. M. Saunders, M. C. Wilce, F. Crawford, B. Stadinsky, D. Jackson, A. G. Brooks, A.W. Purcell, J. W. 
Kappler, S. R. Burrows, J. Rossjohn, and J. McCluskey. 2009. T cell allorecognition via molecular mimicry. 
Immunity. 31: 897-908.
27. Hombrink, P., Y. Raz, M. G. Kester, B. R. de, B. Weissbrich, P. A. von dem Borne, D. H. Busch, T. N.  Schum-
acher, J. H. Falkenburg, and M. H. Heemskerk. 2013. Mixed functional characteristics correlating with TCR-
ligand k -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur. J Immunol. Ford, M. L., 
B. H. Koehn, M. E. Wagener, W. Jiang, S. Gangappa, T. C. Pearson, and C. P. Larsen. 2007. Antigen-specific 
precursor frequency impacts T cell proliferation, differentiation, and require ment for costimulation. J. Exp. 
Med. 204: 299-309.
28. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive 
CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. 
Immunity. 27: 203-213.
29. Nauerth, M., B. Weissbrich, R. Knall, T. Franz, G. Dossinger, J. Bet, P. J. Paszkiewicz, L. Pfeifer,  M. Bunse, W. 
Uckert, R. Holtappels, D. Gillert-Marien, M. Neuenhahn, A. Krackhardt, M. J. Red dehase, S. R. Riddell, and 
D. H. Busch. 2013. TCR-Ligand koff Rate Correlates with the Protective Capacity of Antigen-Specific CD8+ 
T Cells for Adoptive Transfer. Sci Transl Med 5: 192ra87.
30. Wang, X. L., and J. D. Altman. 2003. Caveats in the design of MHC class I tetramer/antigen-specific T lympho-
cytes dissociation assays. J Immunol Methods 280: 25-35.
31. Knabel, M., T. J. Franz, M. Schiemann, A. Wulf, B. Villmow, B. Schmidt, H. Bernhard, H. Wagner, and D. H. 
Busch. 2002. Reversible MHC multimer staining for functional isolation of T-cell populations and effective 






Supplemental Figure 1. The HLA-binding affinity of 25 eluted highly potential MiHA candidates was analyzed by a 
binding assay that is based on HLA-recovery after UV-exchange monomer technology. After UV-exchange the HLA-
monomer rescue score was normalized to the peptides CMV PP65-NLV and CMV PP65-TPR that exhibit a high 
binding affinity for HLA-A*0201 or B*0702, respectively. Peptides with a higher HLA-recovery score (>40%) compared 
to the low affinity HLA-A*0201 binding MART1-WT-AAG were selected for further analysis. As negative control no 
rescue peptide was added. All control peptides are indicated in grey. The percentage of HLA-recovery as a measure 
for HLA-binding affinity for 9 HLA-A*0201 (a) and 16 HLA-B*0702 (b) restricted MiHA candidates was shown. MiHA 
candidates with HLA-recovery score above the selection threshold of 40% are indicated in black. MiHA candidates 
that demonstrated a HLA-recovery below 40% were removed from the study and are indicated with stripes. (C and D) 
Gene expression of CLYBL and TEP1 were analyzed. Normal hematopoietic T-cells, monocytes, B-cells and hemato-
poietic stem cells (HSC) were isolated from (G-CSF mobilized) peripheral blood and bone marrow mononuclear cells 
(PBMC and BMMC) from donors by flowcytometry cell sorting based on expression of  CD3, CD14, CD19 and CD34, 
respectively. Skin derived fibroblasts (FB), keratinocytes (KC) and PTEC were cultured with and without IFN-γ (100 IU/
ml) and hepatocytes were freshly isolated from liver specimen. AML, ALL and CML cells were isolated from peripheral 
blood and bone marrow samples from patients by flowcytometry cell sorting based on expression of CD33, CD19 and 
CD34, respectively. EBV-LCL and PHA blasts were generated using standard procedures. Total RNA was isolated 
and whole-genome gene expression assay was performed as previously described (26). The probe fluorescence for 














HA-2V YIGEVLVSV JY, ALY, HHC JY, HHC 50.4
HA-8R RTLDKVLEV JY, ALY JY, ALY 33.8
LB-SSR1-1S VLFRGGPRGSLAVA HHC HHC 28.6
LB-PRCP-1D MWDVAEDLKAβ HHC HHC 14.3
LB-WNK1-1I TLSPEIITVβ JY, HHC HHC 28.4
LB-NISCH-1A ALAPAPAEV JY JY 39.0
SMCY-A2 FIDSYICQV JY NDγ -
B*07:02
LB-EBI3-1I RPRARYYIQV ALY ALY 14.3
LB-ERAP1-1R HPRQEQIALβ JY, HHC JY, HHC 36.2
LB-GEMIN4-1V FPALRFVEV JY JY 42.5
LB-PDCD11-1F GPDSSKTFLCL ALY, HHC ND -
SMCY-B7 SPSVDKARAEL JY JY 57.8
LB-APOBEC3B-1K KPQYHAEMCF ALY, HHC NDγ -
Supplemental Table 1. Eluted published MiHA epitopes.
Total detected MiHA
α Sequence confirmed by matching the MS spectra of synthetic and eluted peptide 
β Length variant of published MiHA epitope
γ Not Detected (ND)
* Highest detected Best Mascot Ion Score (BMI)
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Supplemental Table 2. Validation scores MiHA candidates.
HLA Peptide Sequenceα Gene PPMβ BMIγ
netMHCµ    
(nM)
A*02:01
P1 GLLGQEGLVEI PARP10 0.7 56 96
P2 ALAPAPAEV NISCH 0.9 40 12
P3 AMLERQFTV FAM119A 0.1 35 3.4
P4 FLSSANEHL GLRX3 0.6 36 10.6
P5 MMYKDILLL HNF4G 0.1 63 6.9
P6 SLAAYIPRL CLYBL 0.8 40 4.1
P7 SLQEKVAKA HMMR 0.5 46 356.4
P8 VLQNVAFSV BCL2A1 1.1 40 12.7
# RLLEAIIRL MYO19 0.1 50 10
B*07:02
P9 APNTGRANQQM BFAR 0.6 44 55.8
P10 LPMEVEKNSTL HDGF 0.1 50 49.7
P11 RPRAPTEELAL C14orf169 0.1 38 3.3
P12 APDGAKVASL TEP1 0.3 45 73.1
P13 APAGVREVM AKAP13 0.1 72 20.5
P14 KPQQKGLRL APOBEC3H 0.3 36 19.6
P15 LPQKKSNAL POP1 0.3 38 6.2
P16 LPQQPPLSL SCRIB 0.4 54 14.2
P17 NPATPASKL C18orf21 0.1 43 71.6
P18 SPASSRTDL MTRR 0.8 45 11.1
P19 SPSLRILAI LLGL2 0.1 48 20.4
P20 HPRQEQIAL ERAP1 1.3 36 9
P21 FPALRFVEV GEMIN4 0.5 43 33
# SPRVGFLSSL WDR91 0.6 56 17
# LPDGGVRLL TSEN54 0.2 46 135
# RPRAPTEEL C14orf169 0.1 36 12
# Low HLA-affinity peptides
α SNP underlined
β Parts-Per-Million: Difference between observed and exact ion mass
γ Best-Mascot-Ion-Score: Match between observed MS spectrum and stated peptide
µ Predicted netMHC affinity (nM), Strong binder ≤50; Weak binder ≤500 
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Supplemental Table 3. 
FHT -/- -/- 0,5 -/- -/- -/- -/- -/- 0,2 
EPP 0,01 -/- -/- 0,2 -/- -/- 0,01 -/- 0,01 0,01 
UBE -/- -/- 0,2 -/- -/- -/- -/- -/- -/- -/- -/- 
AKH -/- -/- -/- -/- -/- -/- -/- 
JSB -/- -/- -/- -/- -/- -/- -/- -/- -/- 2,8 
DSP -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
USQ -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
ABM -/- 5,0 0,01 -/- -/- -/- 0,01 2,0 
UDN -/- -/- 0,2 -/- -/- -/- -/- -/- -/- 
OMH -/- -/- -/- -/- 0,01 -/- -/- -/- 
UBF -/- -/- 0,1 -/- -/- 0,1 -/- 0,1 -/- -/- -/- 
OGV -/- 0,01 -/- -/- -/- 0,01 -/- -/- -/- -/- 
MMY -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 0,01 
CLO -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
UHR -/- -/- -/- -/- -/- -/- -/- -/- 










































































































Expanded T-cell lines after first MHC-multimer pull down  
FHT -/- -/- 0,8 -/- -/- 0,1 -/- -/- 65 
EPP 28 0,3 0,01 8,4 -/- -/- 2,0 -/- 6,7 3,6 
UBE -/- -/- 0,5 -/- -/- -/- -/- -/- -/- -/- -/- 
AKH -/- -/- -/- -/- -/- -/- -/- 
JSB -/- -/- -/- -/- -/- -/- -/- -/- -/- 2,8 
DSP -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
USQ -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 
ABM -/- 28,3 0,2 -/- 0,3 -/- 0,2 5,6 
UDN -/- -/- 85 -/- -/- -/- -/- -/- -/- 
OMH -/- -/- -/- 0,1 38 0,01 0,02 -/- 
UBF -/- -/- 0,1 -/- -/- 0,1 -/- 0,1 0,01 0,02 -/- 
OGV 0,2 54 -/- -/- -/- 0,01 -/- -/- -/- -/- 
MMY -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- 0,04 
CLO -/- 0,1 -/- -/- -/- -/- -/- -/- -/- -/- -/- 
UHR -/- -/- -/- -/- -/- -/- -/- 85 






































































-/- Indicates T-cell population screened for in PBMC donor homozygous negative for the indicated SNP encod-
ing MiHA. Detected T-cell populations are indicated in gray . Frequencies indicate MHC-multimer positive T-




































Expanded T-cell lines after second MHC-multimer pull down  
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Accurate Quantitation of MHC-bound Peptides by Application 




Knowledge of the accurate copy number of HLA class I presented ligands is important in fundamental 
and clinical immunology. Currently, the best copy number determinations are based on mass spectrom-
etry, employing single reaction monitoring (SRM) in combination with a known amount of isotopical-
ly labeled peptide. The major drawback of this approach is that the losses during sample pretreatment, 
i.e.immunopurification and filtration steps, are not well defined and must, therefore, be estimated. In ad-
dition, such losses can vary for individual peptides. Therefore, we developed a new approach in which 
isotopically labeled peptide-MHC monomers (hpMHC) are prepared and added directly after cell lysis, 
i.e. before the usual sample processing. Using this approach, all losses during sample processing can be 
accounted for and allows accurate determination of specific MHC class I-presented ligands. Our study 
pinpoints the immunopurification step as the origin of the rather extreme losses during sample pretreat-
ment and offers a solution to account for these losses. Obviously, this has important implications for 
accurate HLA-ligand quantitation. The strategy presented here can be used to obtain a reliable view of 




Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface play a crucial role in 
immunology, and mediate the communication between T cells and antigen presenting cells. Both the iden-
tity and abundance of these peptides are of great importance in fundamental studies on T cell action and in 
design of T cell-mediated therapy. These include tumor immunotherapy [1] and treatment of hematologi-
cal malignancies by a combination of hematopoietic stem cell transplantation (HSCT) and treatment with 
donor T cells specific for minor histocompatibility antigens (MiHA) expressed on malignant cells from the 
patient [2]. Knowledge of accurate copy number of MHC class I presented epitopes can for example be 
used to study the relationship between differing epitope abundance and T cell immunodominance hierar-
chies [3, 4], and thereby help to improve vaccination strategies to elicit more effective immune responses. 
In addition, knowledge of ligand copy number is important in fundamental studies on antigen processing. 
Currently, the best copy number determinations are based on mass spectrometry, employing SRM in com-
bination with mixing in a known amount of isotopically labeled peptide, known as the AQUA approach [3-
6]. The AQUA standard can be mixed in at different stages during sample pretreatment, but preferably as 
early as possible. The complexity of the ligandome [7] demands various sample pretreatment steps before 
the actual peptide quantitation by LC-MS, involving cell lysis, immunoaffinity purification (IP), filtration 
and usually chromatographic fractionation. The major uncertainty in the accurate quantitation of ligand 
copy number is not caused by the final mass spectrometric experiment, but introduced by the variable 
yields of the sample pretreatment steps, which in addition can be peptide dependent. However, the overall 
yield of the sample pretreatment was not determined in previous studies, but rather estimated.
Therefore, we developed a new approach extending the AQUA approach in which isotopically labeled 
peptide-MHC monomers, i.e. peptide-MHC monomers loaded with a peptide in which two heavy amino 
acids have been incorporated (heavy peptide-MHC, or hpMHC), were prepared as a spike in standard and 
added directly following cell lysis, after which the usual sample processing was applied. Using this ap-
proach all losses during sample processing, including those during immunopurification, can be accounted 
for and it allows accurate determination of specific MHC class I-presented ligands, see Figure 1. We added 
a medium labeled peptide just before final LC-SRM analysis to enable determination of the overall yield 
of the sample pretreatment. Our hpMHC approach (addition of hpMHC before IP) was compared with the 
AQUA approach (addition of heavy peptide after IP).
T cells specific for MiHA have been shown to induce graft versus leukemia reactivity after allogeneic stem 
cell transplantation [2, 8, 9], and a number of MiHA has been used to design strategies for cellular immu-
notherapy but with limited success [10, 11]. An accurate quantitation of the presented peptides involved 
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may help to understand the efficacy of this treatment. Here, we illustrate our approach by analysis of two 
recently discovered minor histocompatibility antigens (MiHA), presented in the HLA-A*0201 molecule 
called (LB-NISCH-1A, ALAPAPAEV) [12], and LB-SSR1-1S, VLFRGGPRGSLAVA [13]. To assess the 
copy number of the endogenous (light) MiHA, we added the HLA-A*0201-monomer loaded with stable 
heavy isotope labeled peptide ALAPAPAEV or VLFRGGPRGSLAVA (∆M=+13 Da) as internal refer-
ence (heavy isotope labeled amino acids are in bold and underlined). The hpMHC were prepared by fold-
ing of recombinant HLA alpha chain and β2m in the presence of the heavy isotope labeled peptide. We 
combined the hpMHC with the AQUA strategy by using the medium labeled peptide ALAPAPAEV or 
VLFRGGPRGSLAVA (∆M=+7 Da), which was added to the chromatographic fractions just before final 
LC-MS quantitation. The medium labeled peptide for AQUA was added to each fraction prior to LC-SRM 
Figure 1. Strategy for the accurate quanti-
tation of MHC-class I-presented peptides. 
An MHC-monomer loaded with heavy la-
beled peptide (hpMHC) is added to the 
cell lysate (step 1) in which the endog-
enous (wt; unlabeled) peptide is present. 
Subsequently, the hpMHC and the wt-
pMHC undergo the same further sample 
pretreatment. Just before LC-MS analysis 
a medium labeled variant of the peptide 
is added (step 4) for determination of the 
yield of the procedure. Black dots: heavy 
peptide, grey dots: medium peptide and 
open dots: wt (unlabeled) peptide. The 
three different forms of the peptide, light, 
medium and heavy, coelute and these 




(or PRM) analysis to determine the overall yield of the sample pretreatment procedure.  In the AQUA ap-
proach the labeled peptide is preferably added as early as possible during sample pretreatment . In contrast, 
we have added the medium peptide just before MS analysis to be able to calculate the overall yield of the 
hpMHC procedure, i.e. the ratio of the medium and heavy labeled peptide. 
The quality of the hpMHC was assessed by mixing equimolar amounts of hpMHC and the medium labeled 
peptide. As can be seen in Supplemental Figure 1, the medium and heavy peptides display the same peak 
height in the MS spectrum, from which we conclude that the purified hpMHC has been correctly loaded with 
a single peptide, and the measured hpMHC concentration, as determined by Bradford, is in line with the pure 
synthetic peptide concentration. Therefore, the intensities of the heavy peptide and the medium peptide can 
be used for their relative quantitation.
Table 1. Quantitation summary of the native LB-NISCH-1A and LB-SSR1-1S peptides for the 3 biological replicates. 
Total peptide amounts, recovery and copy numbers are listed. For the AQUA measurements no copy number is listed, 
since the yield is not known. For the AQUA experiments the amount of heavy peptide and recovery is listed.(n.a.:not 
applicable)
hpMHC-approach




Sample 1 (6.7E9 cells) 8,8 ±0,1% 1.50% 789 ±7
Sample 2 (2E9 cells) 17.6±7.1% 0.90% 5273 ±374





Sample 1 (6.7E9 cells) 33 ±0,4% 2.80% 2943 ±36
Sample 2 (2E9 cells) 33.2±6.7% 0.80% 9960 ±667
Sample 3 (2E9 cells) 40.1±3.2% 0.50% 12030±385
AQUA-approach




Sample 1 (6.7E9 cells) n.a. n.a. n.a.
Sample 2 (2E9 cells) 1.5±7.4% 29.40% n.a
Sample 3 (2E9 cells) 1.3±3.9% 25.80% n.a




Sample 1 (6.7E9 cells) n.a. n.a. n.a.
Sample 2 (2E9 cells) 2.2±11.7% 43.50% n.a.
Sample 3 (2E9 cells) 1.2±2.8% 23.30% n.a.
124
CHAPTER 5
Initial LC-SRM measurements (bioreplicate 1) were performed on a Q-TRAP instrument. Similar SRM 
transitions were used per peptide for the light, medium and heavy labeled peptides (three transitions per 
peptide). After   collision energy  optimization,  the most abundant transitions  were  chosen, as  displayed 
in Supplemental Table 1,  and  Supplemental Figure 2 for the MS2 spectra.  Bioreplicates  2  and  3  were 
recorded  by  PRM  on  a  Q-Exactive.
Next we prepared a calibration curve, in which the linearity of the mass spectrometric determination of 
the medium labeled AQUA peptides ALAPAPAEV and VLFRGGPRGSLAVA were verified with the pure 
synthetic peptides dissolved in buffer A (data not shown) and verified with the pure synthetic peptides dis-
solved in matrix . The matrix was composed of a pool of neighboring first dimension C18 HPLC fractions, 
not containing the peptide of interest. The response was found to be linear between injections of 100 amol 
to100 fmol absolute on column, see Supplemental Figure 3. Following the completion of the calibration 
curve, the MiHA LB-NISCH-1A and LB-SSR1-1S were quantitated. To this end, the cell lysate of 6.7 x 109 
(6.7E9) EBV-LCL JYpp65 cells was spiked with 10 pmol of each hpMHC for bioreplicate 1. For biorepli-
cates 2 and 3, 2.0 x 109 (2E9) cells were spiked with 5 pmol of each hpMHC. After immunopurification of 
HLA class-I molecules, the HLA-class I α-chain and ß2m proteins were separated from the peptides by 10 
kDa filtration and the peptides were fractionated using C18 chromatography and freeze dried. Just before 
mass spectrometric quantitation, fractions were redissolved in solvent A, supplemented with the medium 
labeled peptides to a final concentration of 2.5 and 3.5 fmol/µl for ALAPAPAEV and VLFRGGPRGSLA-
VA, respectively.
The results are listed in Table 1 and shown in supplemental Figure 4. The spiked-in medium labeled peptide 
is present in all fractions. The ratio between the three SRM transitions of each MiHA is constant, so there 
is no interference from other potentially contaminating background peptides. The heavy labeled peptide 
and the light (endogenous) peptide, which both underwent the whole sample pretreatment procedure, are 
coeluting as expected and are only present in two neighboring fractions. The overall yield of the sample 
pretreatment was calculated from the ratio of the medium labeled peptide and the heavy labeled peptide. As 
an example for bioreplicate 1, for LB-NISCH-1A the sum of the heavy labeled peptide peaks in fractions 
16 and 17 (panel C) should correspond to 330 fmol of heavy peptide (i.e. 1/30th of 10 pmol spike in of 
hpMHC in lysate, since 1/30th of the peptide pool was injected on column) at 100% peptide recovery from 
the lysate. However, the actual response corresponds to approximately 4.9 fmol (the sum of the medium 
labeled peptides in fractions 16 and 17 in panel A). Therefore, the yield of the heavy labeled LB-NISCH-
1A peptide, derived from the hpMHC, is determined to be 1.5% (4.9/330). The amount of endogenous LB-
NISCH-1A (panel B) can easily be calculated from the ratio of the heavy peptide and light peptide, and was 
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determined to be 8.8 pmol. The absolute amount of 8.8 pmol on 6.7E9 cells corresponds to a copy number 
of 789, see Table 1. Similarly for LB-SSR1-1S the yield of the heavy labeled peptide (panel F) was deter-
mined to be 2.8%.The amount of endogenous LB-SSR1-1S (panel E) was calculated to be 33 pmol, which 
corresponds to a copy number of 2943, see Table 1. Similarly the numbers for the other bioreplicates were 
determined. These numbers represent the cell surface copy number, since the majority of the pMHC is on 
the cell surface, rather than in an internal compartment, see supplemental Figure 5.
Striking differences in recovery were observed between the hpMHC and AQUA approach. The steps fol-
lowing the IP, comprising filtration, first dimension chromatographic fractionation and the final LC-MS 
run, have an overall recovery of 23 to 43% (which amounts to 3 steps of approximately 70% on average 
per step), as determined by the AQUA approach. In sharp contrast with the former the yield of the hpMHC 
approach was determined to be 0.5-3%. Therefore, rather extreme losses, i.e. 90-99%, occur during the 
immunopurification step. 
Quite some variation in native peptide copy number between biological replicates can be observed in 
Table 1. It is important to note that the ratio between the medium peptide and the heavy peptide (added as 
hpMHC) was constant throughout all experiments, as it should since these were taken from the same stock 
solution for all experiments. The former rules out any issues with the added labeled peptide and hpMHC. 
If the measured variation can be fully attributed to biological variation is not clear. The stability of the 
native pMHC complexes during cell storage might play a role. 
The hpMHC approach was used to account for all losses during MHC ligand isolation and purification. 
Our results show that the use of hpMHC allows accurate quantitation of the HLA class I-presented pep-
tides, by accounting for all losses during sample pretreatment. These losses can be very serious, as shown 
for the MiHA presented in this study. Since our first elution experiments in the mid 1990’s we have found 
these low yields. The fact is that the average yields are indeed low, which we illustrated to be approxi-
mately 5% on the basis of total HLA measured versus total peptide intensity in the mass spectrometer 
[7].Based on the current measurements, with a lower starting number of cells, the average yield seems 
closer to 1-2%. In addition, a simple calculation in combination with final mass spectrometric responses 
shows the same. Starting from 1 billion cells (1E9) and assuming a conservative number of 300.000 HLA 
I molecules on the cell surface of an EBV-LCL, we calculate a total number of 3E14 HLA I molecules. 
Using Avogadro’s number this yields (3E14/6E23 = 0.5E-9 mol), i.e. 500 pmol HLA. Assuming 1,000 
different ligands representing the majority of the total HLA-ligandome, the amount per peptide totals 500 
fmol. These peptide levels, based on 100% yield, are not observed in our nanoHPLC-experiments. We 
detect much lower amounts, compared to known peptide standard responses. Furthermore, we have also 
126
CHAPTER 5
performed MHC-elutions, according to Illing et al.[14] of as low as 25 million cells, still identifying over 
1100 HLA ligands using the same stringent criteria used in Hassan et al. [7]. These 1100 identified ligands 
represent a very competitive number, so the losses we report and compensate for, appear to be real and 
seem a general phenomenon in peptidome analysis. Summarizing the above, we conclude that sample 
loss issues have never been fully addressed analytically. We are confident that the pMHC monomers are 
stable, since we can fold stable pMHC monomers and subsequently stable tetramers for T cell staining. 
All of the above, to our opinion, clearly illustrates the need for an internal standard from the beginning of 
the sample processing, i.e. the need for a hpMHC. Naturally, for every peptide of interest the correspond-
ing hpMHC must be prepared, similar to LC-SRM drug/metabolite monitoring experiments of small com-
pounds in which specific heavy isotopes are introduced by chemical synthesis. Similarly, this strategy is 
applicable to MHC class II complexes, although these cannot yet as easily be produced as class I pMHC 
complexes. The strategy presented here can be used to get a better view of epitope copy number and as 
such improve vaccine design and immunotherapy. 
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Preparation of hpMHC monomers
Recombinant HLA-A2 heavy chain and human β2m light chain were in-house produced in Escherichia coli. 
The refolding was performed by adding 1.8 mg of HLA-A*0201 heavy chain dissolved in 8M urea, 1.2 mg 
of β2m dialyzed to PBS and 2 mg of heavy labeled peptide (ALAPAPAEV or VLFRGGPRGSLAVA) dis-
solved in DMSO, to 50 ml of cold refolding buffer; (400 mM L-arginine HCl, 100 mM Tris-HCl pH 8; 5 
mM reduced glutathione, 0.5 mM oxidized glutatione-Na, 2 mM EDTA, 5% glycerol, Complete protease 
inhibitors (Roche)), and vigorously mixed after each step. The mixture was incubated for 72 hr. at 10 °C [1]. 
The refolded protein mixture was concentrated to a volume of 0.5 ml with an Amicon concentrator (mem-
brane cutoff, 30 kDa), then purified by gel filtration using fast protein liquid chromatography on a Superdex 
75 column (Amersham Biosciences) and PBS as eluent. Complexes were stored at -80°C. The quality of 
the monomers was tested by analysis of a known amount of hpMHC complex (as determined in a Bradford 
assay) relative to pure medium peptide. hpMHC was washed on a microconspin filter with a cutoff  of 10 
kDa to remove residual unbound peptide and small molecule impurities. An equimolar amount of medium 
labeled peptide was added to the washed hpMHC. Subsequently 10% acetic acid was added to the sample 
to dissociate the heavy labeled peptides from the heavy chain and β2m proteins. The medium and heavy la-
beled peptides were spun through the filter and analysed using nano-LC-LTQ-FT, see supplemental Figure 1.
Determination of cell surface pMHC vs non-cell surface pMHC
To distinguish pMHC on the cell surface and pMHC still in the ER or cis-golgi, cells were lysed and to-
tal class I pMHC was isolated by IP with W6/32 mAb [2]. After washing, the samples were split in two. 
One was digested with Endoglycosidase H (EndoH), while the other was left untreated. Subsequently, the 
samples were Western blotted and the heavy chain of MHC class I, was probed using HC10 mAb. As can 
be seen in the left hand side of the supplemental Figure 4, there is hardly any shift in the MHC class I posi-
tion, while the positive control MHC class II fully shifts as expected (right hand side of the picture). Only 
immature MHC class I molecules are endo-H sensitive and are still in the ER/golgi, i.e. not on the surface. 
The fraction of immature MHC class I is very low (<10%), and will hardly change the cell surface copy 
number. The alpha chain of MHC class II was used as a control in these experiments, with mAb L243 (IP) 




Q-TRAP SRM; Biorepilicate 1 was analyzed in triplicate on an Ultimate 3000 RSCL Nanosystem (Dionex), 
hyphenated to a QTRAP® 5500 instrument (AB SCIEX, Foster City,CA) operated in positive SRM mode 
and equipped with a nano-electrospray source with applied voltage of 2.2 kV and a capillary heater tempera-
ture of 175 °C. The Nanoflow LC system and QTRAP® 5500 system were both controlled using Analyst 
1.5.1 software. The scheduled SRM mode comprised the following parameters: SRM detection window 
of 600 sec, centered around the retention time (at 34.5 min for ALAPAPAEV and 37,3 min for VLFRG-
GPRGSLAVA), target scan time of 3.0 s, curtain gas of 15, ion source gas 1 of 15, declustering potential of 
100, entrance potential of 10. Q1 and Q3 resolution were set to unit. Pause between mass ranges was set to 
1 ms. Collision cell exit potential (CXP) was set to 36 for all transitions. Peak integration was performed 
using MultiQuant™ software version 2.1 (AB SCIEX, Foster City, CA) software and manually reviewed. 
Chromatographic separation of peptides was performed by a 68 min gradient at 300 nL/min. Solvent A 
(0.05% formic acid water) and solvent B (0.05% formic acid, 80% acetonitrile) were mixed at 2% B from 
0-3 min, 15% B at 4 min, 36% B at 49 min, 99% B from 50-54 min, 2% B at 55-68 min. The 20 cm x 75 
µm ID fused silica nano-LC columns, custom packed with 3 µm 100 Å ReproSil Pur C18 aqua (Dr Maisch 
GMBH, Ammerbuch-Entringen, Germany), were made in house. After injection, peptides were trapped at 6 
µl/min at 2% B, before elution to the analytical column at 300 nL/min. The mass spectrometer operated in 
SRM mode to detect endogenous (wild type; light), medium and heavy labeled peptides using the optimized 
parameters (supplemental Table 1). The selected and optimized fragment of the medium labeled peptides 
were used to select the fragments of endogenous (light) and heavy labeled versions of peptide. All other 
parameters, CE, CXP, EP, DP and gasses were chosen identical to those for each corresponding transition 
of the medium labeled peptide.
Q-Exactive PRM; biological samples 2 and 3 were analyzed in triplicate with an on-line C18-nano-HPLC-
MS system, consisting of an Easy nLC 1000 gradient HPLC (Thermo, Bremen, Germany), and a Q-Exactive 
mass spectrometer (Thermo). Fractions were injected onto a homemade precolumn (100 μm × 15 mm; Re-
prosil-Pur C18-AQ 3 μm, Dr. Maisch, Ammerbuch, Germany) and eluted via a homemade analytical nano-
HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 3 um). The gradient was run from 0% to 30% solvent 
B (10/90/0.1 water/ACN/FA v/v/v) in 45 min. The nano-HPLC column was drawn to a tip of  approximately 
5 μm and acted as the electrospray needle of the MS source. The Q-Exactive mass spectrometer was record-
ing in parallel reaction monitoring (PRM) mode. One cycle comprised one full scan and nine transitions. 
Full scan parameters were; resolution 70,000 at an AGC target value of 3,000,000, maximum fill time of 
100 ms (full scan), and resolution 35,000 at an AGC target value of 1,000,000/maximum fill time of 100 ms 
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for MS/MS. PRM was performed at a normalized collision energy (NCE) of 27. The isolation window was 
2 m/z.
Data analysis
Q-TRAP SRM: the LC-SRM data were analysed using MultiQuant™ software version 2.1 (AB SCIEX, 
Foster City, CA). Peak integration was performed using MultiQuant™ software and manually reviewed. The 
retention times and ratio of the three transitions were checked for each peptide. The summed peak area of 
the three transitions was used for the calculation of the amount of endogenous (light) peptide. The recovery 
of the enrichment method was assessed using the summed peak area of the three transitions of the heavy la-
beled peptide compared to the peak area of medium labeled peptide. The amount of the MiHA peptides was 
determined from the ratio of the endogenous (light) peptide and the heavy peptide , for which the average of 
three measurements of the summed peak areas of three transitions were used. Q-Exactive PRM; for quantita-
tion, raw files were processed in Skyline v. 2.5.0.6079 [3]. In the transition settings dialog box monoisotopic 
was chosen for precursor and product ion, and resolution was set to 70,000 at m/z 200. The results from 
Skyline were exported as csv-files and further processed with MS Excel, and visualized with Graphpad.
Supplemental Table 1. Parameters used to analyse the endogenous, wild type (light), medium and heavy la-
beled peptides by SRM. z= ion charge, CE=collision voltage.
Labeling NISCH-1A Peptide sequence z(Q1) Q1 mass Q3 mass CE
wt (light; no label) ALAPAPAEV 2 419.8 415.22 (y4) 12
ALAPAPAEV 1 838.5 583.31 (y6) 14
ALAPAPAEV 1 838.5 415.22 (y4) 16
Medium ALAPAPAEV 2 423.3 415.22 (y4) 12
ALAPAPAEV 1 845.5 583.31 (y6) 14
ALAPAPAEV 1 845.5 415.22 (y4) 16
Heavy ALAPAPAEV 2 426.3 415.22 (y4) 12
ALAPAPAEV 1 851.5 589.31 (y6) 14
ALAPAPAEV 1 851.5 415.22 (y4) 16
Labeling SSR1-1S Peptide sequence z(Q1) Q1 mass Q3 mass CE
VLFRGGPRGSLAVA 3 467.3 655.9 (b13 (2+)) 16
wt (light; no label) VLFRGGPRGSLAVA 3 467.3 606.4 (b12 (2+)) 18
VLFRGGPRGSLAVA 3 467.3 570.8 (b11 (2+)) 27
VLFRGGPRGSLAVA 3 469.6 659.4 (b13 (2+)) 16
Medium VLFRGGPRGSLAVA 3 469.6 609.9 (b12 (2+)) 18
VLFRGGPRGSLAVA 3 469.6 574.3 (b11 (2+)) 27
VLFRGGPRGSLAVA 3 471.6 662.4 (b13 (2+)) 16
Heavy VLFRGGPRGSLAVA 3 471.6 612.9 (b12 (2+)) 18
VLFRGGPRGSLAVA 3 471.6 577.3 (b11 (2+)) 27




The Epstein-Barr virus transformed B lymphoblastic cell line (EBV-LCL) LCL-JYpp65 (typing: HLA-
A*0201, B*0702 & Cw*0702) was used as a source of HLA-class I molecules. The MiHA in this study 
have previously been reported by Hombrink et al. [4] and van Bergen et al. [5]. Pellets of LCL-JYpp65 cells 
(6.7E9) were lysed in 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, and 0.5% Zwittergent 3-12, (pH 8.0) 
and supplemented with protease inhibitor (Complete, Sigma Aldrich). The final concentration of the cells in 
the lysis buffer was 1E8 cells/ml. After 2 hours incubation with tumbling at 4 oC, the preparation was centri-
fuged for 10 minutes at 2500 rpm and 4 oC. The supernatant was transferred to a new tube and centrifuged 
for 35 minutes at 11000 rpm and 4 oC. The supernatant of the cell lysate was spiked with 10 pmol monomer 
(recombinant HLA-A*0201 associated with heavy labeled MiHA (hpMHC) and pre-cleared on a 7 ml CL4-B 
column and subjected to the 7 ml immunoaffinity column (W6/32 anti HLA class-I antibody (2.5 mg Ab /ml 
protein-A-Sepharose)) with a flow rate of 2.5 ml/min. For bioreplicates 2 and 3 2 ml CL4-B and IP columns 
were used. After washing, the bound HLA-class I/peptide complexes were dissociated and eluted from the 
column with 10% acetic acid. The proteins and the peptides in the eluate were separated by ultrafiltration us-
ing a 10 kDa membrane filter (Pall Macrosep centrifuge devices). The filtrate was lyophilized, redissolved in 
solvent A and the peptides were purified by solid phase extraction (C18 Oasis, 100 µl bed volume, Waters). 
The purified peptides were fractionated on a homemade RP Reprosil-Pur C18-AQ column (200 µm ID, 3 
um x 15 cm) (Dr. Maisch, GmbH, Ammerbuch, Germany). 40 half minute wide fractions were collected and 
subsequently freeze dried, redissolved in buffer A, containing  2.5 fmol/ul medium labeled peptide (ALA-
PAPAEV) and 3.5 fmol/ul of the medium labeled peptide VLFRGGPRGSLAVA and analyzed by LC-SRM.
Peptide synthesis 
The medium and heavy MiHAs LB-NISCH-1A and LB-SSR1-1S were synthesized by incorporation of stable 
isotope labeled amino acids. The 13C, 15N-labeled amino acids leucine (L) and proline (P) (Sigma-Aldrich, 
Netherlands), were used to synthesize the LB-NISCH-1A and LB-SSR1-1S peptides using standard Fmoc 
chemistry on a SyroII peptide synthesizer (MultiSynTech, Witten, Germany). The peptides were labeled ei-
ther with only leucine (medium) or leucine and proline (heavy) isotope labeled amino acids, see supplemental 
Table 1. The integrity of the peptides was confirmed using reverse phase UHPLC and MS.
Amino acid analysis
Amino Acid Analysis was performed by Eurosequence (Groningen, The Netherlands), the method of which 
is partly proprietary. The Aminoquant method was executed as described by Schuster [6]. Because of the 
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presence of DMSO in the sample, no gas-phase hydrolysis, but liquid phase hydrolysis was used. The 
sample was hydrolyzed in 5.7 M HCl for 24 hours at 110 °C. The hydrolysate was dissolved in 100 µl of 
0.1 N borate buffer containing 100 pmol nVal/µl, and 1 µl was used for the analysis. Columns and reagents 
as described in literature were used [7]. 
Spectroscopic analysis of medium peptide concentration
Spectroscopic peptide concentration determination was performed on a Ultrospec 2100 pro UV/VIS spec-
trophotometer (Amersham/Biosciences) using absorption at either 280 nm fortyrosine (Y) (ε= 1400 mol-
1cm-1), or 355 nm for the o-phthaldialdehyde (OPA)-derivatives. OPA is a particularly favorable reagent 
because the fluorescence and long wavelength absorption only develops due to the reaction with the peptide 
amino terminus, so the reagent itself causes no background, and the reaction is fast (2 to 3 minutes at room 
temperature). Lysine residues are also labeled, but these are not present in our peptide. Since fluorescence 
is mostly quenched in peptides, as we experienced and has been reported by others [6], and references 
therein, we used the absorbance characteristics of the OPA derivatives. First the peptide concentration of 
a Y-containing peptide was determined at 280 nm (with ε(Y) = 1400 mol-1cm-1), and subsequently the 
concentration was used to determine the ε (OPA) at 355 nm. The ε(OPA) at 355 nm was determined to be 
2040 mol-1cm-1. This value for the OPA-derivatives was checked by determination of the concentrations 
of 4 other peptides at 280 nm and at 355 nm after reaction with OPA and the number of 2040 mol-1cm-1 
yielded the same results. So use of the absorbance characteristic of the OPA reagent is just as valuable as 
Supplemental Figure 1. The quality of the hpMHC. Heavy peptide dissociated from the hpMHC was mixed with an 
equimolar amount of synthetic medium labeled peptide. Equal peak heights are observed in the mass spectrometer, 




Supplemental Figure 2. Tandem mass spectra of the light, medium and heavy form of the MiHAs LB-NISCH-1A (top) 
and LB-SSR1-1S (bottom). Bold and underlined letters refer to the heavy labeled amino acids. Notice the shifts in the 
tandem mass spectra of the differently labeled species.
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measurement of Y at 280 nm. This method was subsequently applied to the MiHA LB-NISCH-1A and LB-
SSR1-1S. The concentration was determined to be 0.50 mg/ml, which is in agreement with the AAA value of 
0.48 mg/ml. The results are in the supplemental Table 2.  
 
Formally from the AQUA approach the copy numbers cannot be calculated since the yield of the immuno-
purification step is not known. Note however that the measured peak areas for the native peptides are very 
similar for the hpMHC and AQUA approaches for bioreplicates 2 and 3. 
Sequence Y280* OPA* AAA
SLAAYIPRL 1.5 1.5 -
GVPGADIFYEANPR 0.96 1.12 -
DRVYIHPF 0.77 0.72 -
FLPSDYFPSV 1.04 0.92 -
YVLDHLIVV 0.95 1.15 -
ALAPAPAEV n.a. 0.5 0.48
VLFRGGPRGSLAVA n.a. 0.69 -
Supplemental Table 2. Concentration of medium labeled peptides, numbers in the table are in mg/ml. *Average 
of 3 independent measurements.
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Supplemental Figure 3. (A) calibration curve of medium labeled peptide ALAPAPAEV in matrix, (B) calibration curve 
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Supplemental Figure 4 (see next 5 pages). (A) Average peak area of the (A&D) medium labeled, (B&E) endogenous 
(light) peptide and (C&F) heavy labeled peptide in the chromatographic fractions. Average of three measurements. 
The annotations in the figures indicate the transitions from the doubly charged precursor to fragment y4 (white), singly 
charged precursor to fragment y6 (gray) and singly charged precursor to y4 (black) for LB-NISCH-1A peptides, and the 
transitions from triply charged precursor to doubly charged fragments b13 (white), b12 (gray ) and b11 (black) for LB-
SSR1-1S peptide.
Bioreplicate 1 (hpMHC approach, SRM Q-TRAP)
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Bioreplicate 2 (hpMHC approach, PRM Q-Exactive)
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Bioreplicate 3 (hpMHC approach, PRM Q-Exactive)
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Bioreplicate 2 (AQUA approach, PRM Q-Exactive)
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Supplemental Figure 5: Distribution of pMHC in EBV-JY LCL. As can be seen in the left panel the fraction of 
endoH-sensitive HLA class-I is very small (<10%), marked with the arrow, which indicates that the vast majority of 
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NOTE:
Finally, it is important to note that there are two issues that influence the accuracy of the determined pMHC 
cell surface copy number.  First, it is generally assumed that the large majority of  pMHC is present on the cell 
surface. Therefore, we determined the fraction of cell surface pMHC and non-cell surface pMHC, according to 
Bennett et al. [2]. From supplemental Figure 5 it can be seen that the large majority of the pMHC in our EBV-
JY cells is present on the cell surface. Second, the accuracy of the described approach depends on the accuracy 
of the determination of the peptide and protein standards used in the study, i.e. on the amino acid analysis and 
the Bradford assay used. The intrinsic inaccuracy of these methods is generally estimated to be 10-20%, which 
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Minor histocompatibility antigens (MiHA) are peptides encoded by polymorphic genes that are presented by 
Human leukocyte antigen (HLA) molecules and are recognized by T cells in recipients of allogeneic hemato-
poietic cell transplants. The allelic counterpart (AC) of the MiHA is derived from the same gene and is gener-
ally considered to be non-immunogenic. The polymorphic peptide response is thought to be unidirectional, 
and the lack of immunogenicity of the AC has generally been attributed to the lack of peptide presentation 
at the cell surface. Here we report on the occurrence of both polymorphic forms on the cell surface in the 
context of the same presenting HLA-molecule. This study, based on quantitative mass spectrometric deter-
mination of the specific MiHA/AC pairs, describes three cases in which the abundance of the AC is similar 
to the MiHA. Therefore, the unidirectionality of MiHA specific immune responses can in these cases not 
be explained by absence of the AC, from which we conclude that an underlying immunological selection 




Minor histocompatibility antigens (MiHA) are HLA-presented peptides, derived from polymorphic proteins 
that differ between individuals due to genomic single nucleotide polymorphisms (SNP).  T cells directed 
against these MiHAs can induce beneficial graft versus leukemia reactivity after allogeneic hematopoietic stem 
cell transplantation (allo-SCT) and subsequent donor lymphocyte infusion (DLI) [1-4]. The non-immunogenic 
polymorphic peptide derived from the same gene is called the allelic counterpart (AC).  AC differ from MiHA 
by at least one amino acid in the peptide sequence. The lack of immunogenicity of the AC has generally been 
attributed to the lack of peptide presentation on the cell surface, due to changes in intracellular processing [5, 
6], low HLA binding affinity [7, 8], gene deletion [9], frame shifts due to nucleotide insertion [10], alternative 
splicing [11, 12], or from the introduction of the translation of termination codon [13]. However,  bidirectional 
MiHA immune responses have been described, indicating that the AC of certain MiHAs can be presented 
(BCL2-A1; [14] & HB-1; [15]). The above examples are summarized in Table 1, as immunological situation 
A and B. In situation A the lack of an immunological response towards the AC could be explained by absence 
of the AC on the cell surface. In situation B an immunological response against the AC is found, indicating 
that the AC is at the cell surface. 
The basis of this study is to investigate whether in those cases, where no immune response against AC has 
been documented ( i.e. situation C), the MiHA as well as the AC are present at the cell surface.
To investigate whether  differences between the immunogenicity of the MiHA and the AC are due to dif-
ferences in the cell surface expression level of the two peptide variants, we quantified on the peptide level 
the cell surface expression of the MiHA and the AC. To quantify the absolute copy number of the MiHAs 
Table 1: Overview of the three immunological situations in which a MiHA is present, in combination with the absence 
or presence of a T cell response to the allelic counterpart (AC), and the absence or presence of the AC.
Imm. Situation MiHA AC AC Present? 
A + - -
B + + +
C + - +
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and their ACs presented in the context of HLA on the cell surface, we employed the newly developed heavy 
peptide-MHC (hp-MHC) method using stable isotope labeling in combination with single reaction monitor-
ing (SRM) [16]. SRM is a targeted method with high sensitivity for the detection of peptides isolated from 
biological samples, and enables the accurate quantification of peptides in a complex biological background. 
SRM has been widely used in the field of proteomics for quantitation of in vitro digested proteins (peptides) 
[17-19]. In 2005 Hogan and coworkers [20] used SRM to detect and quantify peptides associated with the 
major histocompatibility complex (pMHC), recently SRM was used for the quantitation of the SIINFEKL 
epitope presented by ovalbumin-transfected cells [21] and presentation of eight vaccinia virus peptide-MHC 
complexes (epitopes) on infected cells [22]. In this study we describe the quantitation of three MiHA and their 
ACs, which  have previously been identified in our lab [23, 24] and chapter 5 of this thesis, on the cell surface 
of heterozygous cells. We show, for three individual MiHA/AC pairs, similar abundance of MiHA and AC. 
The results clearly show that the lack of immunogenicity of the AC cannot be explained by differences in the 
relative abundance on the cell surface.
 
MATERIALS AND METHODS 
Sample preparation 
Epstein-Barr virus transformed B lymphoblastic cell lines (B-LCL) LCL-HHC (typing: HLA-A*0201, 
B*0702, B*4402, Cw*0501 & Cw*0702) and LCL-JY (typing: HLA-A*0201, B*0702 & Cw*0702) were 
used as source of HLA-A*0201 molecules. These two cell lines were selected according to the genotype of the 
SNPs encoding for the three MiHAs that are the subject of this study. The LCL-HHC is heterozygous for the 
SNP genotype of CLYBL (citrate lyase subunit beta-like), while the LCL-JY cell line is heterozygous for the 
SNP genotype of NISCH (Imidazoline receptor 1) and SSR1 (Signal sequence receptor subunit alpha) (Table 
1). B-LCLs were expanded in roller bottles, and cultured in IMDM supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), penicillin/streptomycin and L-glutamine.  B-LCLs were collected, washed with ice 
cold PBS and stored at -80 oC until use. Hybridoma cell lines were expanded in roller bottles to obtain W6/32 
(anti HLA-class I) antibody using protein free hybridoma medium supplemented with penicillin/streptomycin, 
and L-glutamine. Antibodies produced by the hybridoma cell lines were purified from the supernatant using 
Prot-A sepharose beads and eluted from the Prot-A beads with Glycine pH 2.5. The eluted antibodies were 
used to produce immunoaffinity columns (W6/32- Prot-A sepharose 2.5 mg/ml). The W6/32 antibodies were 
covalently bound to Prot-A sepharose beads using dimethylpimelimidate (DMP). The columns were stored in 
PBS pH 8.0 and 0.02% NaN3 at 4 oC.
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Preparation of the heavy peptide loaded monomers (hpMHC)
Recombinant HLA-A2 heavy chain and human β2m light chain were in-house produced in Escherichia coli. 
The refolding was performed by adding 1.8 mg of HLA-A*0201 heavy chain dissolved in 8M urea, 1,2 mg 
of β2m dialyzed with PBS and  2 mg of heavy labeled peptides dissolved in DMSO, to 50 ml of cold refold-
ing buffer; (400 mM L-arginine HCl, 100 mM Tris-HCl pH 8; 5 mM reduced glutathione, 0.5 mM oxidized 
glutatione-Na, 2 mM EDTA, 5% glycerol, complete protease inhibitors (Roche)), vigorously mixed after each 
step, the mixture was incubated for 72 hr. at 10 °C [25]. The refolded mixture was concentrated to a volume of 
less than 0.5 ml with an Amicon concentrator (membrane cutoff, 30 kDa), then purified by fast protein liquid 
chromatography on a Superdex 75 column (Amersham Biosciences) with PBS. Complexes were stored at 
-80°C. The quality of the monomers was confirmed by analysis of a known amount of hpMHC, as determined 
by a Bradford assay, added to a spin filter with a cutoff of 10 kDa. An equimolar amount of the corresponding 
medium labeled peptide was added to the sample and subsequently 10% acetic acid was added to the sample 
to dissociate the hpMHC. The medium and heavy labeled peptides were spun down and analyzed by MS, dis-
playing an equal intensity, see Supplemental Figure 1 and [16].
Peptide synthesis
Isotope labeled peptides were synthesized by incorporation of the stable isotope labeled (13C, 15N) amino 
acids leucine (L) and  proline (P) (Sigma-Aldrich, The Netherlands) using standard Fmoc (N-(9-fluorenyl) 
methoxycarbonyl) chemistry with a SyroII peptide synthesizer (MultiSynTech, Witten, Germany). Peptides 
were labeled either with isotope labeled leucine (medium peptides) or with isotope labeled leucine and isotope 
labeled proline (heavy peptides), see Table 2. The integrity of the peptides was checked using reverse phase 
HPLC and MS.
Isolation of HLA class I-presented peptides 
The peptides associated with HLA-class I molecules were extracted from the pellets of 7 x 109 LCL-JY cells 
and 7 x 109 LCL-HHC cells. The pellets were lysed in 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, and 
0.1% zwittergent 3-12, (pH 8.0) and supplemented with complete protease inhibitors (Roche). The total con-
centration of cells in the lysis buffer was 1 x 108 cells/ml. 10 pmol of HLA-class I monomer loaded with a 
heavy isotope labeled peptide (hpMHC) [16]  of each polymorphic variant was added to the lysate to account 
for all sample loss during the chromatographic process used in extraction of the peptides from the cell lysate 
[26]. After 2 hours incubation with tumbling of the cells in the lysis buffer at 4 oC, the preparation was centri-
fuged for 10 minutes at 2500 rpm and 4oC. The supernatant was transferred to a new tube and centrifuged for 
35 minutes at 11000 rpm and 4 oC. The supernatant was pre-cleared with CL4B beads and subjected to the im-
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munoaffinity column with a flow rate of 2 ml/min. After washing, bound pMHC complexes were eluted from 
the column, and dissociated, with 10% acetic acid. Peptides were separated from the HLA-class I molecules 
by passage through a 10 kDa membrane (Pall macrosep centrifuge devices). The filtrate was freeze dried, 
redissolved and the peptides were further purified by solid phase extraction (C18 Oasis,100 µl bed volume, 
Waters), freeze dried and resuspended in 95/3/0.1 water/ACN/FA, v/v/v.
  
 Peptide separation
To reduce the complexity of the eluted peptide pool, we fractionated the peptide pool using an home-made RP 
Reprosil-Pur C18-AQ column (200 µm ID, 3 um x 15 cm, Dr. Maisch, GmbH, Ammerbuch, Germany). The 
sample was loaded in solvent A (100/0.1 water/FA v/v), and the gradient was run from 0-50% B (10/90/0.1 
water/ACN/FA v/v/v) in 30 min at a flow rate of 4 ul/min. The samples were taken up in a make-up flow of 
50/50/0.1 water/ACN/FA at 100 ul/min supplied via a T-piece through the annular space between the separa-
tion capillary and an auxiliary capillary.  In this way 45 half-a-minute wide fractions were collected, subse-
quently freeze dried and stored at -80 oC pending LC-SRM analyses. An IFN-γ release test was performed of 
all fractions to detect the fractions in which the MiHA is present using MiHA specific T cell clones. In addition 
to the MiHA positive fractions, neighboring fractions were also selected to be analyzed with LC-SRM for 
the eluted (light) MiHA peptides. Since the fractions containing the AC could not be detected with the T cell 
clones, fractions were selected on the basis of their known elution behavior relative to the MiHA. The selected 
fractions were analyzed for quantification of the eluted (light) AC peptides.
LC-SRM-analyses
The selected HPLC fractions were lyophilized and resuspended in 30 ul  mix of medium labeled peptides. 
The concentrations of the peptides were 2.5 fmol/ul (ALAPAPAEV; LB-NISCH-1A), 2.5 fmol/ul (ALA-
PAPVEV; NISCH-1V), 4.5 fmol/ul (SLAAYIPRL; LB-CLYBL-1Y), 4.5 fmol/ul (SLAADIPRL; CLYBL-
1D, 3.5 fmol/ul (VLFRGGPRGSLAVA; LB-SSR1-1S), 3.5 fmol/ul (VLFRGGPRGLLAVA; SSR1-1L). These 
samples were analysed in triplicate on an Ultimate 3000 RSCL Nanosystem (Dionex) that was hyphenated 
to an QTRAP® 5500 instrument (AB SCIEX, Foster City,CA) operated in positive SRM mode and equipped 
with a nano-electrospray source with applied voltage of 2.200 kV and a capillary heater temperature of 175 
°C. The Nanoflow LC system and QTRAP® 5500 system were both controlled using Analyst 1.5.1 Software. 
The scheduled SRM mode comprised the following parameters: SRM detection window of 600 sec, target 
scan time of 3.0 s, curtain gas of 15, ion source gas 1 of 15, declustering potential of 100, entrance potential 
of 10. Q1 and Q3 resolution were set to unit. Pause between mass ranges was set to 1 ms. Collision cell exit 
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potentials (CXP) was set to 36 for all transitions. The retention times for the different peptides were 54.3 
min (SLAAYIPRL; LB-CLYBL-1Y), 46.7 min (SLAADIPRL; CLYBL-1D), 34.6 min (ALAPAPAEV; LB-
NISCH-1A), 41.8 min (ALAPAPVEV; NISCH-1V), and 37.7 min (VLFRGGPRGSLAVA; LB-SSR1-1S), 
47.7 min (VLFRGGPRGLLAVA; SSR1-1L). Peak integration was performed using MultiQuant™ software 
version 2.1 (AB SCIEX, Foster City, CA) software and manually reviewed. Chromatographic separation of 
peptides was performed by a 68 min gradient at 300 nL/min. Solvent A (0.05% formic acid water) and solvent 
B (0.05% formic acid, 80% acetonitrile) were mixed at 2% B from 0-3 min, 15% B at 4 min, 36% B at 49 
min, 99% B from 50-54 min, 2% B at 55-68 min. The nano-LC columns were made in house and consisted of 
20 cm x 75 µm ID fused silica custom packed with 3 µm 100 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, 
Ammerbuch-Entringen, Germany). After injection, peptides were trapped at 6 µl/min at 2% buffer B, before 
elution to the analytical column at 300 nL/min.
SRM assay development
An SRM assay for the target proteins was developed using the MRMPilot™ software version 2.1 from AB 
SCIEX (Concord, ON, Canada).  Assay development included verification of the peptide transitions, and col-
lision energy (CE) optimisation of these transitions. During verification the highest responding transitions 
and optimum CE-energy were determined, see  Supplemental Table 1. During CE-optimisation the transi-
tions selected after verification are optimised during the chromatographic elution of the peptide. All data of 
CE-optimisation were uploaded to the MRM Pilot and for each peptide three transitions at the experimentally 
found optimum and the experimentally found retention time were included in the final assay. The correspond-
ing fragment ions were selected for light, medium and heavy versions of peptides, using the same parameters.
Data analysis
The LC-SRM data were analyzed using MultiQuant™ software version 2.1 (AB SCIEX, Foster City, CA) 
software Peak integration was performed using MultiQuant™ software and manually reviewed. The reten-
tion time and the ratio of the three transitions per peptide were checked to exclude interferences from other 
peptides.  
Quantitation using isotope labeled peptides 
Peptide abundances were calculated by comparing the peak area of the eluted (light) and heavy peptides with 
the peak area of corresponding medium labeled peptide spiked into the fractions prior to LC-SRM analysis, 
as previously described [16].  
Next we prepared a calibration curve, in which the linearity of the mass spectrometric determination of the 
medium labeled AQUA peptides SLAAYIPRL, SLAADIPRL, ALAPAPAEV, ALAPAPVEV, VLFRGGPRG-
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SLAVA and VLFRGGPRGLLAVA were verified with the pure synthetic peptides dissolved in matrix . The 
matrix was composed of a pool of neighboring first dimension C18 HPLC fractions, not containing the peptide 
of interest. The response was found to be linear between injections of 100 amol to 100 fmol absolute on col-
umn, see Supplemental Figure 2.
IFNγ release assay
MiHA specific T-cell clones (2×103) were stimulated with 1 x 104 T2 or HLA-A*0201 expressing B-LCLs 
cells in 384 well plates for 18 hr. at 37°C and 5% CO2. Peptide pulsing was performed by incubating stimula-
tor cells for 1 hr. with the eluted peptides (C18-fractions) or with different concentrations (0.0256 - 250 pM) 
of synthetic MiHA and AC peptides in IMDM containing 2% FCS. The stimulator cells were washed twice 
before addition to the T cells. Cytokine release was measured by IFN γ ELISA (Sanquin, CLB, Amsterdam, 
The Netherlands) according to the manufacturer’s instructions. 
Competition refolding assay
The competition refolding assay has been developed in our lab by Tan et al. [27]. Briefly, this assay employs 
unfolded recombinant heavy chain molecules in combination with β2m and the commercially available fluo-
rescent standard peptide (FLPSDCFlFPSV a modified HBV epitope), and relies on protein folding during the 
assay. The peptide of interest competes with the labeled standard peptide for binding. After 24 hr. of incuba-
tion protein complexes and free peptide are separated by HPLC size-exclusion chromatography, during which 
the fluorescence of protein and peptide fractions is continuously monitored. Following peak integration of 
the fluorescent signals the ratio of label in the protein and peptide fractions is calculated. The affinities of the 
peptides are expressed as IC50 , the peptide concentration at which binding of the standard peptide is reduced 
Table 2. Overview of the gene name, protein name, and cell lines from which the MiHA and AC were derived from. The 
polymorphism is underlined and the heavy isotope labeled amino acids are indicated in bold












NISCH-1V† ALAPAPVEV ALAPAPVEV ALAPAPVEV




VLFRGGPRGSLAVA    VLFRGGPRGSLAVA    VLFRGGPRGSLAVA
SSR1-1L† VLFRGGPRGLLAVA VLFRGGPRGLLAVA VLFRGGPRGLLAVA
*MiHA, and † Allelic counterpart (AC)
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to 50%. In this assay we measured the 3 MiHA/AC pairs,   CLYBL-1Y/D, NISCH-1A/V and SSR1-1S/L.
RESULTS
Differential recognition of MiHA and AC peptide by the MiHA specific T cell clones
To validate the MiHA specificity of the T cell clones, the three MiHA specific T cell clones were stimulated 
with titrated concentrations of each MiHA/AC peptide pair, and the T cell response was determined by mea-
suring IFNγ release overnight, see Figure 1. For all three MiHA specific T cell clones a clear differential 
recognition pattern of the respective MiHA and AC peptide pair was demonstrated. For both the LB-CLYBL-
1Y specific T cell-clone K264 and the LB-SSR1-1S specific clone 11-5 even very  high concentrations of the 
AC CLYBL-1D and SSR1-1L, respectively, were not able to elicit a T cell response.  For the LB-NISCH-1A 
specific clone 10H5 we were able to demonstrate a 1500-fold lower sensitivity for the AC peptide compared 
to the MiHA peptide. In addition, B-LCL cell lines homozygous positive or negative for the MiHA encoding 
Figure 1. Differential reactivity of MiHA and 
AC by the MiHA specificT cell clones (A) 
MiHA specific T cell clone K264,  was tested 
against titrated concentrations of MiHA (LB-
CLYBL-1Y) and respective AC (CLYBL-1D) 
peptide loaded on T2 cells. (B) peptide clone 
10H5 was tested against MiHA (LB-NISCH-
1A) and respective AC (NISCH-1V) peptide 
and (C) clone11-5 was tested against MiHA 
(LB-SSR1-1S) and respective AC (SSR1-
1L). IFN-γ was measured after overnight 
stimulation using standard ELISA.
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SNPs confirm the specificity of the T cell clones. 
MiHA and AC have similar binding affinities
To exclude that the differential reactivity directed to MiHA and AC were due to differences in binding affinity 
of the MiHA and respective AC, the binding affinities of  the MiHA/AC pairs were determined by a competi-
tion assay [27]. The IC50s measured in this assay of the 3 MiHA/ AC pairs were demonstrated to be compa-
rable and are listed in Table 3. The predicted binding affinities were calculated by NetMHC version 3.2. server, 
and these appeared to similar for each MiHA/AC pair. In addition, the determined affinities and the predicted 
binding affinities for each MiHA/AC pair were comparable, see Table 3
Table 3. Predicted and tested binding affinity of MiHA and AC peptides.
Gene name Peptide sequence Length (AA) IC50 (nM)
NetMHC 
prediction (nM)
LB-CLYBL-1Y SLAAYIPRL* 9 22 8
CLYBL-1D SLAADIPRL† 9 16 13
LB-NISCH-1A ALAPAPAEV* 9 52 12
NISCH-1V ALAPAPVEV† 9 46 12
LB-SSR1-1S VLFRGGPRGSLAVA*      14 78 250
SSR1-1L VLFRGGPRGLLAVA† 14 94 221
*MiHA and †Allelic counterpart (AC)
MiHA and AC display similar abundance at the cell surface
To investigate whether the MiHA and AC display differences in abundance at the cell surface that could ex-
plain the differential immunogenicity of the MiHA and AC, the pMHC of MiHAs and corresponding ACs 
were measured by quantitative mass spectrometry. To quantify the amount of MiHA and AC peptides, we 
incorporated as internal standard the different peptides containing one stable isotope labeled heavy amino acid 
(medium peptides), as described previously [20-22, 28, 29]. In addition, to correct for sample losses during 
sample work-up, hpMHC complexes were added, that were loaded with peptides containing two stable isotope 
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labeled heavy amino acids (heavy peptide) [16]. All three forms of the peptide, i.e. the native form to be de-
termined, and the two quantitation standards, are measured in the same LC/MS run and their abundance ratios 
determined for accurate quantitation. As an example the results for LB-CLYBL-1Y and CLYBL-1D are shown 
in Figure 2, in which the intensities are shown of the light eluted peptide, the medium peptide, which was 
added to all fractions just before MS measurement, and the heavy peptide, derived from the added hpMHC. 
The results of LB-SSR1-1S, SSR1-1L, LB-NISCH-1A and NISCH-1V, are shown in the supplemental Figures 
3 and 4. The medium AQUA peptide is  obviously present in all fractions, while the eluted peptide and the 
heavy peptide are present in only one or two fractions, as they should. Since the amounts of added medium 
Table 4. Summary of the quantitation data of MiHA and AC: the amount of eluted (light) peptides, percentage of the 
recovery of heavy peptides, calculated number of copy per cell and the ratio of the MiHA to allelic counterpart.




LB-CLYBL-1Y SLAAYIPRL* 18 ± 1 1616  ± 111
6:1
11%
CLYBL-1D SLAADIPRL† 3  ± 0,04 273 ± 4 10%
LB-NISCH-1A ALAPAPAEV* 8,8 ± 0,08 789  ± 7
1:5
1.5%
NISCH-1V ALAPAPVEV† 40 ± 0,22 3591  ± 20 3%
LB-SSR1-1S VLFRGGPRGSLAVA* 33 ± 0,4 2943  ± 36
2:1
2.8%
SSR1-1L VLFRGGPRGLLAVA† 13 ± 0,2 1242  ± 18 5%
*MiHA and †Allelic counterpart (AC)
peptide and heavy peptide were known, the amount of eluted peptide and the recovery could be easily calcu-
lated. The results are listed in Table 4.
To demonstrate that the similar abundance of the 3 MiHA and their respective AC is not an exception, we 
mined the ligandome presented in chapter 2 and found several MiHA/AC pairs that are similarly expressed 
at the cell surface, which are shown in Table 5. Although not quantitated by use of heavy isotope labelled in-









In this study, we demonstrate by quantitative MS that the immunogenicity of 3 different MiHAs is not deter-
mined by differential surface expression of the immunogenic MiHA and the non-immunogenic AC. The ac-
curate mass spectrometric determination of peptide copy number was achieved by a combination of a recently 
developed procedures in which stable isotope labeled variants of the peptide are spiked in at different stages 
of the procedure, see Figure 2 and supplemental Figure 3 and 4. Known quantities of hpMHC are added to 
the cell lysate, to account for losses during peptide elution, HPLC fractionation and sample preparation [16]. 
Thus, the wild type peptide to be determined and the hpMHC-derived heavy peptide variant undergo all sub-
sequent steps of the procedure together, including affinity chromatography, further chromatographic purifica-
tion and separations steps and final MS measurement. The ratio of the known amount of the heavy peptide 
and the wild type peptide allows a direct determination of the amount of wild type peptide. Just before MS 
measurement a known amount of medium peptide was added, which allows to determine the overall yield of 
the sample pretreatment procedure. 
MiHAs differ from their AC by their ability to elicit T cell responses. This unidirectional reactivity of the T 
cell response is generally explained by the absence or very low abundance of the allelic counterpart on the cell 
surface. The low abundance of non-immunogenic AC has previously been described to be due to differences 
in intracellular processing between the MiHA and the AC [5, 6] or due to low HLA binding affinity of the 
AC  [7, 8]. Furthermore, gene deletion [9], frame shifts due to nucleotide insertion [10], alternative splicing 
[11, 12], and introduction of a termination codon [13] could  potentially result in the absence or low abundant 
expression of the AC at the cell surface.  In previous studies  bidirectional T cell responses against both the 
MiHA and AC have been described [14, 15], indicating that some allelic counterparts are presented at the cell-
surface. We have recently shown that the ACs of some MiHA could be detected on the cell surface [23, 26] 
and in chapter 5 of this thesis, which seems to imply that the immunogenicity of the MiHA cannot always be 
explained by the absence of the AC. 
We  hypothesize that for a surface expressed AC not to be recognized by a T cell, the AC should be clearly 
less abundant than the surface expression of the MiHA, at least by a factor of 10. Probably this factor is even 
greater. 
As can be seen in this study the cell surface expression of MiHA LB-SSR1-1S is approximately 3 times more 
abundant than its corresponding AC (SSR1-1L) and the cell surface expression of MiHA LB-CLYBL-1Y is 
approximately 5 times more abundant than the corresponding AC (CLYBL-1D). However, for the NISCH 
peptide pair, the AC is approximately 4 times more abundant on the cell surface than the corresponding MiHA. 
So in the three cases reported here, the expression of the MiHA and the corresponding AC have a comparable 
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cell surface expression. Therefore the unidirectional reactivity of the three MiHA specific T cell responses 
cannot be explained by a large differential cell surface expression of the MiHA and the AC. 
The heterozygous B-LCLs used in this study presented both polymorphic variants and therefore could theo-
retically be recognized by T cells directed against the MiHA, as well as by T cells directed to its polymorphic 
counterpart. Based on the clear presence and similar abundance of the polymorphic variants we hypothesize 
that immune responses directed towards both variants could be induced. However, thus far we have only found 
immune responses to the MiHAs LB-SSR1-1S, LB-NISCH-1A and LB-CLYBL-1Y, and not against their 
respective ACs.  In short, we screened patient samples after allogeneic stem cell transplantation (allo-SCT) 
and subsequent donor lymphocyte infusion for pMHC multimer positive T cells ([23, 24] and in chapter 5 
of this thesis), and we enriched from the naïve T-cell repertoire MiHA and AC specific T cells using pMHC 
multimers [30]. Although T cells were identified specific for the MiHA LB-SSR1-1S and the LB-CLYBL-1Y 
in leukemia patients who entered complete remission after allo-SCT, no T cells directed against the ACs were 
observed in this cohort of leukemia patients. T cells directed against LB-NISCH-1A and LB-CLYBL-1Y were 
identified from the naïve T-cell repertoire, also here no T cells were observed directed against the two ACs. 
The absence of an immune response to the ACs might be due to the absence of a high affinity TCR repertoire 
due to tolerance against the AC. Tolerance induction against the AC might be based on homology with other 
self-peptides presented in the same HLA or alternative peptide-HLA complexes. Alternatively, absence of an 
immune response directed against the AC variant might be due to a numbers game, meaning that by carefully 
screening of a large cohort of patients experiencing an alloreactive immune responses after allo-SCT and sub-
sequent donor lymphocyte infusion an AC specific immune response might be identified. 
Above we have thoroughly quantified three MiHAs and their ACs. Besides these MiHA/AC pairs we identi-
fied 6 additional MiHA/AC pairs, see Table 5, during the discovery phase of our previously reported reverse 
immunology approach [23, 26] and chapter 5 of this thesis, from which we conclude that the phenomenon of 
clear presence of the AC on the cell surface does not seem to be exception, contrary to the general opinion.
In this study we accurately quantitated three MiHA and their ACs expressed in the context of HLA at the cell 
surface of cells heterogeneous for the two polymorphic variants.  The results clearly demonstrate that both 
variants are expressed to a similar extent at the cell surface, demonstrating that the lack of immunogenicity 




Table 5. Identification of additional  MiHA and AC peptides.
Peptide sequence BMI Cell line Length NetMHC Allele Polymorphic AA
EEFGQAFSF 52 HHC 9 117 B44 Q
EEFGRAFSF 57 HHC 9 129 B44 R
ISISALQSL 40 HHC 9 >1000 ? L
ISISAMQSL 37 HHC 9 >1000 ? M
SPNAQILAL 42 JYpp65 9 6 B7 I
SPNAQVLAL 37 JYpp65 9 6 B7 V
YLIDGAHKI 35 HHC 9 3 A2 A
YLIDGTHKI 43 HHC 9 3 A2 T
MILPVGAAKF 65 HHC 10 >1000 ? K
MILPVGAANF 66 HHC 10 >1000 ? N
SEESAVPERSW 75 HHC 11 35 B44 E
SEESAVPKRSW 51 HHC 11 36 B44 K
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Supplemental Figure 1. The quality of the hpMHC was assessed by mixing equimolar amounts of hpMHC and the 
medium labeled AQUA peptide. Both peptides display the same peak height in the MS spectrum, from which we con-
clude that the hpMHC has been correctly loaded and purified and the measured hpMHC concentration as determined 
by Bradford is in line with the pure synthetic peptide concentration. Therefore the intensities of the heavy peptide and 
the medium peptide can be used for their relative quantitation.
SUPPLEMENTAL DATA
Supplemental Table 1. SRM parameters used for the acquisitions of MiHA(*) and  AC(†) for each eluted (light), 




Gene name Peptide sequence z (Q1) Q1 Q3 CE
LB-CLYBL-1Y*
SLAAYIPRL
2 502,3 803,48 (y7) 18
2 502,3 661,4 (y5) 21
2 502,3 506,28 (b5) 18
SLAAYIPRL
2 505,81 803,48 (y7) 18
2 505,81 661,4 (y5) 21
2 505,81 513,28 (b5) 18
SLAAYIPRL
2 508,81 809,48 (y7) 18
2 508,81 667,4 (y5) 21
2 508,81 513,28 (b5) 18
CLYBL-1D†
SLAADIPRL
2 478,3 498,34 (y4) 32
2 478,3 755,44 (y7) 20
2 478,3 571,33 (b6) 17
SLAADIPRL
2 481,79 498,34 (y4) 32
2 481,79 755,44 (y7) 20
2 481,79 578,33 (b6) 17
SLAADIPRL
2 484,79 504,34 (y4) 32
2 484,79 761,44 (y7) 20
2 484,79 578,33 (b6) 17
LB-NISCH-1A*
ALAPAPAEV
2 419,75 415,22 (Y4) 12
1 838,5 583,31 (Y6) 14
1 838,5 415,22 (Y4) 16
ALAPAPAEV
2 423,25 415,22 (Y4) 12
1 845,5 583,31 (y6) 14
1 845,5 415,22 (y4) 16
ALAPAPAEV
2 426,25 415,22 (y4) 12
1 851,5 589,31 (y6) 14
1 851,5 415,22 (y4) 16
NISCH-1V†
ALAPAPVEV
1 866,53 611,34 (y6) 29
1 866,53 443,25 (y4) 31
1 866,53 620,39 (b7) 36
ALAPAPVEV
1 873,53 611,34 (y6) 29
1 873,53 443,25 (y4) 31
1 873,53 627,39 (b7) 36
ALAPAPVEV
1 879,53 617,34 (y6) 29
1 879,53 443,25 (y4) 31
1 879,53 633,39 (b7) 36
LB-SSR1-1S*
VLFRGGPRGSLAVA     
3 467,32 655,9 (b13 (2+)) 16
3 467,32 606,36 (b12(2+)) 18
3 467,32 570,84 (b11(2+)) 27
VLFRGGPRGSLAVA     
3 469,62 659,4 (b13(2+)) 16
3 469,62 609,86 (b12(2+)) 18
3 469,62 574,34 (b11(2+)) 27
VLFRGGPRGSLAVA
3 471,62 662,4 (b13(2+)) 16
3 471,62 612,86 (b12(2+)) 18
3 471,62 577,34 (b11(2+)) 27
SSR1-1L†
VLFRGGPRGLLAVA
3 476 669,1 (b13(2+)) 16
3 476 619,39 (b12(2+)) 19
3 476 583,87 (b11(2+)) 28
VLFRGGPRGLLAVA
3 478,3 672,42 (b13(2+)) 16
3 478,3 622,89 (b12(2+)) 19
3 478,3 587,37 (b11(2+)) 28
VLFRGGPRGLLAVA
3 480,3 675,42 (b13(2+)) 16
3 480,3 625,89 (b12(2+)) 19
3 480,3 590,37 (b11(2+)) 28
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Supplemental Figure 2. Calibration curve of medium labeled peptide (A) LB-CLYBL-1Y, (B) LB-NISCH-1A, (C) LB- 
SSR1-1S, (D) CLYBL-1D, (E) NISCH-1V and (F) SSR1-1L in matrix.
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Supplementary Figure 3. Combined data of peak area of the selected SRM transitions of MiHA (LB-NISCH-1A) and 
AC (NISCH-1V) in LCL-JY fractions
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Supplemental Figure 4: . Combined data of peak area of the selected SRM transitions of MiHA (LB-SSR1-1S) 
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ABSTRACT
  Human Leukocyte Antigen (HLA) class I molecules generally present peptides (p) of 8 to 11 amino acids 
(aa) in length. Although an increasing number of examples with lengthy (>11 aa) peptides, presented mostly 
by HLA-B alleles, have been reported. Here we characterise HLA-A*02:01 restricted, in addition to the 
HLA-B*0702 and HLA-B*4402 restricted, lengthy peptides (>11 aa) arising from the B-cell ligandome. 
We analysed a number of 15-mer peptides presented by HLA-A*02:01, and confirmed pHLA-I-formation 
by HLA-folding and thermal stability assays. Surprisingly the binding affinity and stability of the 15-mer 
epitopes in complex with HLA-A*02:01 were comparable to the values observed for canonical length (8 to 
11 aa) HLA-A*02:01-restricted peptides. We solved the structures of two 15-mer epitopes in complex with 
HLA-A*02:01, within which the peptides adopted distinct super-bulged conformations. Moreover, we dem-
onstrate that T-cells can recognize the 15-mer peptides in the context of HLA-A*02:01, indicating that these 
15-mer peptides represent immunogenic ligands. Collectively, our data expand our understanding of longer 
epitopes in the context of HLA-I, highlighting that they are not limited to HLA-B family, but can bind the 






 Human Leukocyte Antigen (HLA) class I molecules are expressed on the surface of all nucleated cells 
presenting peptides for CD8+ T-cell recognition. The peptides presented in HLA class I molecules are pro-
tein fragments of intracellular origin, which are degraded by an array of proteases, the most prominent of 
which is the proteasome. The protein fragments are truncated to smaller peptides and translocated into the 
endoplasmic reticulum (ER). In the ER, the peptide-HLA class I molecule (pHLA) is assembled from a 
peptide, a polymorphic heavy chain and the monomorphic light chain called β2-microglobulin (β2m). Both 
β2m and the peptide are required for the stability of the HLA class I molecule. A peptide with adequate 
binding motif residues will bind into the peptide-binding groove of the HLA class I molecule, allowing the 
assembled molecule to leave the ER and be transported via the Golgi complex to the cell surface to display 
the peptides to CD8+ T-cells [1]. 
It has long been reported that HLA class I molecules can accommodate 8-11 mer peptides, typically 9-mers 
[1-3]. Over the last few years, different groups have reported the binding of 12-mer, 13-mer, 14-mer, and 
even a 16-mer peptides to HLA class I molecules [4-13]. Crystallographic and biophysical studies showed 
the binding of a 13-mer viral epitope to the HLA-B*3508 molecule and T-cell recognition of the bulged 
peptide [12, 14-16]. The synthetic elongation of previously defined T-cell epitopes by central amino acid 
insertion revealed binding of 8-25 mer peptides to HLA-B*3508, although central amino acid insertion was 
not generally tolerated well for all peptides [17]. 
Since some longer peptides are recognized by T-cells, such peptides may play an important role in T-cell 
mediated therapies for cancer, and in vaccine design. So far, a rather limited number of naturally processed 
and presented longer peptides have been reported, and notably the majorities involve HLA-B alleles. Gen-
erally, previous reports on longer peptides have focused on a single or a few isolated peptides. A more 
general view on the contribution of longer peptides to the HLA-ligandome, in-depth analysis is required. 
One of our previous studies [8] provided an in-depth analysis, and allowed the selection of longer peptides 
for follow-up studies. Therefore, in the present study, we report on these longer peptides, i.e 14-23-mers, 
binding to the HLA-B family members, namely HLA-B*4402 and HLA-B*0702, and more surprisingly to 
the HLA-A family molecule, HLA-A*02:01. Our analysis was focused on the common HLA-A*02:01 al-
lele and its ability to bind 15 amino acid long epitopes. After elution and sequencing of the 15-mer peptides, 
bound to HLA class I molecules, we analysed the pHLA-A*02:01 stability. We compare the binding affinity 
and stability of 15-mer-HLA-A*02:01 complexes with the canonical length 9 and 10-mer peptides bound to 
the same HLA molecule. We subsequently solved the structures of two distinct 15-mer epitopes in complex 
with the HLA-A*02:01 molecule, and show that they exhibited contrasting conformations of their central 
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bulged region. Finally we formally establish that HLA-A*02:01 loaded with 15-mer peptides are antigenic 
targets for the T-cells, using tetramers loaded with the 15-mer epitopes to isolate reactive T-cells.
EXPERIMENTAL PROCEDURES
  Cellular sample preparation
Sample preparation was as described in [8]. Briefly, Epstein-Barr virus (EBV) transformed B lymphoblas-
tic cell lines (EBV-LCL) LCL-HHC (typing: HLA-A*02:01, B*0702, B*4402, Cw*0501 and Cw*0702) 
and LCL-JYpp65 (typing: HLA-A*02:01, B*0702 and Cw*0702) were expanded in roller bottles, using 
IMDM, supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin/streptomycin and 
L-glutamine, were collected, washed with ice cold PBS and stored at -80 oC until use. Antibodies were pro-
duced, purified and stored as described in [8].
  Isolation of HLA class I-presented peptides
Pellets of LCL-JYpp65 and LCL-HHC cell lines were lysed in 50 mM Tris-HCl, 150 mM NaCl, 5 mM 
EDTA, and 0.5% Nonidet-P40 (pH 8.0) and supplemented with Complete protease inhibitors (Roche). 
The total concentration of the cells in the lysis buffer was 0.1x 109 cells/ml. After 2 hours incubation with 
tumbling of the cells in the lysis buffer at 4 oC, the preparation was centrifuged at 4 oC for 10 minutes at 
2070 xg. The supernatant was transferred to a new tube and centrifuged at 4 oC for 35 minutes at 19,000 
xg. The supernatant was pre-cleared with CL4B beads and subjected to the W6/32 immunoaffinity column 
with a flow rate of 2 ml/min. After washing, bound peptide-HLA class I complexes were eluted from the 
column, and dissociated, with 10% acetic acid. Peptides were separated from the HLA class I molecules by 
passage through a 10 kDa membrane (Pall macrosep centrifuge devices), and further purified by solid phase 
extraction (C18 Oasis, 100 µl bed volume, Waters), freeze dried and resuspended in 95/3/0.1 water/ACN/
FA, v/v/v.   
  Peptide separation
The pools of peptides eluted form the two EBV-LCL lines were divided in three portions (LCL-JYpp65) or 
two portions (LCL-HHC). The LCL-JYpp65 pools were separated by peptide IEF, SCX and C18 chroma-
tography and the LCL-HHC pools were separated by peptide IEF and SCX chromatography, as described in 
[8] to achieve a high number of identified peptides. The fractions obtained from the three off line separation 
techniques were further fractionated and analyzed by nano-LC-MS/MS. 
  Mass Spectrometry data analysis
The tandem mass spectra were matched against the International Protein Index (IPI) human database ver-
sion 3.87, using the mascot search engine version 2.2.04 (Matrix Science, London, UK)), with a precursor 
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mass tolerance of 2 ppm, with methionine oxidation as a variable modification, and a product ion tolerance 
of 0.5 Da. Scaffold software version 3 (www.proteomesoftware.com) was subsequently used to process the 
mascot output files and generate spectrum reports. Duplicates were removed, and peptides longer than 11 
amino acids with mascot ion score ≥35 were selected (Supplemental Table 1). The selection of a mascot ion 
score >35 has been thoroughly discussed in Hassan et al.[8].
  Peptide synthesis
Peptides were synthesized using standard fluorenylmethoxycarbonyl (Fmoc) chemistry using a SyroII pep-
tide synthesizer (MultiSynTech, Witten, Germany) (Table 1). The integrity of the peptides was checked 
using RP-HPLC and MS. The purity of the peptides was higher than 95%.
  Refolding of pHLA monomers
Recombinant HLA-A*02:01 heavy chain and human β2m light chain were in-house produced in Esch-
erichia coli. The refolding was performed by adding 1.8 mg of HLA-A*02:01 heavy chain solubilised in 8 
M urea, 1.2 mg of β2m dialyzed to PBS and 2 mg of peptide dissolved in DMSO, to 50 ml of cold refolding 
buffer; (400 mM L-arginine HCl, 100 mM Tris-HCl pH 8; 5 mM reduced glutathione, 0.5 mM oxidized 
glutatione-Na, 2 mM EDTA, 5% glycerol, Complete protease inhibitors (Roche)), and vigorously mixed 
after each step. The mixture was incubated for 72 hr. at 10 °C. The refolded protein mixture was concen-
trated to a volume of 0.5 ml with an Amicon concentrator (membrane cutoff, 30 kDa), then purified by gel 
filtration using fast protein liquid chromatography on a Superdex 75 column (Amersham Biosciences) and 
PBS as eluent. Complexes were stored at -80°C. The efficiency of the refolding (recovery) is determined by 
protein concentration measurement of the formed pHLA by the Bradford protein assay.
  Preparation of pHLA tetramers 
Biotinylated pHLA complexes containing the FLNKDLEVDGHFVTM (FLNKD) or the ALQDAGDSSR-
KEYFI (ALQDA) peptide bound to HLA-A*02:01 (RAB9AFLNKD:HLA-A*02:01 or GYPCALQDA:HLA-
A*02:01, respectively) were conjugated to streptavidin-coupled phycoerythrin (SA-PE, Invitrogen) or al-
lophycocyanin (SA-APC, Invitrogen) to form pHLA-tetramers. Thereto, RAB9AFLNKD:HLA-A*02:01 
and GYPCALQDA:HLA-A*02:01 complexes were incubated with SA-PE or SA-APC at empirically de-
termined ratios of 12:1 and 10:1, respectively, based on biotinylation efficiency. Concentration of pHLA-
tetramers was adjusted to 0.2 µg/µl with PBS. pHLA-tetramers were stored at 4 °C.
  Isolation of peptide-specific T-cell clones
After having obtained informed consent, peripheral blood mononuclear cells (PBMCs) of HLA-A*02:01-
negative healthy individuals were isolated by Ficoll-density gradient. To isolate RAB9A or GYPC-re-
active T cells by enrichment with pHLA-tetramers, a previously described protocol was used with mi-
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nor modifications (18). PBMCs were incubated with PE-labelled RAB9AFLNKD:HLA-A*02:01 and 
GYPCALQDA:HLA-A*02:01-tetramers for 1 hour at 4 °C. Cells were washed twice and incubated with 
anti-PE magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). PE-labelled cells were en-
riched via magnetic associated cell sorting (MACS) on a LS column (Miltenyi Biotec) according to manu-
facturer’s instructions (Miltenyi Biotec). Subsequently, positive fractions were incubated with an antibody 
against CD8 (Invitrogen/Caltag, Buckingham, UK) in combination with antibodies against CD4, CD14, and 
CD19 (BD Pharmingen, San Jose, CA, USA) for 15 min at 4 °C. Cells were washed twice. pHLA-binding 
CD8+ T-cells were single-cell sorted on a FACSAria (Becton Dickinson Bioscience) into 96-well round-
bottom culture plates containing 50,000 irradiated (35 Gy) autologous PBMCs in 100 µl culture medium 
composed of IMDM (Lonza, Basel, Switzerland) supplemented with 100 IU/ml IL-2 (Proleukine; Novartis 
Pharma, Arnhem, The Netherlands), 5 % FBS (Gibco, Life Technologies, Carlsbad, CA, USA), 5 % human 
serum, and 0.8 µg/ml phytohemagglutinin (PHA; Remel, Lenexa, KS, USA).
 FACS analysis of isolated T-cell clones 
20,000 T-cells of a particular clone were stained with 10 μl of pHLA-tetramers in a final concen-
tration of 2 µg/ml per pHLA-tetramer for 15 min at 37 °C. Cells were washed once and analysed 
on a LSRII (Becton Dickinson Biosciences) using Diva software (Becton Dickson Biosciences).
 Functional analysis of T-cell clones
2,000 T-cell of a particular clone were co-incubated with 30.000 T2 cells or EBV-transformed B lymphoblas-
tic cell lines (B-LCLs). T2 cells were loaded with different concentrations of peptide for 30 min at 37 °C prior 
to co-incubation with T-cell clones. Following 18 hr. of co-culture, supernatant was harvested and GM-CSF 
secretion was assessed using standard enzyme-linked immunosorbent assay (ELISA; R&D systems) follow-
ing manufacturer’s instructions. 
  HLA  competition  refolding assay
The competition refolding assay has been developed previously [19]. Briefly, this assay employs unfolded 
recombinant HLA-A*02:01 heavy chain in combination with folded β2m and the commercially available 
fluorescent standard peptide (FLPSDCFlFPSV, a modified HBV epitope), and relies on protein folding dur-
ing the assay. The peptide of interest competes with the labelled standard peptide for binding. After 24 hr. 
of incubation, protein complexes and free peptide are separated by size-exclusion chromatography, during 
which the fluorescence of protein and peptide fractions are monitored. Following peak integration of the fluo-
rescent signals, the ratio of label in the protein and peptide fraction is calculated. The affinities of the peptides 
are expressed as IC50, the peptide concentration at which binding of the standard peptide is reduced to 50% 
(Table 1). In this assay we used three epitopes with high binding affinity to the HLA-A*02:01 molecules; 
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(LB-NISCH-1A (ALAPAPAEV), CMV-pp65-NLV (NLVPMVATV) and MART1-M-ELA (ELAGIGILTV) 
[18]. We used MART1-WT-AAG (AAGIGILTV) as a low affinity binder to the HLA-A*02:01 molecule [18]. 
  Thermal stability assay
To assess the stability of each peptide in complex with the pHLA-A*02:01, a thermal shift assay was per-






ALQDAGDSSRKEYFI 15 40 414
GNB3
Guanine nucleotide-binding pro-
tein G(I)/G(S)/G(T) subunit 
beta-3
ALWDIETGQQKTVFV 15 39 15




KLFDSTIADEGTWTL 15 75 10
NFKB1
Isoform 2 of Nuclear factor NF-
kappa-B p105 subunit
KLLEIPDPDKNWATL 15 36 24
ZNF828 Zinc finger protein 828 KLMEALEPPLEEQQI 15 55 1366
EEF2 Elongation factor 2 LLYEGPPDDEAAMGI 15 92 55
ARPC3
Actin-related protein 2/3 complex 
subunit 3




ALAPAPAEV 9 42 52
CMV PP65 NLVPMVATV 9 28 45
MART1-M-ELA
Melanoma antigen modified ana-
logue
ELAGIGILTV 10 n.a. 46
MART1-WT-AAG Melanoma antigen wild type AAGIGILTV 9 n.a. 6955
AA, amino acid length; BMI, best mascot ion score; IC50, and binding affinity of peptides; *oxidized methionine 
residue; n.a., not applicable.
Table 1. HLA-A*02:01 specific peptides 
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formed. The fluorescent dye Sypro orange was used to monitor the protein unfolding. The thermal stability 
assay was performed in the Real Time Detection system (Corbett RotorGene 3000), originally designed for 
PCR. Each pHLA-A*02:01 complex in 10 mM Tris-HCl pH 8, 150 mM NaCl, at two concentrations (5 and 
10 µM) in duplicate, was heated from 25 to 95°C with a heating rate of 1°C/min. The fluorescence intensity 
was measured with excitation at 530 nm and emission at 555 nm. The Tm, or thermal melt point, represents 
the temperature required to unfold 50% of the protein [20] (Table 2).
  Crystallisation, data collection and structure determination
Crystals of the HLA-A*02:01-FLNKD and HLA-A*02:01-ALQDA complexes were grown by the hanging-
drop, vapour-diffusion method at 20°C with a protein/reservoir drop ratio of 1:1, at a concentration of 10 mg/
mL of protein using 18-22% PEG 3350; 0.1 M HEPES pH 7.5 and 0.1 M MgCl2. Crystals were soaked in a 
cryoprotectant solution containing mother liquor solution with the PEG concentration increase to 35%(w/v) 
and then flash frozen in liquid nitrogen. The data were collected on the MX1 beamline at the Australian Syn-
chrotron (Clayton) using an ADSC-Quantum 210 CCD detector (at 100K), processed using the XDS software 
[21] and scaled using SCALA software [22] from the CCP4 suite [23]. The structures were determined by 
molecular replacement using the PHASER [24] program with the HLA-A*02:01 minus the peptide as the 
search model for the MHC (Protein Data Bank accession number, 3GSO [25]). Manual model building was 
conducted using the Coot software [26] followed by maximum-likelihood refinement with the PHENIX pro-
gram [27]. The final models have been validated using the Protein Data Base validation web site and the final 
refinement statistics are summarized in Table 3. Coordinates submitted to PDB database, HLA-A*02:01-
FLNKD code 4U6X and HLA-A*02:01-ALQDA code 4U6Y. All molecular graphics representations were 
created using PyMol [28]. The interactions between the peptides and the HLA have been calculated using 




  Non-canonical peptides presented in HLA class I molecules
The list of eluted peptides from the two EBV-LCLs comprised 15,882 peptides, based on a length of 8-23 
amino acids and a mascot ion score >35. The list contained 1,568 peptides of 12-23 length, of which 1,145 
were 12-14 mers and 423 peptides are longer than 14 amino acids (Supplemental Table 1 and Figure 1). 
  The 8-11 mer peptides have been reported by Hassan et al. [8] (Figure 1A), and so we concentrated our 
study on the peptides of non-canonical length (> 11 aa). It is important to note that in large scale proteomics 
experiments a certain false discovery rate (FDR) is acceptable. For HLA-presented peptides 5% is accepted 
as FDR (8, 29). Therefore, it cannot be excluded that a few peptides might have been incorrectly assigned, 
but the large majority will have been correctly assigned. In addition, we performed our immunopurification 
Figure 1. Peptide length distribution of the HLA-ligandome and binding affinity. Distribution of all peptides eluted 
from two EBV-LCL cell lines (A), and a focus on 15-23 mer peptides (B). A substantial percentage of HLA-ligands are 
longer than of canonical 8-11 mers. Binding affinity as determined in an HLA competition refolding assay (C), and an 
HLA refolding efficiency assay (D). 
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experiments with a pan class I-antibody, w6/32, which might complicate assignment of peptides to a particu-
lar allele. However, in this study the A alleles and B alleles have clearly distinct motifs. The known HLA C 
allele present in our cells, as known from the SYFPEITHI database, do not fulfill our A and B motifs.
To estimate the number of potentially relevant non-canonical binders to the HLA-molecules we used Net-
MHC, and initially used a simple definition of binders by definition of the P2 anchor; HLA-A*02:01 (P2: 
LMV), HLA-B*0702 (P2: P), HLA-B*4402 (P2: E). 922 out of the 1,145 12-14 mers (81%) fulfilled this P2 
anchor criterion, which compares well with the 75% of binders as found using NetMHC (with a score <1000 
nM).
  Of the listed 15-23 mer peptides 214 out of 423 (51%) fulfilled the P2 anchor criterion (Figure 1B). Since 
NetMHC does not allow calculation of binding affinities beyond 14-mers, we defined potential binders more 
stringently, based on the following mandatory anchor residues, including the PΩ position; HLA-A*02:01 
(P2: LMV and PΩ: LMIVA), HLA-B*0702 (P2: P and PΩ: L), HLA-B*4402 (P2: E and PΩ: F,Y). This ad-
ditional constraint resulted in the selection of 77 peptides with a length of 15-23 amino acids (Supplemental 
Table 2). 
  Surprisingly, our result indicated that while previous studies on longer epitopes were based on HLA-B 
molecules, it was evident from the elution assay and mass spectrometry analysis that HLA-A molecules, 
including HLA-A*02:01, have also the ability to bind longer epitopes (Figure 1B). 
  Competition refolding assay
From the ten 15-mer peptides found fulfilling the P2 and PΩ criteria for HLA-A*02:01, eight with P2=L 
were synthesized for further characterisation (Table 1). To show the binding efficacy of these naturally pro-
cessed 15-mer peptides, we performed a refolding and competition assays (Table 1) [19]. The two assays 
are complementary. The competition refolding assay shows the ability of the peptide to bind. The refolding 
assay shows the efficiency of formation (i.e. the yield of the HLA-monomer folding process). The yield is 
an additional important parameter for pHLA stability and a predictor of efficient tetramer formation. Several 
other peptides with known binding affinities were included in the assay to evaluate the relative binding affin-
ity of the 15-mer peptides. LB-NISCH-1A (ALAPAPAEV), MART1-M-ELA (ELAGIGILTV), and CMV-
pp65-NLV (NLVPMVATV) peptides are known high affinity binders to the HLA-A*02:01 molecule, and 
were included as control [18]. The MART1-WT-AAG (AAGIGILTV) epitope was included as a low affinity 
binder to the HLA-A*02:01 molecule. In the competition assay the fluorescein (F1)-labeled reference pep-
tide (FLPSDCFl FPSV), known to bind efficiently to the HLA-A*02:01 molecule, and the peptide of interest 
compete for binding in the HLA class I groove during folding. The affinities of the peptides are expressed 
as IC50 (Table 1). The calculated percentage of bound fluorescent reference peptide after competition with 
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Figure 2. Electron density map of 15-mer epitopes bound to HLA-A*02:01. The A and B panels show the omit map 
(Fo-Fc) at 3σ in green for the FLNKD and ALQDA peptides in complex with the HLA-A*02:01 respectively. The 
C and D panels show the 2Fo-Fc map contoured at 1σ in blue after final refinement for the FLNKD and ALQDA 
peptides respectively. The HLA-A*02:01 is represented as white cartoon; the peptides are represented in stick and 
coloured in orange for the FLNKD and pink for the ALQDA.
the 15-mer peptides, and the high and low affinity reference peptides are listed in Table 1, and are plotted 
in Figure 1C. 
  The results showed that all eight synthesized 15-mer peptides, fulfilling the HLA A*0201-motif, have an 
IC50 between 10 nM to 1366 nM, most of which are in the high binding affinity range [19]. For compari-
son, the low binding affinity peptide MART1-WT-AAG (AAGIGILTV) has a higher IC50 of approximately 
7,000 nM, while the high binding affinity peptide pp65-NLV has an IC50 of 45 nM. These results illustrate 
that the 15-mer peptides bind to the HLA-A*02:01 molecule with similar affinity as 8-11-mer peptides, and 
some even with higher affinity such as the KLFDS (IC50 of 10 nM, Table 1).
  In summary the 15-mer epitopes exhibited affinities comparable to that of 9-10 mers bound to HLA-
A*02:01, showing that the length was not an obstacle for peptides to bind the common HLA-A*02:01 
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allele. 
  pHLA complexes refolding efficiency assay
We next applied an HLA refolding efficiency assay to assess the binding of 15-mer peptides to HLA-A*02:01 
by measurement of the yield of formation of pHLA. This assay determined the capacity of the peptides to sup-
port stable refolding of the heavy chain and β2m recombinant subunits of the HLA-A*02:01 complex. The 
yield of folded pHLA-A*02:01 was determined for the classical length (9-mer) and longer peptides (15-mer) 
under the same refolding conditions. HLA recovery levels of 47%-59% were obtained for the eight 15-mer 
peptides. The yields of the three known high affinity binders LB-NISCH-1A, CMV-pp65-NLV and MART1-
M-ELA were 49 %, 58.8 % and 34% respectively. The weak binder MART-1-WT-AAG showed a pHLA 
recovery yield of 5.4% (Figure 1D). These results indicate that the 15-mer peptides have a similar binding 
efficiency as the classical high affinity 9-mer peptides, and so are able to stabilize the formation of the HLA-
A*02:01-ß2m complex as well as canonical peptides.
Stability of the 15-mer-HLA-A*02:01 complexes
We then assessed the thermal stability, after refolding, of HLA-A*02:01 bound to four distinct 15-mer pep-
tides and compared these values to HLA-A*02:01 bound to a canonical 9-mer epitope CMV-pp65-NLV [25]. 
The thermal melt point, or Tm, observed for HLA-A*02:01 in complex with the CMV-pp65-NLV peptide 
was 63.9°C (Table 2). We then performed the same assay with the four HLA-A*02:01-15-mer complexes, 
along with the HLA-A*02:01-NLV complex. The FLNKD and ALQDA peptides exhibited the lowest Tm, 
with a value of ~ 48°C, which was notably lower than the HLA-A*02:01-NLV complex. In contrast the AL-
WDI and KLLEI Tm were 58°C and 66.5°C respectively (Table 2). Interestingly the two 15-mer peptides 
with the lowest Tm have non-optimal HLA-A*02:01 anchor residue at PΩ, namely a valine residue (Table 
Table 2. Thermal stability of peptide-HLA-A*02:01 complexes. Tm represents the temperature required to unfold  
50% of the protein.
Peptide-HLA-A*02:01 Tm (°C)
FLNKDLEVDGHFVTM 47.9 ± 0.5
ALQDAGDSSRKEYFI 48.0 ± 1.0
KLLEIPDPDKNWATL 66.5 ± 1.8
ALWDIETGQQKTVFV 58.0 ± 1.0
NLVPMVATV 63.9  ± 0.5
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1). In summary the HLA-A*02:01-restricted 15-mer epitopes can exhibit a range of Tm, with some of them 
highly stable in the cleft of HLA-A*02:01. 
Crystal structures of 15-mer-HLA-A*02:01 complexes
To date only seven structures of HLA in complex with long epitopes (> 11 aa) are available [4, 7, 12, 13, 29, 
30] as well as one structure of a rat MHC in complex with a 13-mer peptide [31]. The seven pHLA struc-
tures include: two 12-mer EBV epitopes bound to HLA-B*4403 [30] and to HLA-B*3508 [13]; a 13-mer 
EBV epitope in complex with closely related allomorphs HLA-B*3501 and HLA-B*3508 [12]; a 13-mer 
epitope bound to HLA-B*0702 [7], a self 14-mer peptide in complex with HLA-B*3501 [7, 29] and a self 
16-mer peptide bound to HLA-B*4102 [4]. These structures solved to date reveal that the N and C termini 
of the peptides bind in similar fashion to the one observed for the classical length peptides, and that the 
Figure 3. Crystal structures of 15-mer peptides in complex with HLA-A*02:01 molecule. Side view (A, C and E pan-
els) and top-view (B, D and F panels) of the HLA-A*02:01 cleft (white cartoon) bind to the FLNKD peptide (orange 
stick and loop) or the ALQDA peptide (pink stick and loop). The bottom panels (E and F) show a superimposition of 
the two peptides in the cleft of HLA-A*02:01 molecule in the same orientation as the above panels. 
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central part of the peptide bulges out of the binding cleft. 
  Interestingly of the long epitopes characterized none of them were in complex with HLA-A molecule. In 
order to understand how the HLA-A*02:01 molecule can present long epitopes of 15 residues in length, we 
determined the structure of the HLA-A*02:01-FLNKD and HLA-A*02:01-ALQDA complexes at high reso-
lution (Table 3). The two peptide-HLA complexes were crystallized in the same space group with the same 
unit cell dimension. Therefore, the difference in peptide structures was attributable to the peptide sequence. 
The two peptides bind with the canonical P2-Leu into the B pocket and with non-canonical PΩ-Val residues 
Data Collection Statistics HLA-A*02:01-FLNKD HLA-A*02:01-ALQDA
Resolution range (Å) 29.44  - 1.46 (1.51  - 1.46) 39.53  - 1.67 (1.73  - 1.67)
Space group P 21 P 21
Cell Dimensions (a,b,c) (Å)
50.88, 79.76, 54.84 51.04, 79.06, 54.90 
ß=111.75° ß=111.11°
Total number of observations 392206 (37550) 264156 (24945)
Number of unique observations 69403 (6859) 46434 (4518)
Multiplicity 5.6 (5.5) 5.7 (5.5)
Data completeness (%) 99.79 (98.69) 99.71 (97.75)
I/σ(I) 19.3 (2.5) 17.8 (2.4)
aRpim (%) 2.5 (29.7) 3.1 (31.8)
Refinement Statistics HLA-A*02:01-FLNKD HLA-A*02:01-ALQDA
bRfactor (%) 16.12 (23.54) 15.49 (21.89)
bRfree (%) 19.04 (27.17) 19.78 (28.18)
Number of non-hydrogen atoms 4037 3859
  Macromolecules 3472 3460
  Ligands 15 27
  Water 550 372
           Rms deviations from ideality
Bond lengths (Å) 0.009 0.008
Bond angles (°) 1.26 1.13
          Ramachandran plot (%)
Allowed region (%) 98 98
Generously allowed region (%) 2 2
Ramachandran outliers (%) 0 0
          Average B-factor 21.5 23.7
  Macromolecules 19.4 22.2
  Ligands 42.4 59.7
  Water 33.8 34.8
aRp.i.m = Σhkl [1/(N-1)]1/2  Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl> 
b Rfactor = Σhkl  | | Fo | - | Fc | | / Σhkl | Fo | for all data except ≈ 5% which were used for Rfree 
calculation. 
Table 3. Data collection and refinement statistics
Values in parentheses are for the highest resolution shell.
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in the F pocket for HLA-A*02:01, a methionine for FNLKD peptide and an isoleucine for the ALQDA pep-
tide (Figures 2 A & B). The FNLKD peptide density was clear and unambiguous in the cleft of the HLA-
A*02:01 molecule (Figures 2 A & C), while the central part of the ALQDA was poorly defined (Figures 2B 
& D). Despite the two 15-mer peptides exhibiting a similar Tm value to the same HLA-A*02:01 (Table 2), 
the conformation of the two peptides were notably different (Figure 3). 
  The ALQDA was mobile in the cleft of the HLA-A*02:01 molecule (Figure 2D), and as a result the central 
region from P6 to P10 was not built in the final model of the pHLA complex. Flexibility is often associated 
with long peptide presentation by HLA class I molecules, as exemplified by the 16 mer AEMY self-peptide 
presented by the HLA-B*41:03 molecule [4]. The ALQDA binds the HLA-A*02:01 molecule via 9 of its 
residues and forms 188 contacts with the HLA (9 salt-bridges and 16 hydrogen bonds). The number of 
bonds formed by the 15-mer ALQDA was similar to the 9-mer NLV peptide (185 contacts, 2 salt bridges 
and 14 hydrogen bonds), despite the extra 6 residues. A small amino acid such as valine is optimal at the 
C-terminal part of the peptide sequence as it fits well in the F pocket of the HLA-A*0201 cleft. As observed 
in the NLV peptide structure (PDB code: 3GSO(25)), whereby the P9-Val sat on the top of  Tyrosine 116 
of the HLA-A*0201 molecule. The change to larger amino acids, such as methionine or isoleucine, at the 
C-terminal position of the peptide leads to rotation of the Tyrosine 116 to avoid steric clashes that pushes 
the Arginine 97. This rearrangement of buried amino acids within the antigen binding cleft appears to be 
less favourable to the overall stability of the pHLA-A*0201 complex (Table 2).
  Contrasting the flexible ALQDA 15-mer, the FNLKD peptide was well defined in the cleft of the HLA-
A*02:01 molecule (Figure 2C), and is the longest well-defined epitope observed in complex with a HLA 
class I molecule to date. The FNLKD bulges out of the HLA-A*02:01 cleft forming a ß-sheet hairpin 
structure from P7 to P12 residues (Figure 3A). The secondary structure formation in the bulged part of the 
peptide made intra-molecular contacts, constraining and rigidifying the peptide [33] and probably explains 
how the FNLKD can be such a long peptide and being so rigid in HLA-A*02:01 cleft. Interestingly the ß-
sheet hairpin formation is higher than the hinge of the α2-helix of the HLA-A*02:01 and would represent 
an immediate contact point for T cell receptor. The stable conformation of the FLNKD was also associated 
with a higher number of contacts with the HLA-A*02:01 molecule, with the peptide engaging 11 of its resi-
dues to interact with the HLA, and making a total of 215 contacts (6 salt bridges and 14 hydrogen bonds). 
This β-sheet hairpin structure is the first reported for an epitope bound to class I HLA. An α-helix has been 
previously reported in the 12-mer CPS bound to the HLA-B*3508 complex [13].
 The crystal structures of the two 15-mers in complex with HLA-A*02:01 show that,like the HLA-B mol-
ecule, HLA-A can present long peptides in a diverse array of conformations from mobile to highly stable, 
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and could represent some new antigen for T-cells.
15-mer epitopes presented by HLA-A*02:01 can activate CD8+ T-cells
We demonstrate that HLA-A*02:01 can bind longer peptides with high binding affinity, forming stable 
pHLA complexes, and determined how HLA-A*02:01 can present 15-mer peptides. In order to establish if 
15-mer-HLA*0201 complexes were antigenic and recognized by T-cells, we used pHLA-tetramers with the 
two structurally characterized 15-mer peptides FLNKD and ALQDA (RAB9AFLNKD:HLA-A*02:01 and 
GYPCALQDA:HLA-A*02:01, respectively). Since negative selection during thymic development depletes 
Figure 4. Specific T-cell clone recognition of 15-mer peptide FLNKD presented by HLA-A*02:01
T cell clone PVO A5 and PVO A7 were isolated using pHLA-tetramers composed of GYPC-derived peptide ALQDA 
or RAB9A-derived peptide FLNKD bound to HLA-A*02:01 (GYPCALQDA:HLA-A*02:01 or RAB9AFLNKD:HLA-
A*02:01)from an HLA- A*02:01-negative individual. (A) T cell clone PVO A5 (left) and PVO A7 (right) specifically 
bound to GYPCALQDA:HLA-A*02:01-tetramer andRAB9AFLNKD:HLA-A*02:01-tetramer, respectively, after stain-
ing with PE-labelled RAB9AFLNKD:HLA-A*02:01 and APC-labelled GYPCALQDA:HLA-A*02:01-tetramer. (B) The 
panel shows the lack of staining with two control tetramers composed of HLA-A*02:01 displaying two virus-derived 
epitopes for T cell clone PVO A5 (left) and PVO A7 (right). All plots are shown with bi-exponential axis. Numbers 
in corners indicate percent cells in each quadrant. (C) GM-CSF production was measured after co-culturing T-cell 
clone PVO A7 with HLA-A*02:01-positive T2 cells loaded with decreasing concentration of FLNKD peptide. (D) 
GM-CSF production was measured after co-culturing T cell clone PVO A7 with T2 cells, T2 cells loaded with 500 
nM peptide (+GYPCALQDA or +RAB9AFLNKD), three HLA-A*02:01-positive B-LCLs (A2+) which naturally express 
and present RAB9A or three HLA-A*02:01-negative B-LCLs (A2-). Experiments were performed in triplicate. Shown 
is one representative experiment of two independent experiments. Error bars indicate standard deviation.
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T-cells recognizing such self-antigens bound to self-HLA, T-cells were isolated from HLA-A*02:01-neg-
ative healthy individuals which contain a naïve T-cell repertoire capable of recognizing such self-antigens 
presented in HLA-A*02:01. From PBMCs of HLA-A*02:01-negative individuals, CD8+ T-cells clones 
were expanded that bind pHLA-tetramers RAB9AFLNKD:HLA-A*02:01 and GYPCALQDA:HLA-
A*02:01 by first enriching pHLA-tetramer binding cells by MACS followed by immediate single-cell 
FACS sorting. Among the isolated T-cells, clone PVO A5 showed specific binding of GYPCALQDA:HLA-
A*02:01-tetramer while binding to RAB9AFLNKD:HLA-A*02:01-tetramer was absent (Figure 4A). In 
contrast, T-cell clone PVO A7 specifically bound to tetramer RAB9AFLNKD:HLA-A*02:01 while binding 
to GYPCALQDA:HLA-A*02:01 was absent (Figure 4A). In addition, both T-cell clones did not bind to 
two control tetramers composed of HLA-A*02:01 displaying either EBV-derived peptide GLCTLVAML or 
human cytomegalovirus (CMV)-derived peptide NLVPMVATV, further indicating specific binding of both 
T-cell clones to their respective pHLA-tetramer displaying a 15-mer peptide (Figure 4B). Next, peptide-
dependent recognition for both T-cell clones was assessed by pulsing HLA-A*02:01-positive T2 cells with 
the two 15-mer peptides. GYPCALQDA-specific T-cell clone PVO A5 did not recognize peptide pulsed T2 
cells indicating insufficient sensitivity for HLA-bound ALQDA (data not shown). In contrast, T-cell clone 
PVO A7 recognized T2 cells pulsed with peptide FLNKD (Figure 4C). This recognition was peptide-specif-
ic since no recognition of T2 cells pulsed with ALQDA was observed (Figure 4D). In addition, T-cell clone 
PVO A7 recognized three HLA-A*02:01-positive B-LCLs which naturally express RAB9A and were used 
to elute the 15-mer peptide FLNKD (Figure 4D). Lack of recognition of three HLA-A*02:01-negative B-
LCLs indicates that the observed reactivity of T-cell clone PVO A7 was HLA-A*02:01-dependent (Figure 
4D). These data indicate that 15-mer peptide FLNKD presented in HLA-A*02:01 on the cell surface can be 
recognized by T-cells in a peptide-dependent manner.
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DISCUSSION
  Classically, HLA class I molecules present 8-11-mer peptides, although, an expanding list of lengthy (>11 
aa) HLA-restricted peptides have emerged [6]. Crystallographic studies have reported on seven pHLAs struc-
tures involving a 12-mer to 16-mer epitopes [4, 7, 12, 13, 29, 30]. These previous studies were all focused on 
HLA-B molecules, and here we describe the ability of HLA-A*02:01 molecule to bind long epitopes too, with 
538 12-14-mers being defined. Further, 77 peptides are listed of 15-23 amino acids long that fulfill both the 
P2 and PΩ anchors criteria in either HLA-A*02:01, HLA-B*0702 or HLA-B*44. A comparable percentage 
of longer peptides was found in the reprocessed data of Mommen et al [9] , in particular in HLA-A*0301 and 
HLA-B*0702, and to a lesser extent in HLA-A*0101 and HLA-B*2705. The listing of peptides shows that 
HLA-A molecules appear to be just as suitable for presenting longer peptides as the HLA-B alleles. Both the 
intensity and the hydrophobicity of the longer peptides resemble that of the canonical 8 to 11-mer peptides. 
There was a steady decline in the number of longer peptides for every additional amino acid, which probably 
represents the probability of a peptide to survive in the cellular proteolytic environment. Longer peptides 
have an increasing chance of being cut by a protease. Of note, the amino acids between the P2 and PΩ anchors 
are not generally enriched for specific amino acid residues, so, the amino acid stretch between the anchors 
does not seem to be specifically resistant to proteolytic degradation on the basis of its primary structure. Lon-
ger peptides can be translocated by TAP into the ER, although generally somewhat less efficiently [34]. In 
the ER, peptides are protected from being trimmed to short peptides for presentation in HLA by the nature of 
ERAAP [35]. The fact that there seems to be no clear-cut length limitation (on the long side) imposed by the 
HLA class I binding groove, can be explained by the phenomenon of (super)bulging of the peptide, with the 
P2 and PΩ anchors residues position fixed in the peptide binding groove, but freedom to ‘leave’ the binding 
groove for (part) of the peptide between these anchors residues. The two refolding assays we employed, both 
showed that the behavior of the 15-mer peptides resembled that of the canonical 8-11-mer peptides, i.e the 15-
mer peptides just as easily formed pHLA complexes and competed to the same degree as known good binders 
of 8-11-mer length. From the two 15-mer peptides solved in complex with the HLA-A*02:01, we observed 
two different conformations of the long epitopes in the cleft of HLA-A*02:01. Firstly the ALQDA peptide 
was highly mobile, and its central region was poorly defined, reminiscent of the 16-mer self-peptide observed 
in complex with the HLA-B*4103 [4]. Contrasting with the high flexibility of the ALQDA, the FLNKD was 
well defined and adopted one single rigid conformation when bound to HLA-A*02:01, similar to the 13-mer 
EBV epitope in complex with HLA-B*3508 [12]. The FLNKD peptide central region formed a ß-hairpin 
secondary structure that bulged out of the HLA-A*02:01 cleft, and could be a potential contact point for the 
FLNKD-specific T-cells, and it will be of high interest to know how T-cells can engage a highly rigid bulge 
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peptide like the FLNKD epitope. The TCR could potentially “struggle” to bind it or it will mostly focus on 
the peptide (like SB27,(15)) or might bind on the side of the peptide.
T-cells could be isolated from HLA-A*02:01-negative healthy individuals that contain a naïve T-cell reper-
toire capable of recognizing self-antigens presented in HLA-A*02:01. T-cell clones demonstrated specific 
binding of pHLA-tetramer and furthermore, peptide-dependent recognition was observed for selected T-
cell clones with HLA-A*02:01-positive T2 cells pulsed with the peptides as well as recognition of endog-
enously processed peptide on HLA-A*02:01-positive B-LCLs. Clone PVO A5 lacks functional reactivity 
against peptide-loaded target cells although there is specific staining of that clone with GYPCALQDA:A2 
pHLA-tetramer. We have previously demonstrated that pHLA-tetramer staining alone is a poor indicator of 
functional avidity of a T-cell clone (18). Therefore, it is most likely that clone PVO A5’s avidity for HLA 
bound peptide GYPCALQDA is insufficient to trigger T-cell activity while binding of pHLA-tetramer is 
possible. To circumvent the depletion of high avidity T cells targeting self-peptides presented in self-HLA 
during thymic development, pHLA-tetramer binding T cells were isolated from a healthy HLA-A2-nega-
tive individual. Based on, previous results we estimated to isolate both high as well as low affinity T cells 
(18). The results demonstrate that PVO A5 represents a low avidity T cell clone for GYPCALQDA:A2 
while clone PVO A7 represents a high avidity T cell clone specific for RAB9AFLNKD:A2.
Clone PVO A7 demonstrated peptide-dependent recognition of peptide-loaded T2 stimulator cells in the 
nanomolar range. Virus-specific T cells demonstrate peptide sensitivity as low as in the picomolar range. 
However, caution must be exerted when comparing sensitivity between T cell clones recognizing different 
epitopes based solely on recognition of peptide-loaded stimulator cells. Not only affinity of the TCR for 
its cognate peptide is important but also binding properties of the peptide to its respective HLA-molecule 
is critical, since exogenously loaded peptide need to compete with already HLA-bound peptide. These 
properties can differ between peptides. Furthermore, PVO A7 is able to recognize endogenously processed 
and presented peptide on three HLA-A2-positive B-LCL indicating high functional avidity comparable 
to virus-specific T cells. From these findings, T-cells appear to be capable to specifically recognize longer 
peptides. So far, there seems to be no clear limitation on peptide length for T-cell recognition of HLA class 
I presented peptides.
  Altogether our data show that HLA class I restricted presentation and recognition is less restrictive than 
previously anticipated. Our data expand our understanding of HLA class I ligand presentation, and show 
that longer peptides are regular members of the HLA-ligandome, and should not be discarded in epitope 
discovery experiments, since these peptides might be useful in immunotherapy. Furthermore, the non-
canonical peptide sequences presented here provide insight in antigen presentation and antigen processing. 
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Minor histocompatibility antigens (MiHA) are naturally processed polymorphic peptides originated from en-
dogenous proteins which are presented in human leukocyte antigen (HLA) molecules on the cell surface to be 
recognized by T cells from HLA-matched individuals. The involvement of MiHA in the graft versus tumor is 
described about three decades ago. Nowadays, there are many evidences that, after HLA-matched allogeneic 
hematopoietic stem cell transplantation (HSCT) MiHA specific T cells mediate both graft versus leukemia 
(GVL) reactivity and graft versus host disease (GVHD), which is a major cause of morbidity and mortality. To 
allow skewing of a donor derived T cell response against MiHA towards GVL while preventing GVHD, the 
identification of many MiHA is essential. So far, approximately 50 MiHA have been identified using different 
approaches. The two main approaches used for identification of MiHA are forward and reverse approaches. 
The forward approach can only be explored if there is indication of a GVL and/or GVHD response in a pa-
tient received allogeneic HSCT and the relevant T cells can be isolated and characterized. A reverse approach 
uses algorithms and available databases to predict novel MiHA. The major limitation of reverse approach is 
that  most predicted MiHA might not be presented on the cell surface and that post-translationally modified 
peptides cannot be predicted. To avoid these limitations and to improve the outcome of the reverse approach 
we decided to establish a new strategy based on the bone fide eluted ligandome. In Chapter 2 we applied 
our new strategy by identifying the peptide content of HLA molecules from two B-lymphoblastoid cell lines 
(B-LCL). We built a HLA-class I ligandome library from the obtained data. Since the dynamic range of the 
peptides eluted from HLA-class I molecules is very high, it is not possible to identify as many ligands as pos-
sible using single dimension separation techniques. Therefore, we applied multidimensional chromatography. 
Three different first dimension separation techniques were used including peptide isoelectric focusing (IEF), 
strong cation exchange chromatography (SCX) and RP-C18 chromatography. The fractions obtained from 
these three first dimension separation techniques were analysed using nano-RP-C18 liquid chromatography 
coupled to mass spectrometry (nano-LC-MS/MS). The results have shown that application of different first 
dimension separation techniques leads to increased numbers of identified HLA-ligands. Our new strategy 
applied to reverse immunology resulted in the identification of at least 16,000 ligands with high mascot ion 
score (BMI>35) from HLA-A2, HLA-B7 and HLA-B44 including the polymorphic and post translationally 
modified ligands. This huge number of identified HLA-ligands formed the basis for the next steps of our study. 
To validate the identification of these peptides we used different methods including synthesis of selected pep-
tides and comparison of the MS/MS spectra of the synthetic peptides with the counterpart eluted peptides. In 
addition, we checked different physicochemical properties of the peptides like the binding affinity to HLA 
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molecules using the NetMHC algorithm, length and hydrophobicity. After validation of these peptides we 
looked in depth into the characteristics of HLA-ligands and antigen processing. To improve the identifica-
tion of polymorphic peptides/MiHA, in Chapter 3 we developed a database dedicated for identification of 
polymorphic peptides called human short peptide variation database (HSPVdb). This database is based on 
the human mRNA sequences from the well-annotated reference sequence (RefSeq) database and associated 
variation information derived from the Single Nucleotide Polymorphism Database (dbSNP). Investigation of 
the frequencies of SNPs in the dbSNP revealed that many SNPs are non-polymorphic “SNPs”. Therefore, we 
removed those from our dedicated database, and this resulted in a comprehensive high quality database. We 
identified 1500 polymorphic peptides with high mascot ion score (BMI>35) using the developed database. To 
identify potential MiHA among the huge number of polymorphic peptides eluted from HLA-A*0201 or HLA-
B*0702 in Chapter 4 we selected the top 25 MiHA candidates identified in chapter 2. From this set of data we 
could validate 2 novel potential MiHA being (LB-CLYBL-1Y & LB-TEP1-1S). Since we knew that we did 
not obtain a comprehensive view of the ligandome yet, although the number of ligands we found was already 
impressive, we decided to study all aspects/steps of the work-up process, to find out at which stages the great-
est losses occurred. In Chapter 5 we developed a method to be able to quantitate MiHA on the cell surface. 
We used  stable isotope labeled peptides coupled to recombinant HLA-class I molecule (hpMHC), spiked in 
the first step of the purification method to account for all losses in the procedure. In addition, for determina-
tion of the recovery of the purification method, we added medium isotope labeled peptide to the fractions 
prior LC-SRM or LC-PRM analysis. The previously identified MiHA LB-NISCH-1A and LB-SSR1-1S were 
used to determine the recovery of the purification method and to determine the copy number of MiHA. Major 
losses, from 90-99%, were determined to be in the immunopurification step. Since the developed method is 
very accurate in quantitation of MiHA on the cell surface, in Chapter 6 we studied the phenomenon of the 
unidirectional T cell responses against MiHA. The unidirectional phenomenon means that T cells can recog-
nize only the MiHA, but not their allelic counterpart (AC). The absence of immunogenicity against AC may be 
explained by the absence of AC on the cell surface. However in the heterozygous cells presenting both MiHA 
and AC this explanation is not valid anymore, as we have found a couple of MiHA and their AC in the data 
obtained in chapter 2. Therefore, we hypothesized that the expression of MiHA should be a factor 10 higher on 
the cell surface in comparison with their AC to be able to elicit T cell response. To investigate our hypothesis 
we selected three MiHA and their AC: LB-NISCH-1 (MiHA/AC; A/V), LB-SSR1-1 (MiHA/AC; S/L) and 
LB-CLYBL-1 (MiHA/AC; Y/D). We used the approach developed in chapter 5 to determine the copy number 
of both the MiHA and their AC on the cell surface. The results showed that the expressions of both MiHA and 
their AC were similar. Therefore, the unidirectional response of T cells against MiHA cannot be explained by 
201
CHAPTER 8
the higher copy number of MiHA on the cell surface than of the AC. Other immunological reactions might 
be involved in eliciting T cell responses that need to be investigated. The high number of identified HLA-
class I ligands from chapter 2 include a high number of non- canonical long peptides. Therefore, in Chapter 
7 we studied in depth the presentation of non-canonical long peptides in HLA-A*0201 molecules. From the 
elution data described in chapter 2 we could find 1,568 HLA-ligands with lengths of 12-23 amino acids and 
BMI ≥ 35, of which 423 peptides had a length of 15-23 amino acids. To study in depth the binding affinity of 
these peptides to HLA-A*0201 we selected eight 15 mer peptides, having binding motifs for HLA-A*0201 
molecule. We used two binding assays: a competition refolding assay,and a pHLA refolding efficiency. Both 
assays showed high binding affinity of the 15 mer similar to the binding affinity of the 9 mer peptides to HLA-
A*0201 molecule. Furthermore, we determined the thermal stability of the 15-mer pHLA complexes, and 
also in this assay the 15-mer and 9-mer peptides showed similar thermal stability. Moreover, we showed that 
the 15-mer epitopes presented by HLA-A*02:01 can activate CD8+ T-cells. Finally, we used crystallography 
technique to determine the structure of the pHLA complexes and the data showed that the 15 mer peptides are 




The identification of HLA class I ligands and MiHA
MiHA and other tumor-specific T cell epitopes are important candidates for immunotherapy. In the introduc-
tion of this thesis we described the main strategies that have been used in the identification of these peptides. 
In this thesis we developed and used an alternative strategy to identify MiHA which are presented in HLA 
class I molecules. The data obtained from this new strategy were the basis of our ligandome database as 
identified by peptidomics. The developed strategies in this thesis can be applied to other tumor-specific T 
cell epitopes.
Previously, the number of different HLA class I presented peptides per cell has been estimated at over 10,000 
different molecules per cell (reviewed in [1]). Although different groups have used different approaches to 
identify these peptides, the number of the reported peptides was very limited [2-12]. Since the last two years 
the large scale analysis of HLA-ligandome increased the number of reported HLA-class I associated peptides 
to about 50,000 in three different studies including the data presented in chapter 2 of this thesis [13-15]. The 
number of identified post translationally modified peptides and polymorphic peptides were also limited. The 
number of MiHA identified so far is approximately 50 [16-46] and recently reviewed in [47]. MiHA can be 
elucidated by forward and reverse immunology approaches. The forward approach is based on the isolation 
of a T cell clone after induction of an immunological reaction in a patient who underwent allogeneic hema-
topoietic stem cell transplantation (HSCT). Reverse immunology approaches were based on algorithms, e.g. 
for HLA-binding and proteasome processing, to predict potential MiHA and subsequently the search for and 
the selection of T cells. The advantage of this approach is that many MiHA candidates can be selected, while 
the major limitation of this strategy is that most candidate MiHA will not be presented on the cell surface, 
as most candidates will not ‘survive’ antigen processing [48]. In addition, the available algorithms do not 
predict post-translationally modified antigens.
To avoid the major limitation of the classical reverse approach in chapter 2 we designed a strategy which 
is based on the bona fide eluted ligandome, as identified by mass spectrometry, which means that peptide 
presentation in HLA is guaranteed, before subsequent experiments are performed. Furthermore, post-trans-
lationally modified peptides and polymorphic peptides can be identified with this ligandomics approach. 
The data can also be used to learn more about antigen processing and general features of the ligandome, 
which can be used to build an immunopeptidome atlas [49], and to improve the software packages used in 
the prediction of HLA-class I ligands (e.g. binding affinity, length, hydrophobicity..etc.) [50-54]. The post 
translationally modified ligands are getting more interest, especially phosphorylated ligands, that have been 
associated with deregulated signalling and cancer [55-58]. Furthermore, the binding of non-canonical long 
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peptides to HLA-class I molecules has emerged from the eluted peptide data using the peptidomics approach 
(chapter 7).
Furthermore, using the peptides library to select peptides specific for the B cell receptor (BCR) CD79b gene 
to study the benefits and limitations of these peptides in the treatment of B-cell malignancies or hematological 
malignancies has illustrated the benefit of this approach [59]. Altogether, the results and the wide application 
of the peptidomics approach show the benefits of this new strategy in the identification of relevant HLA-
ligands. 
Despite the high number of HLA-ligands identified (>10,000-20,000) using our peptidomics approach, the 
peptide recovery was found to be remarkably low, ranging from <1 to 5%, estimated from the whole ligan-
dome study (chapter 2) and the heavy peptide-MHC approach (chapter 5). The low recovery presents a serious 
limitation of the peptidomics approach and should be addressed. Our results show that the main loss of the 
peptides occurs in the immunoaffinity step (chapter 5).Therefore, more work has to be done to improve the 
recovery of this step. For instance, utilization of CNBr activated beads instead of protein-A coupled to CL4B 
sepharose beads has been reported to reduce the loss of peptides during immunoaffinity isolation of HLA as-
sociated ligands [58,60], although our experiments on lower cell numbers do not confirm these findings. Ad-
ditional issues are the dimensions of the immunoaffinity column and leaving out the ultra-filtration step, and 
perform a C18-chromatography separation of proteins and peptides instead, as was applied by Illing et al., [61] 
might increase the recovery of the method, depending on the number of cells used during sample pretreatment.
The validation of all HLA-ligands obtained from large scale peptidomics experiments, by comparison of the 
MS/MS spectra of the eluted peptides with the synthetic counterparts, is not easy due to the huge number of 
identified peptides. In addition, selection of peptides according to the low false positive percentage (1% FDR), 
as it is commonly applied in shotgun proteomics [62,63], was found impossible in combination with a low 
mass accuracy MS2 instrument, such as ion traps. The enormously increased database search space, due to the 
undefined peptide termini of HLA-ligands and the limited MS2 accuracy, led us to synthesize interesting can-
didate peptides, such as e.g. CMV epitopes and previously identified MiHA, and compare the MS2 spectra of 
the eluted peptides with the MS2 spectra of their synthetic counterparts. The results of this comparison yielded 
a mascot ion score cut-off value of 35 as a good working number, which was further applied. Further compari-
son of our peptide listings with very recently produced lists obtained on a high mass accuracy instrument [14], 
confirmed that a cut-off value of 35 is a good number. However, for immunological applications it is advisable 
to include also low scoring peptides and validate these by peptide synthesis and MS2, since we found in our 
data set many known relevant peptides, which showed low matching scores, due to low quality MS2 spectra.
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At present, quantitation of HLA class I ligands is largely lacking. The best reported mass spectrometry-based 
strategy was the AQUA approach. In this approach a heavy isotope labeled counterpart of the epitope of in-
terest was added to compensate for losses during sample pre-treatment [64]. Since we showed that the major 
losses occurred in the IP step the AQUA approach as such is not sufficient to accurately determine HLA-
peptide copy number. To this end, we developed the hpMHC approach (chapter 5), which takes the AQUA 
approach to the next level by spiking in HLA-monomers loaded with heavy isotope labeled peptides, which 
are added to the cell lysate, i.e. before immunopurification step. For this approach hpHLA complexes need to 
be prepared for every peptide of interest. The number of peptides that can be measured in parallel with this 
approach would be mainly limited by the preparation of all the different pHLA molecules.
The results of our peptidomics approach opens the possibility for immunologist to identify HLA-ligands and 
epitopes presented in different disease states. A recent paper on peptides eluted from leukemia cells, using the 
strategy of our reversed immunology approach, identified several leukemia-specific peptides, which might 
become candidates for immunotherapy [13]. The peptidomics strategy described in this thesis, and the knowl-
edge gained from it, may help in the improvement of vaccination strategies and immunotherapy by studying 
the different stages of malignant transformation in tumors, studying autoimmune diseases to identify ‘trigger 
proteins/peptides’, studying rejection of transplanted organs after transplantation.
 
HSPV database and MiHA
To identify polymorphic peptides/MiHA eluted with the large number of HLA-ligands in chapter 2, we devel-
oped in chapter 3 a specific database dedicated for identification of polymorphic peptides, called the Human 
short peptide variation (HSPV) database [65], which is based on the SNP information in dbSNP. The main 
advantage of this database is the small size of the database which reduces the false positive identified polymor-
phic peptides and increases the chance of identification of polymorphic peptides with a relatively poor data-
base matching score. Other advantages of  the HSPV database are the incorporation of SNP information by its 
good annotation and hyperlinks to dbSNP databases to have the genome (SNP) information directly available 
with the polymorphic peptide sequence. To further improve HSPVdb some issues has to be addressed: clean-
ing up the database from all non-polymorphic peptides, which have frequencies with unknown or (?) quan-
tifications. Incorporation of correct SNP information from dbSNP and HSPVdb has to be updated with the 
new identified polymorphisms. Although, the HSPVdb is very useful in immunology area, a drawback of this 
database is the limited utilization of the database by other biologist due to the specificity of the database for a 
specific field in biology as immunology. From the HSPV database we identified 1500 polymorphic peptides 
using the data of chapter 2 [15]. As it is known, not all polymorphic peptides can be MiHA and therefore, we 
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used the polymorphic peptides list to select MiHA candidates using a homemade and developed algorithm by 
Hombrink et al.[39].
Selection and validation of MiHA among a list of  polymorphic peptides
Selection of MiHA among the large number of the eluted polymorphic peptides needs more effort. In order to 
identify a clinically relevant MiHA restricted to hematopoietic cells in chapter 4 we used the data obtained in 
chapter 2, matched with HSPV database in combination with in our group developed algorithm (used in the 
selection of MiHA and T cell recognizing the selected MiHA exclusively) [39].
The selection steps in the previously in our group developed algorithm include: (1) mass spectrometry based 
validation of eluted peptides, (2) frequency of MiHA allele, (3) binding affinity of peptides to HLA molecule, 
(4) generation of MHC-tetramer with the selected MiHA candidate, (5) pull down experiment by selection of 
homozygous negative donors for the SNP encoding MiHA, (6) detection of MHC tetramer positive  T cells 
using FACS analysis, (7) generation of T cell clones, and functional test to detect high avidity  T cells. 
In chapter 4 we could identify a new clinically relevant MiHA called LB-CLYBL-1Y. In addition another 
MiHA (LB-TEP1-1S) has been identified as well. Although, we could not prove the clinical relevancy of the 
LB-TEP1-1S, still it can be used in immunotherapy strategies and in vaccine production against hematological 
malignancy or any hematological disorder. 
Since the number of identified MiHA is low, we studied in depth the developed algorithm to improve the 
selection steps. Most of the polymorphic peptides (10 from 40 candidates) were excluded in the first step of 
the algorithm using mascot ion score (BMI )>30 and mass deviation of 10 ppm. Selection of polymorphic 
peptides using the  combination of high (BMI) >35% and mass deviation <2 ppm might increase the selection 
efficiency. Furthermore, setting the allele frequency between 0.05-0.07% might increase the efficiency of the 
selection of homozygous negative donor. In addition, utilization of multimer in the fishing of T cells from the 
peripheral blood of homozygous negative donors is very specific and sensitive but the clear  limitation of this 
method is that the MiHA candidate with low binding affinity has to be excluded due to the folding efficiency 
of the multimer, which may explain the low number of identified MiHA.
hpMHC in combination with AQUA in immunology 
Quantitation of MiHA on the cell surface can be useful for improving vaccination strategy but it is still chal-
lenging. Two groups have reported the quantitation of T cell epitopes using AQUA approach by addition of 
isotope labeled peptides to the fractions prior to LC-MS/MS or LC-SRM analysis [64,67]. Since the isolation 
of HLA-ligands/epitopes (MiHA) goes through a number of steps (Immunoaffinity purification (IP), filtration 
and separation) prior to LC-MS/MS or LC-SRM [15], addition of labeled peptides to the last step prior to LC-
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MS/MS or LC-SRM cannot cover the losses in all preparation steps as performed by Tan et al. [64] and Croft 
et al. [66]. Therefore, in chapter 5 we developed a new method to account for all losses during sample prepara-
tion using heavy peptide MHC (hpMHC). hpMHC is based on stable isotope labeled peptide associated with 
recombinant MHC. Our methodology has the benefit of adding the labeled peptide associated with recombi-
nant MHC (hpMHC) to the first step (IP) of the preparation method which enables monitoring all losses during 
sample preparation. In addition, we add a medium labeled peptide (AQUA) to the sample prior to the filtration 
step or the LC-SRM step to determine the recovery of different steps of the purification method. Our data show 
that the losses of MiHA are mainly in the IP step, with losses of 90-99%. The low recovery of the peptides by 
IP step highlights the need for hpMHC in the quantitation of the HLA-ligands/epitopes (MiHA). To improve 
the recovery of the isolation method especially immunoaffinity column CNBr activated beads can be used 
instead of Protein-A coupled to CL4B beads and reducing the dimension of the column might be helpful.
The production of hpMHC can be seen as a drawback of this method if higher number of peptides has to be 
analysed. From our experience up to 20 peptides is very well possible in an immunological environment. 
The hpMHC method has been applied in chapter 7 to six candidates, to study the unidirectional phenomenon 
of the T cell recognition of MiHA by quantitation of the copy number of MiHA and their allelic counterparts 
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Appendix
NEDERLANDSE SAMENVATTING
Minor histocompatibiliteits antigenen (of minor antigenen) zijn natuurlijk gevormde peptiden die gepresen-
teerd worden in HLA-moleculen op het celmembraan, waar ze herkend kunnen worden door T cellen van 
individuen met hetzelfde HLA type. Reeds dertig jaar geleden is de rol van minor antigenen beschreven bij 
het graft versus tumor effect. Inmiddels is er een overvloed aan bewijs dat in allogene stamceltransplantatie 
(alloSCT) minor antigenen zowel het graft versus tumor effect als het graft versus host effect mediëren. Het 
graft versus host effect is een belangrijke, soms fatale, complicatie tijdens deze behandeling. Om alloSCT 
succesvol te maken is het belangrijk om minor antigenen te vinden die wel het graft versus tumor effect 
vertonen, maar niet, of nauwelijks, aanleiding geven tot het graft versus host effect. Op dit ogenblik zijn er 
ongeveer 50 minor antigenen geïdentificeerd. Deze antigenen zijn peptiden, die gevormd zijn door enzyma-
tische afbraak in de cel. Een deel van deze peptiden wordt geladen in HLA-moleculen, en de HLA-peptide 
complexen worden vervolgens naar de membraan getransporteerd, waar enkele honderdduizenden complexen 
worden gepresenteerd. Om te identificeren welke peptiden worden gepresenteerd, worden de HLA-peptide 
complexen vrijgemaakt uit de membraan en opgezuiverd, en wordt de pool van enkele tienduizenden peptiden 
vervolgens geïsoleerd en geïdentificeerd. Er zijn twee hoofdstrategieën te onderscheiden om minor antigenen 
te identificeren, de voorwaartse benadering en de terugwaartse benadering. De voorwaartse benadering kan 
worden toegepast als er reactieve T cellen zijn gevonden na alloSCT. De terugwaartse benadering gebruikt 
algoritmes en beschikbare databanken om nieuwe minor antigenen te voorspellen. Een belangrijke beperking 
van de terugwaartse benadering is dat veel van de voorspelde antigenen niet op het celmembraan worden ge-
presenteerd. Daarnaast kunnen post-translationeel gemodificeerde peptiden niet voorspeld worden. Daarom 
verkennen we in deze thesis de mogelijkheden om op basis van het geëlueerde peptidenrepertoire, het ligan-
doom, nieuwe minor antigenen te identificeren.
In hoofdstuk 2 passen we deze nieuwe strategie toe, door het ligandoom van twee EBV-getransformeerde B 
cellen zo goed volledig mogelijk te bepalen. Vanwege de grote complexiteit en het dynamisch bereik van het 
ligandoom hebben we multidimensionele chromatografie toegepast, met in de eerste dimensie een scheiding 
met isoelectrische focussering, ionenuitwisseling of omkeerfase chromatografie gevolgd door een tweede 
scheiding met omkeerfase chromatografie gekoppeld met een massaspectrometer. Met onze strategie wer-
den ongeveer 16.000 liganden, waaronder minor antigenen en post-translationeel gemodificeerde peptiden, 
geïdentificeerd met hoge betrouwbaarheid uit de HLA typen A2, B7 en B44. De identificatie van de peptiden 
werd gevalideerd door synthese van geselecteerde peptiden, het controleren op physicochemische eigenschap-
pen, bindingsaffiniteit op basis van het NetMHC algoritme, lengte en hydrofobiciteit. Deze grote set peptiden 
vormt de basis voor de volgende stappen van deze studie. Om minor antigenen beter te kunnen identificeren 
hebben we in hoofdstuk 3 een databank ontwikkeld, de Human Short Peptide Variation databank (HSPVdb), 
die geconstrueerd is door combinatie van de humane mRNA sequenties in de RefSeq databank en de geassoci-
eerde informatie uit de Single Nucleotide Polymorphism Databank (dbSNP). Het merendeel van de irrelevan-
te SNPs werden verwijderd, wat resulteerde in een compacte databank van hoge kwaliteit om minor antigenen 
met verhoogde kans op te sporen. Door matching van onze data met de HSPVdb konden we 1500 polymorfe 
peptiden met grote betrouwbaarheid identificeren. Om potentiele minor antigenen te identificeren uit de set 
van 1500 polymorfe peptiden hebben we in hoofdstuk 4 de 25 meest veelbelovende kandidaten geselecteerd. 
In deze selectie van 25 peptiden werden 2 nieuwe minor antigenen geïdentificeerd, te weten LB-CLYBL-1Y 
en LB-TEP1-1S.
Omdat we weten dat we het ligandoom nog niet volledig kunnen identificeren hebben we verschillende stap-
216
Appendix
pen in het identificatieproces, en met name de opwerking, in detail bestudeerd. In hoofdstuk 5 hebben we 
daarom een methode ontwikkeld om HLA gepresenteerde peptiden nauwkeurig te kwantificeren. Dit werd ge-
daan door stabiel isotoop gelabelde peptiden te binden in HLA moleculen. Een bekende hoeveelheid van deze 
peptide/HLA complexen werd helemaal aan het begin van de opwerking toegevoegd, waardoor verliezen in 
het opwerkingsproces verrekend konden worden. Om ook de opbrengst van de opwerking te kunnen bepalen 
werd een andere stabiel isotoop gelabelde variant van dezelfde peptiden toegevoegd voor de finale massaspec-
trometrische metingen. Van de minor antigenen LB-NISCH1-1A en LB-SSR1-1S werd de opbrengst van de 
opwerking bepaald op 1-5%. De verliezen bleken bijna volledig toe te schrijven aan de eerste verrijkingsstap 
waarin HLA complexen worden opgezuiverd met behulp van een antilichaam gericht tegen HLA moleculen. 
Deze kwantificeringsmethode werd in hoofdstuk 6 toegepast om de unidirectionele aard van de T cel respons 
tegen minor antigenen te bestuderen. De unidirectionele aard van de T cel respons betekent dat er slechts een 
respons is tegen het minor antigeen maar niet tegen de allelische variant. Dat laatste zou verklaard kunnen 
worden door afwezigheid van voornoemde variant op het celmembraan. We hebben echter in hoofdstuk 2 
op verschillende heterozygote cellen van meerdere peptiden beide allelische varianten geïdentificeerd. Van 3 
peptiden werden beide allelische varianten in detail bestudeerd: LB-NISCH1 (minor antigeen/allelische va-
riant; A/V), LB-SSR1 (S/L) en LB-CLYBL (Y/D). Uit kwantificering van deze peptiden bleek dat het minor 
antigeen en de allelische variant in vergelijkbare aantallen op het celmembraan aanwezig waren. Daarmee 
werd de werkhypothese, dat de antigeendichtheid op het celmembraan minstens 10x lager moet zijn om het 
verschil in T cel respons te kunnen verklaren, verworpen. De unidirectionele aard van de T cel respons tegen 
minor antigenen kan dus niet algemeen verklaard worden door de afwezigheid van de allelische variant op het 
celmembraan. Andere immunologische mechanismen spelen dus een rol.
In hoofdstuk 7 bestuderen we in detail een aantal, voor HLA klasse I, ongewoon lange peptiden, welke wer-
den gevonden in de studie beschreven in hoofdstuk 2. De data uit hoofdstuk 2 bevatte 1.568 peptiden met een 
lengte van 12-23 aminozuren, waarvan 423 met een lengte van 15-23 aminozuren. Acht 15-meer peptiden 
werden geselecteerd voor diepgaande studie, waarin de efficiëntie van peptide/HLA monomeervorming werd 
bestudeerd, en hun thermische stabiliteit. Hieruit bleek dat de 15-meren zich gedroegen als ‘normale’ 9-meer 
peptiden. Vervolgens werd van twee 15-meer peptide/HLA complexen de kristalstructuur bepaald, waaruit 
bleek dat de peptiden een zogenaamde ‘super bulged’ structuur aannamen, wat wil zeggen dat de peptiden de 
normale ankerposities gebruiken, en ver uit de HLA groeve steken.
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